0001493152-16-014579.txt : 20161107 0001493152-16-014579.hdr.sgml : 20161107 20161107163230 ACCESSION NUMBER: 0001493152-16-014579 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 47 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161107 DATE AS OF CHANGE: 20161107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CombiMatrix Corp CENTRAL INDEX KEY: 0001383183 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 470899439 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33523 FILM NUMBER: 161978554 BUSINESS ADDRESS: STREET 1: 310 GODDARD STREET 2: SUITE 150 CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: 949-753-0624 MAIL ADDRESS: STREET 1: 310 GODDARD STREET 2: SUITE 150 CITY: IRVINE STATE: CA ZIP: 92618 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

[X]

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For The Quarterly Period Ended September 30, 2016

[ ]

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO .

Commission File Number 001-33523

COMBIMATRIX CORPORATION

(Exact Name of Registrant as Specified in Its Charter)

Delaware		47-0899439
(State or Other Jurisdiction of		(I.R.S. Employer
Incorporation or Organization)		Identification No.)

310 Goddard, Suite 150,
Irvine, CA		92618
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (949) 753-0624

N/A

(Former name, former address and former fiscal year, if changed since last report.)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer [ ]

Accelerated filer [ ]

Non-accelerated filer [ ]

(Do not check if a smaller
reporting company)

Smaller reporting company [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes [ ] No [X]

As of November 4, 2016, 2,500,629 shares of CombiMatrix Corporation common stock, $0.001 par value were issued and outstanding.

COMBIMATRIX CORPORATION

Table of Contents

Part I. Financial Information

Item 1.	Financial Statements (Unaudited)

	Consolidated Balance Sheets as of September 30, 2016 and December 31, 2015	3

	Consolidated Statements of Operations for the Three and Nine months Ended September 30, 2016 and 2015	4

	Consolidated Statements of Comprehensive Loss for the Three and Nine months Ended September 30, 2016 and 2015	5

	Consolidated Statements of Cash Flows for the Nine months Ended September 30, 2016 and 2015	6

	Notes to Consolidated Financial Statements	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	21

Item 4.	Controls and Procedures	21

Part II. Other Information

Item 1.	Legal Proceedings	21

Item 1A.	Risk Factors	21

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	23

Item 3.	Defaults Upon Senior Securities	23

Item 4.	Mine Safety Disclosures	23

Item 5.	Other Information	23

Item 6.	Exhibits	23

Signatures		24

Exhibit Index		25

Part I. Financial Information

Item 1. Financial Statements (Unaudited)

COMBIMATRIX CORPORATION

CONSOLIDATED BALANCE SHEETS

(In thousands)

	September 30,			December 31,
	2016			2015
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	4,345		$	653
Short-term investments		-			3,248
Accounts receivable, net of allowance for doubtful accounts of $244 and $235		3,235			2,682
Supplies		459			418
Prepaid expenses and other assets		169			200
Total current assets		8,208			7,201
Property and equipment, net		651			691
Other assets		30			30
Total assets	$	8,889		$	7,922

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable, accrued expenses and other	$	1,623		$	1,591
Current portion, long-term debt		129			193
Total current liabilities		1,752			1,784
Capital lease obligations, net of current portion		49			71
Secured promissory note payable, net of current portion		-			34
Deferred rent		153			177
Total liabilities		1,954			2,066

Commitments and contingencies (Note 7)

Stockholders’ equity:
Convertible preferred stock; $0.001 par value; 5,000,000 shares authorized;
Series F - 8,000 shares authorized; 1,690 and none issued and outstanding		-			-
Series E - 2,202 shares authorized; none and 2,201.493 issued and outstanding		-			-
Common stock; $0.001 par value; 50,000,000 shares authorized; 2,487,450 and 845,374 shares issued and outstanding		14			13
Additional paid-in capital		108,952			102,651
Accumulated other comprehensive loss		-			(2	)
Accumulated deficit		(102,031	)		(96,806	)
Total stockholders’ equity		6,935			5,856
Total liabilities and stockholders’ equity	$	8,889		$	7,922

The accompanying notes are an integral part of these consolidated financial statements.

COMBIMATRIX CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share and per share information)

(Unaudited)

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2016			2015			2016			2015

Revenues:
Diagnostic services	$	3,211		$	2,481		$	9,190		$	7,292
Royalties		37			45			137			112
Total revenues		3,248			2,526			9,327			7,404

Operating expenses:
Cost of services		1,476			1,400			4,327			4,028
Research and development		88			133			380			352
Sales and marketing		1,055			1,295			3,532			3,658
General and administrative		1,450			1,249			4,562			4,212
Patent amortization and royalties		25			25			75			75
Impairment of cost-basis investment		-			97			-			97
Total operating expenses		4,094			4,199			12,876			12,422
Operating loss		(846	)		(1,673	)		(3,549	)		(5,018	)
Other income (expense):
Interest income		7			5			19			13
Interest expense		(17	)		(19	)		(52	)		(59	)
Total other income (expense)		(10	)		(14	)		(33	)		(46	)
Net loss	$	(856	)	$	(1,687	)	$	(3,582	)	$	(5,064	)

Deemed dividend from issuing Series F convertible preferred stock and warrants	$	-		$	-		$	(1,877	)	$	-
Deemed dividend paid for right to repurchase Series E convertible preferred stock		-			-			(656	)		-
Deemed dividend from issuing Series E convertible preferred stock and warrants		-			-			890			(890	)
Net loss attributable to common stockholders	$	(856	)	$	(1,687	)	$	(5,225	)	$	(5,954	)

Basic and diluted net loss per share	$	(0.38	)	$	(2.00	)	$	(2.38	)	$	(6.13	)
Deemed dividend paid for right to repurchase Series E convertible preferred stock		-			-			(0.44	)		-
Deemed dividend from issuing Series E convertible preferred stock		-			-			0.59			(1.08	)
Deemed dividend from issuing Series F convertible preferred stock		-			-			(1.25	)		-
Basic and diluted net loss per share attributable to common stockholders	$	(0.38	)	$	(2.00	)	$	(3.48	)	$	(7.21	)

Basic and diluted weighted average common shares outstanding		2,253,834			845,395			1,502,680			825,956

The accompanying notes are an integral part of these consolidated financial statements.

COMBIMATRIX CORPORATION

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(In thousands, except share and per share information)

(Unaudited)

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2016			2015			2016			2015

Net loss	$	(856	)	$	(1,687	)	$	(3,582	)	$	(5,064	)
Unrealized gain on available-for-sale investments		-			-			2			4
Total comprehensive loss	$	(856	)	$	(1,687	)	$	(3,580	)	$	(5,060	)

The accompanying notes are an integral part of these consolidated financial statements.

COMBIMATRIX CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

	Nine Months Ended
	September 30,
	2016			2015
Operating activities:
Net loss	$	(3,582	)	$	(5,064	)
Adjustments to reconcile net loss to net cash flows from operating activities:
Depreciation and amortization		195			227
Non-cash stock compensation		591			519
Provision for bad debts		302			218
Impairment fo cost-basis investment		-			97
Changes in assets and liabilities:
Accounts receivable		(855	)		(455	)
Supplies, prepaid expenses and other assets		(35	)		(153	)
Accounts payable, accrued expenses and other		23			440
Net cash flows from operating activities		(3,361	)		(4,171	)

Investing activities:
Purchases of property and equipment		(148	)		(66	)
Purchase of available-for-sale investments		(4,998	)		(4,000	)
Sale of available-for-sale investments		8,248			4,230
Net cash flows from investing activities		3,102			164

Financing activities:
Proceeds from issuance of Series F convertible stock and common stock warrants		8,000			-
Costs from issuance of Series F convertible convertible stock and common stock warrants		(1,064	)		-
Repurchase of Series E convertible prefered stock and dividends		(2,842	)		-
Proceeds from issuance of Series E convertible stock, common stock and warrants		-			4,900
Costs from issuance of Series E convertible convertible stock, common stock and warrants		-			(220	)
Repayments of long-term debt		(143	)		(135	)
Net cash flows from financing activities		3,951			4,545

Change in cash and cash equivalents		3,692			538
Cash and cash equivalents, beginning		653			1,010
Cash and cash equivalents, ending	$	4,345		$	1,548

Non-cash financing activities:
Deemed dividends from issuing Series E convertible preferred stock	$	(890	)	$	890

Deemed dividends from issuing Series F convertible preferred stock	$	1,877		$	-

Accrued property, plant and equipment	$	9		$	-

Property and equipment purchased under capital lease	$	23		$	72

Warrant modifications recognized as non-cash Series E offering-related costs	$	-		$	336

Tenant improvements recognized as deferred rent	$	-		$	164

The accompanying notes are an integral part of these consolidated financial statements.

1. OVERVIEW AND BACKGROUND

CombiMatrix Corporation (the “Company,” “we,” “us” and “our”) was originally incorporated in October 1995 as a California corporation and later reincorporated as a Delaware corporation in September 2000. In December 2002, we merged with, and became a wholly owned subsidiary of Acacia Research Corporation (“Acacia”). In August 2007, we split-off from Acacia and became publicly traded on The NASDAQ Stock Market. As a result of the split-off, we ceased to be a subsidiary of, or affiliated with, Acacia.

Description of the Company

We are a family health-focused clinical molecular diagnostic laboratory specializing in pre-implantation genetic screening, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. We strive to provide best-in-class clinical laboratory support to healthcare professionals, allowing them to maximize the clinical utility of their patients’ test results and to optimize patient care. Our testing focuses on advanced technologies, including single nucleotide polymorphism chromosomal microarray analysis, next generation sequencing, fluorescent in situ hybridization and high resolution karyotyping. Our approach to testing is to offer sophisticated technology along with high-quality clinical support to our ordering physicians and their patients. Our laboratory facilities and corporate headquarters are located in Irvine, California.

We also own a one-third minority interest in Leuchemix, Inc. (“Leuchemix”), a private drug development company focused on developing a series of compounds to address a number of oncology-related diseases.

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, certain information and notes required by generally accepted accounting principles in annual financial statements have been omitted or condensed. These interim consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2015, as reported by us in our Annual Report on Form 10-K filed with the SEC on February 18, 2016. The year-end consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. The consolidated financial statements include all adjustments of a normal recurring nature which, in the opinion of management, are necessary for a fair statement of our financial position as of September 30, 2016, and results of operations and cash flows for the interim periods presented. The results of operations for the three and nine months ended September 30, 2016 are not necessarily indicative of the results to be expected for the entire year.

Reverse Stock Split

On January 29, 2016, we filed a Certificate of Amendment to our Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a reverse split of our common stock at a ratio of one-for-fifteen (the “Reverse Stock Split”), which became effective at the close of business on that day. As a result, each share of CombiMatrix common stock outstanding as of January 29, 2016 was automatically changed into one-fifteenth of a share of common stock. No fractional shares were issued in connection with the Reverse Stock Split, and cash paid to stockholders for potential fractional shares was insignificant. The number of shares of common stock subject to outstanding options, warrants and convertible securities were also reduced by a factor of fifteen as of January 29, 2016. All historical share and per share amounts reflected throughout this document have been adjusted to reflect the Reverse Stock Split. The authorized number of shares and the par value per share of our common stock were not affected by the Reverse Stock Split.

Liquidity and Risks

We have a history of incurring net losses and net operating cash flow deficits. We are also deploying new technologies and continue to develop and improve existing commercial diagnostic testing services and related technologies. As of September 30, 2016, we had cash, cash equivalents and short-term investments of $4.3 million and anticipate that our cash, cash equivalents and short-term investments will be sufficient to meet our cash requirements for at least the next twelve months. In order for us to ultimately achieve profitability, we may be required to obtain capital from external sources, increase revenues and reduce operating costs. However, there can be no assurance that our operations will become profitable or that external sources of financing, including the issuance of debt and/or equity securities, will be available at times and at terms acceptable to us, or at all. The issuance of additional equity or convertible debt securities will also cause dilution to our stockholders. If external financing sources are not available or are inadequate to fund our operations, we will be required to reduce operating costs, including research projects and personnel, which could jeopardize our future strategic initiatives and business plans.

Our business operations are also subject to certain risks and uncertainties, including:

	●	market acceptance of our technologies and services;

	●	technological advances that may make our technologies and services obsolete or less competitive;

	●	increases in operating costs, including costs for supplies, personnel and equipment;

	●	variability in third-party reimbursement of our tests;

	●	the availability and cost of capital; and

	●	governmental regulation that may restrict our business.

Our services are concentrated in a highly competitive market that is characterized by rapid technological advances, frequent changes in customer requirements and evolving regulatory requirements and industry standards. Failure to anticipate or respond adequately to technological advances, changes in customer requirements, changes in regulatory requirements or industry standards, or any significant delays in the development or introduction of planned services, could have a material adverse effect on our business and operating results. The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the matters discussed herein.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates. The preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) in the United States of America requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

Principles of Consolidation. The accompanying consolidated financial statements include the accounts of the Company and our wholly owned and majority-owned subsidiaries. Investments for which we possess the power to direct or cause the direction of the management and policies, either through majority ownership or other means, are accounted for under the consolidation method. Material intercompany transactions and balances have been eliminated in consolidation. Investments in companies in which we maintain an ownership interest of 20% to 50% or exercise significant influence over operating and financial policies are accounted for under the equity method. The cost method is used where we maintain ownership interests of less than 20% and do not exercise significant influence over the investee.

Revenue Recognition. We recognize revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been performed, (iii) amounts are fixed or determinable and (iv) collectability of amounts is reasonably assured.

Service revenues from providing diagnostic tests are recognized when the testing process is complete and test results are reported to the ordering physician or clinic. These diagnostic services are billed to various payors, including commercial insurance companies, healthcare institutions, government payors including various state Medicaid programs, and individuals. We report revenues from contracted payors based on a contractual rate, or in the case of state Medicaid contracts, published fee schedules for our tests. We report revenues from non-contracted payors based on the amounts expected to be collected. The differences between the amounts billed and the amounts expected to be collected from non-contracted payors are recorded as contractual allowances to arrive at net recognized revenues. The expected revenues from non-contracted payors are based on the historical collection experience of each payor or payor group, as appropriate, and also take into account recent collection trends. In each reporting period, we review our historical collection experience for non-contracted payors and adjust our expected revenues for current and subsequent periods accordingly. We also recognize additional revenue from actual cash payments that exceed amounts initially recognized, in the period the payments are received. Because a substantial portion of our revenues is from non-contracted third-party payors, it is likely that we will be required to make adjustments to accounting estimates with respect to contractual allowances in the future, which may positively or adversely affect our results of operations. In all cases described above, we report revenues net of any applicable statutory taxes collected from customers, as applicable. No single customer exceeded 10% of revenues for the three or nine months ending September 30, 2016, nor for the three months ended September 30, 2015. For the nine months ended September 30, 2015, 10% of our revenues were generated from one customer.

Cash Equivalents and Short-Term Investments. We consider all highly liquid investments purchased with original maturities of three months or less when purchased to be cash equivalents. Short-term investments consist of fixed income investments with maturities between three and 12 months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company’s consolidated balance sheet. Unrealized holding gains and losses are reported within comprehensive loss in the consolidated statements of comprehensive loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations or other observable inputs. If a decline in the fair value of a short-term investment below our cost basis is determined to be other than temporary, such investment is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. To-date, no permanent impairment charges have been realized or recorded.

Fair Value Measurements. We measure fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

●	Level 1:	Observable market inputs such as quoted prices in active markets;

●	Level 2:	Observable market inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

●	Level 3:	Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions.

We classify our cash equivalents within the fair value hierarchy as Level 1 as these assets are valued using quoted prices in active markets for identical assets at the measurement date. We classify short-term investments within the fair value hierarchy as Level 2, primarily utilizing broker quotes in a non-active market for valuation of these investments. Financial instruments that contain valuation inputs that are not readily determinable from active markets or from similar securities trading in active markets, such as derivative financial instruments, are classified within the fair value hierarchy as Level 3.

Impairment of Long-Lived Assets. Long-lived assets and intangible assets are reviewed for potential impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. In the event the sum of the expected undiscounted future cash flows resulting from the use of the asset is less than the carrying amount of the asset, an impairment loss equal to the excess of the asset’s carrying value over its fair value is recorded. If an asset is determined to be impaired, the loss is measured based on quoted market prices in active markets, if available. If quoted market prices are not available, the estimate of fair value is based on various valuation techniques, including a discounted value of estimated future cash flows.

During the third quarter of 2015, management determined that the carrying value of a cost-basis investment in the stock of a privately held company was impaired, resulting in a one-time, non-cash impairment charge of $97,000 for the three and nine months ended September 30, 2015.

Derivative Financial Instruments. We evaluate financial instruments for freestanding or embedded derivatives. Derivative instruments that do not qualify for permanent equity classification are recorded as liabilities at fair value, with changes in value recognized as other income (expense) in the consolidated statements of operations in the period of change. Derivative liabilities are categorized as either short-term or long-term based upon management’s estimates as to when the derivative instrument may be realized or based upon the holder’s ability to realize the instrument.

Concentration of Credit Risks. Cash and cash equivalents are invested in deposits with certain financial institutions and may, at times, exceed federally insured limits. We have not experienced any significant losses on our deposits of cash and cash equivalents. We do not believe that we are exposed to significant credit risk on cash and cash equivalents or on our short-term investments. As of September 30, 2016, accounts receivable from two commercial insurance carriers of $418,000 and $346,000 exceeded 10% of our total accounts receivable balance. As of December 31, 2015, accounts receivable from one commercial insurance carrier of $316,000 exceeded 10% of our total accounts receivable balance.

Substantially all of the components and raw materials used in providing our testing services, including array slides and reagents, are currently provided to us from a limited number of sources or in some cases from a single source. Although we believe that alternative sources for those components and raw materials are available, any supply interruption in a sole-sourced component or raw material might result in up to a several-month production delay and materially harm our ability to provide testing services until a new source of supply, if any, could be located and qualified.

Accounts Receivable and Allowance for Doubtful Accounts. For our contracted third-party payors, governmental payors or direct-bill customers, accounts receivable are stated at principal amounts and are primarily comprised of amounts contractually due from customers for services performed. For our non-contracted customers, accounts receivable are stated at amounts expected to be collected based on historical collection experience with the third-party payor. The payment realization cycle for certain governmental and commercial insurance payors can be lengthy, involving denial, appeal and adjudication processes, and is subject to periodic adjustments that may be significant. Accounts receivable are periodically written off when identified as uncollectible after appropriate collection efforts have been exhausted. Such write-offs increase the contractual allowances (which reduce revenues) for those accounts in the period of adjustment. Collection of governmental, private health insurer, and client receivables are generally a function of providing complete and correct billing information to the insurers and clients within the filing deadlines required by each payor.

Collection of receivables due from patients and private-pay clients is generally subject to increased credit risk due to credit-worthiness or inability to pay. For these customers, an allowance for doubtful accounts is recorded for estimated uncollectible amounts, and involves significant assumptions and judgments. Specifically, the allowance for doubtful accounts is adjusted periodically and is principally based upon specific identification of past due or disputed accounts. We also review the age of receivables to assess our allowance at each period end. Additions to the allowance for doubtful accounts are charged to bad debt expense as a component of general and administrative expenses in the consolidated statements of operations.

Stock-Based Compensation. The compensation cost for all employee stock-based awards is measured at the grant date, based on the fair value of the award, and is recognized as an expense, on a straight-line basis, over the employee’s requisite service period (generally the vesting period of the equity award) which is generally four years. The fair value of each stock option award is estimated on the date of grant using a Black-Scholes option valuation model. The fair value of each restricted stock unit (“RSU”) award is based on the number of shares granted and the closing price of our common stock as reported on NASDAQ on the date of grant. Stock-based compensation expense is recognized only for those awards that are expected to vest using an estimated forfeiture rate. We estimate pre-vesting option forfeitures at the time of grant and reflect the impact of estimated pre-vesting option forfeitures in compensation expense recognized. Stock-based compensation expense for all periods presented attributable to our functional expense categories from stock option and RSU awards vesting during the periods presented were as follows (in thousands):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2016		2015		2016		2015

Cost of services	$	14	$	11	$	34	$	21
Research and development		-		-		-		-
Sales and marketing		19		15		63		46
General and administrative		153		147		494		452
Total non-cash stock compensation	$	186	$	173	$	591	$	519

Net Loss Per Share. Basic and diluted net loss per share has been computed by dividing the net loss by the weighted average number of common shares issued and outstanding during the periods presented. Options and warrants to purchase common stock as well as preferred stock convertible into shares of common stock are anti-dilutive and therefore are not included in the determination of the diluted net loss per share. The following table reflects the excluded dilutive securities:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2016		2015		2016		2015

Common stock options		66,687		70,028		66,687		70,028
Restricted stock units		59,000		38,800		59,000		38,800
Common stock warrants		2,701,754		643,260		2,701,754		643,260
Series E preferred stock convertible into common stock		-		83,866		-		83,866
Series F preferred stock convertible into common stock		436,662		-		436,662		-
Excluded potentially dilutive securities		3,264,103		835,954		3,264,103		835,954

Segments. We have determined that we operate in one segment for financial reporting purposes.

Recent Accounting Pronouncements. In August 2016, the Financial Accounting Standards Board (“FASB”) issued new accounting guidance aimed at reducing the existing diversity in GAAP regarding how certain cash receipts and cash payments are classified in the statement of cash flows. The new guidance is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is also permitted. We do not expect the adoption of this guidance to have a material impact on our consolidated statements of cash flows.

In March 2016, the FASB issued guidance regarding employee share-based payment accounting. The guidance is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification on the statement of cash flows and provides the choice for companies to estimate forfeitures during the vesting period of an award (which is required under current GAAP) or recognize forfeitures at the time an award is cancelled and forfeited. The standard is effective for us on January 1, 2017. We do not expect the adoption of this guidance to have a significant impact on our consolidated financial statements. However, we have elected to change our policy regarding forfeitures to recognize if and when an award is cancelled and forfeited rather than estimating forfeitures up front. We will be required to implement this policy change using the modified retrospective approach, during the first quarter of 2017. We estimate that the impact from implementing this policy change will be to reduce retained earnings and increase additional paid-in capital by approximately $40,000, but we will not know the actual amount until after the fourth quarter of 2016.

In February 2016, the FASB issued guidance regarding leases, which requires lessees to recognize on the balance sheet a right-of-use asset, representing their right to use the underlying asset for the lease term, and a lease liability for all leases with terms greater than 12 months. The guidance also requires qualitative and quantitative disclosures designed to assess the amount, timing and uncertainty of cash flows arising from leases. The guidance requires the use of a modified retrospective transition approach, which includes a number of optional practical expedients that entities may elect to apply. The guidance is effective for us beginning January 1, 2019, and we are currently evaluating the impact that this guidance will have on our consolidated financial statements.

In January 2016, the FASB issued accounting guidance regarding recognition and measurement of financial assets and financial liabilities. This guidance enhances the reporting model for financial instruments, which includes amendments to address aspects of recognition, measurement, presentation and disclosure. The guidance is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those annual periods. We do not expect the adoption of this guidance to have a significant impact on our consolidated financial statements.

In July 2015, the FASB issued accounting guidance regarding simplifying the measurement of inventory. The new guidance applies only to inventory for which cost is determined by methods other than last-in, first-out and the retail inventory method, which includes inventory that is measured using first-in, first-out or average cost. Inventory within the scope of this standard is required to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The new standard will be effective for us on January 1, 2017. We do not expect the adoption of this guidance to have a material impact on our consolidated financial statements.

In August 2014, the FASB issued new guidance requiring management of all entities to evaluate whether there are conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the financial statements are issued (or available to be issued when applicable). The guidance is effective for fiscal years ending after December 15, 2016 and for annual and interim periods thereafter. While we do not expect the adoption of this guidance to have a material effect on our consolidated financial statements, adoption will increase disclosures in the notes to our consolidated financial statements if management concludes that substantial doubt about our ability to continue as a going concern within twelve months of the date that our consolidated financial statements are issued is present.

In May 2014, the FASB issued new accounting guidance regarding revenue recognition from contracts with customers, which when effective will supersede existing revenue recognition requirements and will eliminate most industry-specific guidance from GAAP. The core principle of the new guidance is to require an entity to recognize as revenue the amount that reflects the consideration to which it expects to be entitled in exchange for goods or services as it transfers control to its customers. The new guidance requires additional qualitative and quantitative disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. An entity can apply the new guidance retrospectively to each prior reporting period presented (i.e., the full retrospective method) or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. As originally issued, the new revenue recognition standard would be effective for us beginning January 1, 2017. However, in 2015, the FASB voted to defer the effective date of the new guidance for one year. We are currently evaluating the appropriate transition method and any further impact of this guidance on our consolidated financial statements and related disclosures.

Reclassifications. Certain prior period amounts have been reclassified to conform to the current period presentation.

3. CASH AND SHORT-TERM INVESTMENTS

As of September 30, 2016, we held $4.3 million in cash, cash equivalents and short-term investments, which are reported at fair value. Cash, cash equivalents and short-term investments consisted of the following as of September 30, 2016 and December 31, 2015 (in thousands):

	As of September 30, 2016								As of December 31, 2015
			Unrealized				Fair				Unrealized					Fair
	Cost		Gains		Losses		Value		Cost		Gains		Losses			Value

Cash and money market securities	$	4,345	$	-	$	-	$	4,345	$	653	$	-	$	-		$	653
Commercial paper		-		-		-		-		-		-		-			-
Certificates of deposit		-		-		-		-		3,250		-		(2	)		3,248
	$	4,345	$	-	$	-	$	4,345	$	3,903	$	-	$	(2	)	$	3,901

There were no realized gains or losses for the periods ended September 30, 2016 or 2015.

4. FAIR VALUE MEASUREMENTS

The following table summarizes, for each major category of financial assets measured on a recurring basis, the respective fair value at September 30, 2016 and December 31, 2015 and the classification by level of input within the fair value hierarchy defined above (in thousands):

			Fair Value Measurements
September 30, 2016	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	3,033	$	3,033	$	-	$	-
Short-term investments		-		-		-		-
Cash equivalents	$	3,033	$	3,033	$	-	$	-

			Fair Value Measurements
December 31, 2015	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	99	$	99	$	-	$	-
Short-term investments		3,248		-		3,248		-
Cash equivalents	$	3,347	$	99	$	3,248	$	-

The carrying amounts of accounts receivable, accounts payable, accrued expenses, capital leases and the secured promissory note approximate fair value due primarily to the short-term nature of these financial instruments.

5. SECURED PROMISSORY NOTE

On May 20, 2014 (“Execution Date”), we executed a secured promissory note (the “Note”) with ACC Investment Ltd. in the amount of $350,000, payable in equal amortized payments over a thirty-six month period (the “Term”) from the Execution Date. The Note bears an annual interest rate of 10% and is secured by certain laboratory equipment used in our microarray services business. Legal and other closing costs totaling $22,000 were capitalized with the Note and are being amortized over the Term as interest expense. As of September 30, 2016 and December 31, 2015, components of the Note were as follows (in thousands):

	September 30,			December 31,
	2016			2015

Carrying value	$	76		$	168
Unamortized legal and closing costs		(4	)		(10	)
		72			158
Less- current portion		(72	)		(124	)
Long-term portion	$	-		$	34

6. STOCKHOLDERS’ EQUITY

Series A through E Convertible Preferred Stock and Warrants Financings

Between 2012 and 2015, we executed several financing transactions whereby we issued convertible preferred stock and warrants to purchase common stock to investors. As of September 30, 2016, none of the Series A through E convertible preferred stock remained outstanding. For as long as the Series A warrants remain unexercised through their expiration date, except under certain permitted circumstances, we may not issue, or enter into any agreement to issue, common stock or common stock equivalents at a price per share below the $73.65 exercise price of the Series A warrants, unless waivers from the Series A investors are obtained. Until the time that less than 7.5% of the Series B, C and E warrants remain unexercised through their expiration date, except under certain permitted circumstances, we may not issue, or enter into any agreement to issue, common stock or common stock equivalents at prices per share below the $29.55, $29.55 and $32.51 exercise prices of the Series B, C and E warrants, respectively, unless waivers from the Series B, C and E investors are obtained. In addition, until there are no longer Series A, C and E warrants outstanding we may not sell any variable rate securities except for certain exempt issuances.

Series E Convertible Preferred Stock Financing

On February 13, 2015, we and certain accredited institutional pre-existing investors (the “Series E Investors”) entered into a securities purchase agreement (the “Series E Purchase Agreement”), pursuant to which we sold 102,800 shares common stock at a price of $26.25 per share, 2,201.493 shares of Series E 6% Convertible Preferred Stock (the “Series E Preferred Stock”) and warrants to purchase 46,676 shares of common stock initially at an exercise price of $29.55 per share, which was the consolidated closing bid price of our common stock on NASDAQ immediately prior to entering into the Series E Purchase Agreement (the “Series E Warrants”, and the transactions contemplated by the Series E Purchase Agreement, the “Series E Financing”). The Series E Preferred Stock and Series E Warrants were sold in a fixed combination consisting of one share of Series E Preferred Stock and a Series E Warrant to purchase approximately 21.1977 shares of common stock. Each fixed combination of Series E Preferred Stock and Series E Warrants were sold at a price of $1,000. The Series E Preferred Stock sold was convertible into 83,871 shares of common stock at an initial conversion price of $26.25 per share. The closing under the Series E Purchase Agreement occurred on February 18, 2015 (the “Series E Closing Date”), where we received gross proceeds of $4.9 million from the Series E Investors. After closing-related costs and expenses, net proceeds from the Series E Financing were approximately $4.7 million. Given that the effective conversion price of the Series E Preferred Stock, inclusive of amounts allocated to common stock and Series E Warrants, was below the closing market price of our common stock at the time of the Series E Closing Date, we recognized a beneficial conversion feature in the amount of $890,000. Since the Series E Preferred Stock was immediately convertible into common stock, the beneficial conversion feature was treated as a deemed dividend charged to retained earnings.

The Series E Warrants issued have a 5 ½ year term and have a cashless exercise provision in the event there is no effective registration statement covering the common stock issuable upon exercise of the Series E Warrants. The Series E Warrants are not subject to price based anti-dilution protection. See below for modifications made to the Series E Preferred Stock and the Series E Warrants.

Private Placement Warrant Financing

Substantially concurrently with the closing of the Series E Financing, on February 13, 2015, we entered into a separate securities purchase agreement (the “Warrant Purchase Agreement”) with selected accredited institutional pre-existing investors (the “Private Placement Investors”), pursuant to which we agreed to sell to the Private Placement Investors warrants to purchase 102,678 shares of Common Stock (the “Private Placement Warrants”, and the transactions contemplated by the Warrant Purchase Agreement, the “Warrant Financing”). In consideration of an aggregate of $1,000, we had agreed to sell the Private Placement Warrants, which would not be issued unless and until our stockholders approved amending our Certificate of Incorporation to increase our authorized common stock to permit the issuance of the common stock issuable upon exercise of the Private Placement Warrants (the “Charter Amendment”). We estimated the fair value of the Private Placement Warrants using the Black-Scholes valuation model to be $1.82 million, which was classified as a warrant subscription payable within additional paid-in capital in our consolidated balance sheet using the following assumptions: (i) closing stock price and Private Placement Warrants contractual exercise price; (ii) 5.5 year term; (iii) historical volatilities commensurate with the term of the Private Placement Warrants of 113.2%; and (iv) risk-free interest rates commensurate with the term of the Private Placement Warrants of 1.5%. We allocated the proceeds received from the Series E Financing to the Private Placement Warrants based on the relative fair value of the instruments issued to the Series E Investors. As a result of the special stockholders meeting held on April 28 2015, we issued the Private Placement Warrants to the Private Placement Investors and the warrant subscription payable was reclassified to additional paid-in capital.

Each Private Placement Warrant initially had an exercise price of $32.505 per share of common stock (subject to adjustment for stock splits and the like), which was 110% of the consolidated closing bid price of our common stock on NASDAQ immediately prior to entering into the Warrant Purchase Agreement, and is exercisable at any time after the six month anniversary of entering into the Warrant Purchase Agreement and on or prior to the close of business on the five year anniversary of the initial exercise date, subject to a beneficial ownership limitation. The Private Placement Warrants are not subject to price based anti-dilution protection. If, at the time of exercise of a Private Placement Warrant, there is no effective registration statement registering for resale the shares of common stock issuable upon exercise of the Private Placement Warrant, the holder may exercise the Private Placement Warrant on a cashless basis. When exercised on a cashless basis, a portion of the Private Placement Warrant is cancelled in payment of the purchase price payable in respect of the number of shares of common stock purchasable upon such exercise.

Modification of Certain Other Outstanding Warrants

In connection with the purchase of the Private Placement Warrants, we modified previously issued and outstanding warrants held by the Private Placement Investors that were issued in connection with the Series A, B and C financings described above, to (i) reduce the exercise prices thereunder to $29.55, which represents the consolidated closing bid price of our common stock on NASDAQ immediately prior to the date we entered into the Warrant Purchase Agreement; (ii) prohibit the exercise of such modified warrants for a period of six months after the date of the modification; and (iii) extend the exercise period of such modified warrants for an additional six months (such modifications, collectively, the “Warrant Price Modifications”). Separately, we also agreed to a Warrant Price Modification with a holder of Series C Warrants solely in consideration for such holder’s waiver of certain preemptive rights. We estimated the change in fair value of these warrants immediately prior to and immediately subsequent to the Warrant Price Modification to be $336,000, and such amount was recorded as a non-cash equity offering cost.

Series E Modifications

On October 12, 2015, we entered into an Amendment No. 1 to Common Stock Purchase Warrants (the “Warrants Amendment”) with each of the holders of the Series E Warrants and each of the holders of the Private Placement Warrants. Under the terms of the Warrants Amendment, all of the Series E Warrants and 100,847 of the Private Placement Warrants had their exercise prices reduced to $16.50 per share. Accordingly, with respect to the Private Placement Warrants, 100,847 of the Private Placement Warrants have an exercise price of $16.50 per share and 1,831 of the Private Placement Warrants retain their original exercise price of $32.505 per share. In consideration for entering into the Warrants Amendment, each Series E Investor agreed to irrevocably waive ab initio and for all time its right to receive cash dividends on its shares of our Series E Preferred Stock. We estimated the change in fair value of the Series E Warrants and the affected Private Placement Warrants prior to and immediately subsequent to the Warrants Amendment to be $168,000, which was recognized as a deemed dividend and as an increase to additional paid-in capital during the fourth quarter of 2015.

On February 4, 2016, we entered into a Series E 6% Convertible Preferred Stock Repurchase Agreement (the “Repurchase Agreement”) with the Series E Investors. Pursuant to the terms of the Repurchase Agreement, we agreed to pay each Series E Investor $300 per share of Series E Preferred Stock, or approximately $656,000, in consideration for the right to repurchase the Series E Investor’s Series E Preferred Stock at a price per share of $1,000 (the “Repurchase Price”), which was the original price per share paid by the Series E Investors for their Series E Preferred Stock in February 2015. We recognized the $656,000 payments as a deemed dividend paid to the Series E investors.

Immediately following the closing of our Series F public offering discussed below, we paid $2.2 million to the Series E Investors to repurchase all of the outstanding Series E Preferred Stock, in accordance with the terms of the Repurchase Agreement. Since none of the Series E Preferred Stock had converted by the time we repurchased the Series E Preferred Stock, the original $890,000 beneficial conversion feature that we recognized as a deemed dividend in 2015 was reversed as a return of capital from the Series E Preferred stockholders to the common stockholders.

Series F Convertible Preferred Stock and Warrants Financing

On March 24, 2016 (the “Series F Closing”), we closed an underwritten public offering (the “Series F Offering”) and issued 8,000 immediately separable units of securities to investors, with each unit consisting of: (i) one share of Series F convertible preferred stock (“Series F Preferred Stock”) convertible into shares of our common stock equal to 1,000 divided by the conversion price of $3.87, which was 75% of the consolidated closing bid price of our common stock on the NASDAQ Capital Market on March 18, 2016, the date we executed the underwriting agreement (“UA date”); and (ii) 258.397875 warrants, each to purchase one share of our common stock at an exercise price per share equal to $5.17 (“Series F Warrants”), which was 100% of the consolidated closing bid price of our common stock on the NASDAQ Capital Market on the UA date. The Series F Preferred Stock, the Series F Warrants, and the shares of common stock underlying the Series F Preferred Stock and Series F Warrants were registered on Form S-1, which was declared effective by the SEC on March 18, 2016. The Series F Preferred Stock was immediately convertible and the Series F Warrants were immediately exercisable for shares of common stock and have a term of five years. The Series F Warrants are exercisable for cash or, solely in the absence of an effective registration statement or prospectus, by cashless exercise. In total, there were 2,067,183 shares of common stock issuable upon conversion of the Series F Preferred Stock and up to 2,067,183 shares of common stock issuable upon exercise of the Series F Warrants. The units were sold for a purchase price equal to $1,000 per unit, resulting in gross proceeds received by us of $8 million. Total offering-related costs paid through September 30, 2016 were $1.06 million, resulting in net proceeds recognized of $6.94 million. Given that the effective conversion price of the Series F Preferred Stock was below the closing market price of our common stock at the time of the Series F Closing, we recognized a beneficial conversion feature in the amount of $1.9 million. Since the Series F Preferred Stock was immediately convertible into common stock, the beneficial conversion feature was treated as a deemed dividend charged to retained earnings at closing. Also, from the time of the Series F Closing through September 30, 2016, 6,310 shares of the Series F Preferred Stock have converted into 1,630,521 shares of common stock. Subsequent to September 30, 2016 and through the date of this report, an additional 51 shares of Series F Preferred Stock were converted into 13,179 shares of common stock.

The Series F Preferred Stock is non-voting (except to the extent required by law and except for certain consent rights relating to amending the certificate of incorporation or bylaws, and the like), but ranks senior to our common stock with respect to distributions upon our dissolution, liquidation or winding-up. Until the volume weighted average price of our common stock on NASDAQ exceeds 200% of the conversion price of the Series F Preferred Stock for any 20 of 30 consecutive trading days, and the daily dollar trading volume during such period exceeds $200,000 per trading day, the Series F Preferred Stock is subject to full ratchet price based anti-dilution protection, subject to certain limitations. Also, the Company can force holders of Series F Preferred Stock to convert into our common stock if the volume-weighted average price of our common stock exceeds 200% of the Series F Preferred Stock conversion price for any 20 of 30 consecutive trading days, and the daily dollar trading volume during such period exceeds $200,000 per trading day, subject to certain other conditions. The Series F investors have agreed to be subject to a blocker that would prevent each of their respective common stock ownership at any given time from exceeding 4.99% of our outstanding common stock (which may be increased on 61 days’ notice, but not above 9.99%).

The Series F Warrants have a 5-year term and have a cashless exercise provision in the event there is no effective registration statement covering the common stock issuable upon exercise of the Series F Warrants. The Series F Warrants are not subject to price based anti-dilution protection. The Series F Warrants are listed on the NASDAQ Capital Market under the trading symbol “CBMXW.”

Common Stock Purchase Warrants Repurchase Agreement

On July 11, 2016, we entered into a Common Stock Purchase Warrants Repurchase Agreement (the “Warrants Repurchase Agreement”) with the holders (the “Holders”) of our outstanding common stock purchase warrants issued in October 2012, March 2013, May 2013, June 2013, June 2014, February 2015 and April 2015 (collectively, the “Warrants”) in connection with our Series A, Series B, Series C and Series E financings. Pursuant to the terms of the Warrants Repurchase Agreement, we have agreed to repurchase such Warrants from each Holder upon execution of a “Fundamental Transaction” (as defined in such Warrants) at various negotiated prices per Warrant share as set forth in the Warrants Repurchase Agreement. Under the terms of the Warrants Repurchase Agreement, we will repurchase half of such Warrants upon the announcement of a Fundamental Transaction and the remaining half of such Warrants upon the closing of a Fundamental Transaction. In addition, upon the closing of a Fundamental Transaction, all Securities Purchase Agreements and Registration Rights Agreements associated with the original issuances of such Warrants will be terminated and the various restrictions set forth therein will no longer be of any force or effect. In connection with entering into the Warrants Repurchase Agreement, we were granted certain consents and waivers relating to a Fundamental Transaction. In the event that a Fundamental Transaction is announced and consummated, we will be obligated to repurchase such Warrants for approximately $459,000 of cash consideration paid to the Holders. One half of this amount will be due within three business days of announcing the Fundamental Transaction, and the remaining half will be due within three business days of closing the Fundamental Transaction. In the event that we announce a Fundamental Transaction but never close, for whatever reason, then one-half of such Warrants will be repurchased and cancelled and one-half will remain issued and outstanding. In the event that a Fundamental Transaction is never announced nor consummated, we will not be obligated to repurchase such Warrants, and the underlying terms and conditions of such Warrants will remain in effect.

Warrants

Outstanding warrants to purchase common stock are as follows:

	Shares of Common Stock Issuable from Warrants
	Outstanding as of
	September 30,		December 31,		Exercise
	2016		2015		Price		Expiration
Equity-classified warrants:
March 2016		2,067,183		-	$	5.17	March 2021
April 2015		100,847		100,847	$	16.50	August 2020
April 2015		1,831		1,831	$	32.51	August 2020
February 2015		46,676		46,676	$	16.50	August 2020
June 2014		1,690		1,690	$	30.90	April 2018
December 2013		388,365		388,365	$	46.80	December 2018
June 2013		32,788		32,788	$	29.55	June 2019
May 2013		32,788		32,788	$	29.55	May 2019
March 2013		18,334		18,334	$	29.55	March 2019
October 2012		11,252		11,252	$	29.55	September 2018
April 2011		-		8,746	$	321.00	April 2016
Total		2,701,754		643,317

7. COMMITMENTS AND CONTINGENCIES

Executive Severance

We provide certain severance benefits such that if an executive officer of CombiMatrix Corporation is terminated for other than cause, death or disability, the executive will receive payments equal to three months’ base salary plus medical and dental benefits. In addition, we have implemented a Restated Executive Change of Control Severance Plan (as amended, the “Severance Plan”) that affects certain of our senior management-level employees who are classified as “Section 16 Officers” of the Company. Pursuant to the Severance Plan, if a participating employee is involuntarily terminated (other than for death, disability or for cause) or resigns for “good reason” (as defined in the Severance Plan) during the two-year period following a “change of control” (as defined in the Severance Plan) of the Company, then, subject to execution of a release of claims against the Company, the employee will be entitled to receive: (i) one-half times annual base salary (one times annual base salary for the CEO); (ii) immediate vesting of outstanding compensatory equity awards; and (iii) payment of COBRA premiums for the participating employee and eligible dependents for a pre-determined period of time. Payment of benefits under the Severance Plan will be limited by provisions contained in Section 409A of the U.S. Internal Revenue Code. The Severance Plan is administered by a plan administrator, which initially is the Compensation Committee of the Board of Directors. In order to participate in the Severance Plan, an eligible employee must waive any prior retention or severance agreements. The Severance Plan automatically renews annually unless terminated upon 12 months prior written notice.

Also, our Board of Directors has adopted a Transaction Bonus Plan (the “Transaction Bonus Plan”), which provides for certain bonus payments to be made, upon the consummation of a qualifying change of control transaction, to certain employees of the Company as shall be determined by the Compensation Committee of our Board of Directors. The aggregate value of the bonuses payable under the Transaction Bonus Plan shall be the greater of (i) $1,000,000 or (ii) ten percent of the net proceeds received in connection with a qualifying change of control transaction, and the percentage of such bonus pool awarded to each eligible participant shall be determined by our Compensation Committee. As there are no transactions deemed imminent or probable, no amounts have been recognized in the consolidated financial statements relating to these plans.

Litigation

In 2002, we entered into a settlement agreement with Nanogen, Inc. (“Nanogen”) to settle all pending litigation between the parties. Pursuant to the terms of the settlement agreement, we agreed to make quarterly payments to Nanogen equal to 12.5% of total sales of products developed by us and our affiliates based on the patents that had been in dispute in the litigation, up to an annual maximum amount of $1.5 million. The minimum quarterly payments under the settlement agreement are $25,000 per quarter until the patents expire in 2018. Royalty expenses recognized under the agreement were $25,000 and $75,000 for both of the three and nine months ended September 30, 2016 and 2015, respectively, and are included in patent amortization and royalties in the accompanying consolidated statements of operations.

From time to time, we are subject to other claims and legal actions that arise in the ordinary course of business. We believe that the ultimate liability with respect to these claims and legal actions, if any, will not have a material effect on our financial position, results of operations or cash flows. Any legal costs resulting from claims or legal actions are expensed as incurred.

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Cautionary Statement

You should read the following discussion and analysis in conjunction with the consolidated financial statements and related notes thereto contained in Part I, Item 1 of this report. The information contained in this Quarterly Report on Form 10-Q is not a complete description of our businesses or the risks associated with an investment in our common stock. We urge you to carefully review and consider the various disclosures made by us in this report and in our other reports filed with the U.S. Securities and Exchange Commission, or “SEC,” including our Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on February 18, 2016.

This report contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact included in this report, are forward-looking statements. Reference is made in particular to the description of our plans and objectives for future operations, assumptions underlying such plans and objectives, and other forward-looking statements included in this report. Such statements may be identified by the use of forward-looking terminology such as “may,” “will,” “should,” “would,” “could,” “expect,” “believe,” “estimate,” “anticipate,” “intend,” “plan,” “predict,” “seek,” “potential,” “more likely to,” “with a view to,” “our future success depends,” “continue,” “focus,” “ongoing,” or similar terms, variations of such terms or the negative of such terms, and include, but are not limited to, statements regarding projected results of operations, capital expenditures, earnings, management’s future strategic plans, development of new technologies and services, litigation, regulatory matters, market acceptance and performance of our services, the success and effectiveness of our technologies and services, our ability to retain and hire key personnel, the competitive nature of and anticipated growth in our markets, market size, market position of our services, marketing efforts and partnerships, liquidity and capital resources, our accounting estimates, and our assumptions and judgments. Such statements are based on management’s current expectations, estimates and projections about our industry, management’s beliefs, and certain assumptions made by us, all of which are subject to change. These forward looking statements are not guarantees of future results and are subject to a number of risks, uncertainties and assumptions that are difficult to predict and that could cause actual results to differ materially and adversely from those described in the forward-looking statements. The risks and uncertainties referred to above include, but are not limited to, our ability to successfully increase the volume of our existing tests, expand the number of tests offered by our laboratory, increase the number of customers and partners and improve reimbursement for our testing; market acceptance of chromosomal microarray analysis (“CMA”) as a preferred method over karyotyping; the rate of transition to CMA from karyotyping; changes in consumer demand; third-party reimbursement of CMA; our ability to attract and retain a qualified sales force and key technical personnel; our ability to successfully develop and introduce new technologies and services; rapid technological change in our markets; supply availability; our ability to bill and obtain reimbursement for highly specialized tests; the rate of growth of the in vitro fertilization (“IVF”) diagnostic testing market; our ability to comply with regulations to which our business is subject, including changes in coding and reimbursement methods; legislative, regulatory and competitive developments in markets in which we and our subsidiaries operate; our limited market capitalization; our ability to obtain additional financing for working capital on acceptable terms and in a timely manner; future economic conditions; other circumstances affecting anticipated revenues and costs; and other factors as more fully disclosed in our discussion of risk factors in Item 1A of Part II of this report and in the “Risk Factors” described in our Annual Report on Form 10-K for the year ended December 31, 2015 filed with the SEC on February 18, 2016. Additional factors that could cause such results to differ materially from those described in the forward-looking statements are set forth in connection with the forward-looking statements. These forward-looking statements speak only as of the date of this report and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

General

We are a family health-focused clinical molecular diagnostic laboratory specializing in pre-implantation genetic screening, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. We strive to provide best-in-class clinical laboratory support to healthcare professionals, allowing them to maximize the clinical utility of their patients’ test results and to optimize patient care. Our testing focuses on advanced technologies, including single nucleotide polymorphism chromosomal microarray analysis, next generation sequencing, fluorescent in situ hybridization and high resolution karyotyping. Our approach to testing is to offer sophisticated technology along with high quality clinical support to our ordering physicians and their patients. Our laboratory facilities and corporate headquarters are located in Irvine, California.

Overview

For the three and nine months ended September 30, 2016, our operating activities included the recognition of $3.2 million and $9.3 million of total revenues, respectively, which increased by $722,000 and $1.9 million, respectively, from the comparable periods in 2015, due primarily to increased volumes of molecular diagnostic tests performed and improved third-party reimbursement of those tests, particularly in the reproductive health testing market. Our net losses for the three and nine months ended September 30, 2016 decreased over the comparable periods in 2015 due primarily to increased sales, improved gross margins and reduced sales and marketing expenses, partially offset by increased general and administrative expenses for the comparable periods presented. Also for the nine months ended September 30, 2016, our net loss attributable to common stockholders decreased by $729,000 from the comparable period in 2015 due to improved net operating losses, partially offset by increases in deemed dividends recognized from a premium paid to Series E investors as well as from issuing Series F convertible preferred stock with a conversion price below the fair value of our common stock at closing.

Critical Accounting Estimates

Our unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. Preparation of these statements requires management to make judgments and estimates. Some accounting policies have a significant impact on amounts reported in these financial statements. A summary of significant accounting policies and a description of accounting policies that are considered critical may be found in our Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on February 18, 2016, in the Notes to the Consolidated Financial Statements and the Critical Accounting Estimates sections. In addition, refer to Note 2 to the consolidated interim financial statements included in Part I, Item 1 of this report.

Comparison of the Results of Operations for the Three and Nine months Ended September 30, 2016 and 2015

Revenues and Cost of Services (dollars in thousands):

	Three Months Ended											Nine Months Ended
	September 30,						Change					September 30,						Change
	2016			2015			$			%		2016			2015			$			%

Diagnostic services revenues	$	3,211		$	2,481		$	730			29%	$	9,190		$	7,292		$	1,898			26%
Royalty revenues		37			45			(8	)		(18%)		137			112			25			22%
Cost of services		(1,476	)		(1,400	)		(76	)		(5%)		(4,327	)		(4,028	)		(299	)		(7%)

Diagnostic Services Revenues. Diagnostic services revenues are generated from providing DNA-based genomic testing services primarily in the areas of pre-implantation genetic screening (or “PGS”), pre-implantation genetic diagnostics (or “PGD”), miscarriage analysis, prenatal diagnostics (collectively referred to as “reproductive health” testing) and postnatal development disorders in children. The key drivers and metrics relating to the change in diagnostic services revenues were as follows:

	Three Months Ended								Nine Months Ended
	September 30,				Change				September 30,				Change
	2016		2015		#		%		2016		2015		#		%

Total billable tests		2,835		2,495		340		14%		8,263		7,439		824		11%
Total reproductive health tests(1)		1,483		1,265		218		17%		4,312		3,757		555		15%
Reproductive health percentage of total billable tests		52.3%		50.7%						52.2%		50.5%

Revenue per test - total billable tests	$	1,133	$	994	$	139		14%	$	1,112	$	980	$	132		13%
Revenue per test - total reproductive health tests(1)	$	1,562	$	1,314	$	248		19%	$	1,545	$	1,296	$	249		19%

(1) includes PGS, PGD, prenatal and miscarriage analysis microarray tests.

For the three months ended September 30, 2016, total billable tests and total diagnostic services revenues increased by 14% and 29%, respectively, compared to the three months ended September 30, 2015. For the nine months ended September 30, 2016, total billable tests and total diagnostic services revenues increased by 11% and 26%, respectively, compared to the nine months ended September 30, 2015. Driving the increase in total billable tests and diagnostic service revenues for all periods presented were the increases in reproductive health testing volumes, which increased by 17% and 15% for the three and nine months ended September 30, 2016 compared to the 2015 periods, respectively. We believe this reflects the commercialization strategies and focus of our sales force, which have emphasized reproductive health diagnostic testing over traditional testing. In addition, improved reimbursement from third-party payors primarily for our miscarriage analysis microarray test drove higher revenues per test in our reproductive health segment, thereby resulting in a higher percentage increase in total diagnostic services revenues compared to the increase in billable testing volumes.

Diagnostic services revenues are recognized based on: i) contractual rates billed to our customers and third party payors; and ii) amounts that we expect to collect from non-contracted third-party payors, which include adjustments for changes in estimates of contractual allowances as well as from receiving cash payments in excess of amounts previously recognized. Because approximately 71% of our diagnostic revenues are billed to third-party payors, most of which are non-contracted, it is likely that we will be required to make adjustments to these accounting estimates in the future, which may positively or adversely affect our revenues and results of operations.

Royalties. In 2010, we entered into an exclusive licensing agreement with CustomArray, Inc. (“CA”), a private company located in Washington State, to license certain patents and intellectual property developed as part of our prior microarray manufacturing business. This agreement requires CA to pay us royalties as a percentage of their gross revenues, not less than $25,000 per quarter. The changes in royalty revenues reported reflect changes in CA’s revenues. It is uncertain whether in future periods, CA’s revenues will increase or continue at the minimum contractual amounts.

Cost of Services. Cost of services relating to our diagnostic tests performed include direct materials such as microarray slides, reagents and related laboratory materials, direct laboratory labor (wages and benefits), allocation of administrative overhead and stock-compensation expenses. Increases in cost of services for all periods presented were due primarily to increased diagnostic testing volumes described above. For the three and nine months ended September 30, 2016 and 2015, non-cash stock compensation expenses were not significant.

Operating Expenses (dollars in thousands):

	Three Months Ended									Nine Months Ended
	September 30,				Change					September 30,				Change
	2016		2015		$			%		2016		2015		$			%

Research and development	$	88	$	133	$	(45	)		(34%)	$	380	$	352	$	28			8%
Sales and marketing		1,055		1,295		(240	)		(19%)		3,532		3,658		(126	)		(3%)
General and administrative		1,450		1,249		201			16%		4,562		4,212		350			8%
Impairment of cost-basis investment		-		97		(97	)		(100%)		-		97		(97	)		(100%)

Research and Development. These expenses include labor (wages and benefits), non-cash stock compensation expenses and laboratory supply costs associated with investigating and validating new tests and technology platforms, costs to maintain and improve our existing suite of diagnostic tests offered and process improvement projects. Prior to launching a new test or technology, or modifying an existing test, appropriate clinical trials and extensive laboratory validations, consistent with the various regulations that govern our industry, must be performed. These costs are classified as research and development for all periods presented. For the three months ended September 30, 2016, research and development expenses decreased from the comparable 2015 period due primarily to increased efforts in launching a new microarray platform for our miscarriage analysis test during 2015 that did not repeat during 2016. For the nine months ended September 30, 2016, research and development expenses increased from the comparable 2015 period due primarily to increased efforts during 2016 in launching a next generation sequencing platform for our PGS testing services.

Sales and Marketing. These expenses include salaries and wages associated with our sales force and marketing resources, sales commissions and other expenses associated with promotional and advertising efforts as well as non-cash stock compensation expenses. For the three and nine months ended September 30, 2016, sales and marketing expenses decreased from the comparable 2015 periods due primarily to reduced headcount in sales representatives and reduced travel and entertainment costs from fewer sales headcount compared to the 2015 period. For the three and nine months ended September 30, 2016 and 2015, non-cash stock compensation expenses were not significant.

General and Administrative. These expenses include compensation and benefit costs of our administrative staff, client billing and collections, information technology, executive management, human resources and accounting personnel, as well as facilities-related costs, insurance, legal, audit and other professional services. For the three and nine months ended September 30, 2016, general and administrative expenses increased from the comparable 2015 periods due primarily to increased salaries and bad debt expense, investor relations and consulting expenses, partially offset by decreased legal fees as a result of litigation which concluded in 2015. Also included in general and administrative expenses are non-cash stock-based compensation expenses, which were $153,000, $494,000, $147,000 and $452,000 for the three and nine months ended September 30, 2016 and 2015, respectively. Changes to stock-based compensation expenses are driven by timing of when option awards are granted compared to when older awards become fully vested or expire due to forfeitures from employee turnover, as well as by the changes to valuations attributed to individual awards at the time they are granted. See Note 2 to our consolidated interim financial statements included elsewhere in this report for a detailed description of the amounts of non-cash stock compensation expense recognized for the periods presented.

Impairment of cost-basis investment. During the third quarter of 2015, management determined that the carrying value of a cost-basis investment in the stock of a privately held company was impaired, resulting in a one-time, non-cash impairment charge of $97,000 for the three and nine months ended September 30, 2015. There were no such charges in the 2016 comparable periods in 2016.

Inflation

Inflation has not had a significant impact on our business, results of operations or financial condition.

Liquidity and Capital Resources

At September 30, 2016, cash, cash equivalents and short-term investments totaled $4.3 million, compared to $3.9 million at December 31, 2015. Cash is held primarily in general checking accounts as well as in money market mutual funds backed by U.S. government securities. Short-term investments are comprised primarily of commercial paper issued by U.S. financial institutions. Working capital was $6.5 million and $5.4 million at September 30, 2016 and December 31, 2015, respectively. The primary reason for the increase in working capital was due to higher cash balances at September 30, 2016 compared to December 31, 2015, driven by operating, investing and financing activities described below.

The net change in cash and cash equivalents for the periods presented was comprised of the following (in thousands):

	Nine Months Ended
	September 30,
	2016			2015			Change
Net cash provided by (used in):
Operating activities	$	(3,361	)	$	(4,171	)	$	810
Investing activities		3,102			164			2,938
Financing activities		3,951			4,545			(594	)
Increase (decrease) in cash and cash equivalents	$	3,692		$	538		$	3,154

Operating Activities. Improved cash reimbursement, partially offset by higher laboratory supply costs from increased testing volumes during the nine months ended September 30, 2016 resulted in lower overall cash used in operating activities compared to the nine months ended September 30, 2015.

Investing Activities. Cash flows from investing activities relate primarily to the sales of short-term investments to fund operations, which increased in 2016 compared to 2015.

Financing Activities. The net decrease in net cash flows from financing activities was due primarily to the $6.9 million of net proceeds received in March 2016 from the Series F Financing, partially offset by the combined $2.8 million of payments made to the Series E investors, compared to $4.7 million in net proceeds from the Series E financing that closed in February of 2015.

Future Liquidity. We have a history of incurring net losses and net operating cash flow deficits. We are also deploying new technologies and continue to develop commercial technologies and services. However, we believe that our cash, cash equivalents and short-term investment balances at September 30, 2016 will be sufficient to meet our expected cash requirements for the next twelve months. In order for us to continue as a going concern beyond this point and ultimately to achieve profitability, we may be required to obtain capital from external sources, increase revenues and reduce operating costs. However, there can be no assurance that our operations will become profitable or that external sources of financing, including the issuance of debt and/or equity securities, will be available at times and at terms acceptable to us, or at all. The issuance of additional equity or convertible debt securities will also cause dilution to our stockholders. If external financing sources are not available or are inadequate to fund our operations, we will be required to reduce operating costs, including research projects and personnel, which could jeopardize our future strategic initiatives and business plans. See Note 1 to the consolidated financial statements included elsewhere in this report for additional discussion of these matters.

Capital Requirements. We may also encounter unforeseen difficulties that may deplete our capital resources more rapidly than anticipated. As a result, we may be required to seek additional funding through equity, debt or other external financing, and there can be no assurance that additional funding will be available on favorable terms, in a timely fashion or at all. At this time, we have no significant commitments for capital expenditures in 2016 or beyond. However, our long-term capital requirements could be substantial and the adequacy of available funds will depend upon many factors, including:

	●	the costs of commercialization activities, including sales and marketing costs and capital equipment;

	●	competing technological developments;

	●	the creation and formation of strategic partnerships;

	●	variability in third-party reimbursement for our diagnostic tests;

	●	the costs associated with leasing and improving our Irvine, California facility; and

	●	other factors that may not be within our control.

Off-Balance Sheet Arrangements

As of September 30, 2016, we did not have any significant off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of Regulation S-K promulgated by the SEC. We have entered into an operating lease for our laboratory space and corporate offices, totaling approximately 12,200 square feet, expiring in early 2020. We have no significant commitments for capital expenditures for the remainder of 2016 or beyond. We currently have ten active capital leases totaling $254,000 for certain laboratory and IT-related equipment, with lease payments continuing through July of 2019.

Recent Accounting Pronouncements

See Note 2 to the consolidated interim financial statements located elsewhere in this report for a discussion on recent accounting pronouncements.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not required for smaller reporting companies.

Item 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based on this evaluation, our principal executive officer and our principal financial officer concluded that as of September 30, 2016, our disclosure controls and procedures were effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods prescribed by the SEC and (ii) accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during our last fiscal quarter (the quarter ended September 30, 2016) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

Item 1. LEGAL PROCEEDINGS

From time to time, we are involved in other litigation arising in the normal course of business. Management believes that resolution of these other matters will not result in any payment that, in the aggregate, would be material to our financial position or results of operations.

Item 1A. RISK FACTORS

The following risk factors include any and all material changes to, and should be read in conjunction with, the risk factors contained in Part 1, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, filed with the SEC on February 18, 2016.

We have a history of losses and expect to incur additional losses in the future.

We have sustained substantial losses since our inception. We may never become profitable, or if we do, we may not be able to sustain profitability. We expect to incur significant research and development, marketing, general and administrative expenses. As a result, we expect to incur losses for the foreseeable future.

To date, we have relied primarily upon selling equity and convertible debt and equity securities to generate the funds needed to finance the implementation of our business strategies. We cannot assure you that we will not encounter unforeseen difficulties, including the outside influences identified below that may deplete our capital resources more rapidly than anticipated. We may be required to obtain additional financing through bank borrowings, debt or equity financings or otherwise, which would require us to make additional investments or face a dilution of our equity interests. We cannot be sure that additional funding will be available on favorable terms, if at all. In order to issue securities at a price below the exercise prices of our outstanding warrants issued in connection with our past preferred stock private placement financings, we must obtain the affirmative consent of holders of at least 67% of each series of such outstanding warrants. If we are unable to obtain the consent of these holders in connection with future financings, we may be unable to raise additional capital on acceptable terms, or at all. If external financing sources are not available in a timely manner or at all, or are inadequate to fund our operations, it could result in reduced revenues and cash flows from the sales of our diagnostic services and/or could jeopardize our ability to launch, market and sell additional products and services necessary to grow and sustain our operations. If we fail to obtain additional funding when needed, we may not be able to execute our business plans or continue operations, and our business may be materially adversely affected.

We began commercialization of our molecular diagnostics services in 2006. Accordingly, we have a limited operating history of generating revenues from services. In addition, we are still developing our technologies and service offerings and are subject to the risks, expenses and difficulties frequently encountered by companies with such limited operating histories. Since we have a limited operating history, we cannot assure you that our operations will become profitable or that we will generate sufficient revenues to meet our expenditures and support our activities.

As a public company, we are subject to complex legal and accounting requirements that will require us to incur substantial expense and will expose us to risk of non-compliance.

As a public company, we are subject to numerous legal and accounting requirements that do not apply to private companies. The cost of compliance with many of these requirements is substantial, not only in absolute terms but, more importantly, in relation to the overall scope of the operations of a small company. Failure to comply with these requirements can have numerous material adverse consequences including, but not limited to, our inability to file required periodic reports on a timely basis, which would result in the loss of our eligibility to use Form S-3 for raising capital, loss of market confidence, delisting of our securities, governmental or private actions against us and/or liquidated damages payable to the holders of our Series A Warrants, Series C Warrants, our April 2015 private placement warrants, and our Series F Preferred Stock and Series F Warrants. We cannot assure you that we will be able to comply with all of these requirements or that the cost of such compliance will not prove to be a substantial competitive disadvantage compared to our privately held and larger public competitors.

Future sales or the potential for future sales of our securities in the public markets may cause the trading price of our common stock to decline and could impair our ability to raise capital through subsequent equity offerings.

Sales of a substantial number of shares of our common stock or other securities in the public markets, or the perception that these sales may occur, could cause the market price of our common stock or other securities to decline and could materially impair our ability to raise capital through the sale of additional securities. The shares of common stock issuable upon conversion of our Series F preferred stock and upon exercise of our outstanding warrants are freely tradable, without restriction, in the public market. We have obligations to the investors in our 2012 private placement offering of Series A convertible preferred stock and warrants to purchase common stock and in our 2013 private placement offering of Series C convertible preferred stock and warrants to maintain the public registration of common stock underlying their issued and outstanding warrants. If we raise additional capital in the future through the use of our existing shelf registration statement or if we register existing, or agree to register future, privately placed shares for resale on a registration statement, such additional shares would be freely tradable, and, if significant in amount, such sales could further adversely affect the market price of our common stock. The sale of a large number of shares of our common stock also might make it more difficult for us to sell equity or equity-related securities in the future at a time and at the prices that we deem appropriate.

Our stock price could decline because of the potentially dilutive effect of future financings, the Series F preferred stock anti-dilution provision or exercises of warrants and common stock options.

As of September 30, 2016, we had approximately 2.5 million shares of common stock issued and outstanding. Assuming exercise in full of all options, warrants and convertible securities outstanding as of September 30, 2016 (not taking into account any price-based or anti-dilution adjustments related to the Series F preferred stock), approximately 5.8 million shares of our common stock would be outstanding. Any additional equity or convertible debt financings in the future could result in further dilution to our stockholders. Existing stockholders also will suffer significant dilution in ownership interests and voting rights and our stock price could decline as a result of potential future application of anti-dilution feature of our Series F preferred stock.

Our capital structure and the significant influence over stockholder voting matters that may be exercised by our 5% or greater stockholders may limit your ability to influence corporate actions and could reduce the amount of consideration paid to common stockholders in the event of a change in control.

As of December 31, 2015, our 5% or greater stockholders collectively have voting power over approximately 38% of our outstanding common stock. As a result, our 5% or greater stockholders, acting together, may be able to influence matters requiring stockholder approval, including the election of directors, management changes and approval of significant corporate transactions. This concentration of voting power may have the effect of delaying, preventing or deterring a change in control, could reduce the amount of consideration paid to our common stockholders as part of a change in control and might reduce the market price of our common stock. In addition, although we entered into the Warrants Repurchase Agreement to repurchase, upon the occurrence of a Fundamental Transaction, the Warrants that were issued in connection with our Series A, Series B, Series C and Series E financings, such Warrants Repurchase Agreement does not cover the warrants that were issued in connection with our Series F financing (the “Series F Warrants”) or the Series F Preferred Stock. Depending on the circumstances, upon a change in control constituting a Fundamental Transaction, the holders of Series F Preferred Stock may be entitled to a 30% premium and the holders of Series F Warrants may have the right to require us to purchase the Series F Warrants for an amount in cash that is determined in accordance with a formula set forth in the Series F Warrant. Such provisions could reduce the amount of consideration paid to common stockholders in the event of a change in control by reducing the amount of proceeds available for common stockholders.

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

Item 3. DEFAULTS UPON SENIOR SECURITIES

None.

Item 4. MINE SAFETY DISCLOSURES

Not applicable.

Item 5. OTHER INFORMATION

None.

Item 6. EXHIBITS

An index of exhibits is found on page 25 of this report.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	COMBIMATRIX CORPORATION

	By:	/s/ MARK MCDONOUGH
		Mark McDonough
		Chief Executive Officer
		(Principal Executive Officer)

	By:	/s/ SCOTT R. BURELL
		Scott R. Burell
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

Date: November 7, 2016

EXHIBIT INDEX

Exhibit Number		Description

3.1		Amended and Restated Certificate of Incorporation. Incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form S-1 (SEC File No. 333-139679) filed with the SEC on December 26, 2006.

3.2		Certificate of Amendment to Amended and Restated Certificate of Incorporation. Incorporated by reference to Exhibit 3.1A to the Company’s Quarterly Report on Form 10-Q (File No. 001-33523) filed with the SEC on August 14, 2008.

3.3		Certificate of Amendment to Amended and Restated Certificate of Incorporation. Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-33523) filed with the SEC on December 4, 2012.

3.4		Certificate of Designation of Preferences, Rights and Limitations of Series A 6% Convertible Preferred Stock. Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-33523) filed with the SEC on October 1, 2012.

3.5		Certificate of Designation of Preferences, Rights and Limitations of Series B 6% Convertible Preferred Stock. Incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K (File No. 001-33523) filed with the SEC on March 20, 2013.

3.6		Certificate of Designation of Preferences, Rights and Limitations of Series C 6% Convertible Preferred Stock. Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-33523) filed with the SEC on May 6, 2013.

3.7		Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock. Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-33523) filed with the SEC on December 23, 2013.

3.8		Certificate of Designation of Preferences, Rights and Limitations of Series E 6% Convertible Preferred Stock. Incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K (File No. 001-33523) filed with the SEC on February 13, 2015.

3.9		Certificate of Amendment to Amended and Restated Certificate of Incorporation. Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-33523) filed with the SEC on April 29, 2015.

3.10		Certificate of Amendment to Amended and Restated Certificate of Incorporation. Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-33523) filed with the SEC on January 29, 2016.

3.11		Certificate of Designation of Preferences, Rights and Limitations of Series F Convertible Preferred Stock. Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-33523) filed with the SEC on March 24, 2016.

3.12		Second Amended and Restated Bylaws. Incorporated by reference to Exhibit 3.2 to the Company’s Annual Report on Form 10-K (File No. 001-33523) filed with the SEC on March 18, 2010.

10.1		Form of Common Stock Purchase Warrants Repurchase Agreement. Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-33523) filed with the SEC on July 11, 2016.

31.1		Certification of Chief Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002 (*)

31.2		Certification of Chief Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002 (*)

32.1		Certification of Chief Executive Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith)

32.2		Certification of Chief Financial Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith)

101.0		The following materials from CombiMatrix Corporation’s Quarterly Report on Form 10-Q for the three and nine month periods ended September 30, 2016, formatted in XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets as of September 30, 2016 and December 31, 2015; (ii) Consolidated Statements of Operations for the three and nine months ended September 30, 2016 and 2015; (iii) Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2016 and 2015; (iv) Consolidated Statements of Cash Flows for the nine months ended September 30, 2016 and 2015; and (v) Notes to Consolidated Financial Statements.(*)

(*) Included herewith.

EX-31.1 2 ex31-1.htm

EXHIBIT 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Mark McDonough, certify that:

	1.	I have reviewed this Quarterly Report on Form 10-Q of CombiMatrix Corporation;

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in the Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 7, 2016	/s/ MARK MCDONOUGH
	Mark McDonough Chief Executive Officer (Principal Executive Officer)

EX-31.2 3 ex31-2.htm

EXHIBIT 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Scott R. Burell, certify that:

	1.	I have reviewed this Quarterly Report on Form 10-Q of CombiMatrix Corporation;

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in the Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 7, 2016	/s/ SCOTT R. BURELL
	Scott R. Burell Chief Financial Officer (Principal Financial and Accounting Officer)

EX-32.1 4 ex32-1.htm

EXHIBIT 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CombiMatrix Corporation (the “Company”) on Form 10-Q for the quarterly period ended September 30, 2016, as filed with the Securities and Exchange Commission (the “Report”), I, Mark McDonough, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	By:	/s/ MARK MCDONOUGH
		Mark McDonough
		Chief Executive Officer
		(Principal Executive Officer)
		November 7, 2016

This certification accompanies this report and is being furnished pursuant to Item 601(b)(32) of Regulation S-K promulgated under the Securities Act of 1933, as amended (the “Securities Act”) and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. This certification shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed “filed” by the Registrant for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, or incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Registrant specifically incorporates it by reference into such a filing.

EX-32.2 5 ex32-2.htm

EXHIBIT 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CombiMatrix Corporation (the “Company”) on Form 10-Q for the quarterly period ended September 30, 2016, as filed with the Securities and Exchange Commission (the “Report”), I, Scott R. Burell, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	By:	/s/ SCOTT R. BURELL
		Scott R. Burell
		Chief Financial Officer
		(Principal Financial and Accounting Officer)
		November 7, 2016

EX-101.INS 6 cbmx-20160930.xml XBRL INSTANCE FILE 0001383183 2016-01-01 2016-09-30 0001383183 2016-11-04 0001383183 2016-09-30 0001383183 2015-12-31 0001383183 us-gaap:SeriesFPreferredStockMember 2016-09-30 0001383183 us-gaap:SeriesFPreferredStockMember 2015-12-31 0001383183 us-gaap:SeriesEPreferredStockMember 2016-09-30 0001383183 us-gaap:SeriesEPreferredStockMember 2015-12-31 0001383183 2015-01-01 2015-09-30 0001383183 2015-09-30 0001383183 2014-12-31 0001383183 us-gaap:MaximumMember 2016-09-30 0001383183 us-gaap:MinimumMember 2016-09-30 0001383183 us-gaap:SalesRevenueNetMember CBMX:NoSingleCustomerMember 2016-01-01 2016-09-30 0001383183 us-gaap:SalesRevenueNetMember CBMX:OneCustomerMember 2015-01-01 2015-09-30 0001383183 us-gaap:AccountsReceivableMember CBMX:CommercialInsuranceOneMember 2016-01-01 2016-09-30 0001383183 us-gaap:AccountsReceivableMember CBMX:CommercialInsuranceOneMember 2015-01-01 2015-12-31 0001383183 us-gaap:AccountsReceivableMember CBMX:CommercialInsuranceOneMember 2016-09-30 0001383183 us-gaap:AccountsReceivableMember CBMX:CommercialInsuranceOneMember 2015-12-31 0001383183 us-gaap:CostOfSalesMember 2016-01-01 2016-09-30 0001383183 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-09-30 0001383183 us-gaap:SellingAndMarketingExpenseMember 2016-01-01 2016-09-30 0001383183 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-09-30 0001383183 us-gaap:CostOfSalesMember 2015-01-01 2015-09-30 0001383183 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-09-30 0001383183 us-gaap:SellingAndMarketingExpenseMember 2015-01-01 2015-09-30 0001383183 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-09-30 0001383183 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-09-30 0001383183 us-gaap:RestrictedStockMember 2016-01-01 2016-09-30 0001383183 CBMX:CommonStockWarrantsMember 2016-01-01 2016-09-30 0001383183 CBMX:SeriesEConvertiblePreferredStockMember 2016-01-01 2016-09-30 0001383183 CBMX:SeriesFConvertiblePreferredStockMember 2016-01-01 2016-09-30 0001383183 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-09-30 0001383183 us-gaap:RestrictedStockMember 2015-01-01 2015-09-30 0001383183 CBMX:CommonStockWarrantsMember 2015-01-01 2015-09-30 0001383183 CBMX:SeriesEConvertiblePreferredStockMember 2015-01-01 2015-09-30 0001383183 CBMX:SeriesFConvertiblePreferredStockMember 2015-01-01 2015-09-30 0001383183 CBMX:CashAndMoneyMarketSecuritiesMember 2016-09-30 0001383183 us-gaap:CommercialPaperMember 2016-09-30 0001383183 us-gaap:CertificatesOfDepositMember 2016-09-30 0001383183 CBMX:CashAndMoneyMarketSecuritiesMember 2015-12-31 0001383183 us-gaap:CommercialPaperMember 2015-12-31 0001383183 us-gaap:CertificatesOfDepositMember 2015-12-31 0001383183 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2015-12-31 0001383183 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2015-12-31 0001383183 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2015-12-31 0001383183 us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0001383183 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2016-09-30 0001383183 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2016-09-30 0001383183 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2016-09-30 0001383183 us-gaap:FairValueMeasurementsRecurringMember 2016-09-30 0001383183 us-gaap:SecuredDebtMember 2014-05-19 2014-05-20 0001383183 us-gaap:SecuredDebtMember 2014-05-20 0001383183 CBMX:SeriesAWarrantsMember us-gaap:MaximumMember 2016-09-30 0001383183 CBMX:SeriesBWarrantsMember 2016-09-30 0001383183 CBMX:SeriesCWarrantsMember 2016-09-30 0001383183 CBMX:SeriesEPurchaseAgreementMember 2015-02-11 2015-02-13 0001383183 CBMX:SeriesEPurchaseAgreementMember 2015-02-13 0001383183 CBMX:SeriesEPurchaseAgreementMember CBMX:SeriesESixPercentConvertiblePreferredStockMember 2015-02-11 2015-02-13 0001383183 CBMX:SeriesEWarrantMember CBMX:SeriesEPurchaseAgreementMember us-gaap:CommonStockMember 2015-02-13 0001383183 CBMX:WarrantPurchaseAgreementMember CBMX:ModificationOfCertainOutstandingWarrantsMember us-gaap:PrivatePlacementMember 2015-02-13 0001383183 CBMX:SeriesEPurchaseAgreementMember CBMX:FixedCombinationMember 2015-02-13 0001383183 CBMX:SeriesEPurchaseAgreementMember CBMX:SeriesESixPercentConvertiblePreferredStockMember us-gaap:CommonStockMember 2015-02-13 0001383183 CBMX:SeriesEPurchaseAgreementMember CBMX:SeriesESixPercentConvertiblePreferredStockMember 2015-02-17 2015-02-18 0001383183 CBMX:SeriesESixPercentConvertiblePreferredStockMember 2015-02-17 2015-02-18 0001383183 CBMX:WarrantPurchaseAgreementMember CBMX:PrivatePlacementInvestorsMember us-gaap:CommonStockMember 2015-02-13 0001383183 CBMX:WarrantPurchaseAgreementMember CBMX:PrivatePlacementInvestorsMember 2015-02-10 2015-02-13 0001383183 CBMX:WarrantPurchaseAgreementMember us-gaap:PrivatePlacementMember 2015-02-13 0001383183 CBMX:WarrantPurchaseAgreementMember us-gaap:PrivatePlacementMember 2016-01-01 2016-09-30 0001383183 us-gaap:PrivatePlacementMember 2016-09-30 0001383183 CBMX:ModificationOfCertainOtherOutstandingWarrantsMember 2016-01-01 2016-09-30 0001383183 CBMX:ModificationOfCertainOtherOutstandingWarrantsMember 2016-09-30 0001383183 CBMX:SeriesEModificationsMember us-gaap:PrivatePlacementMember 2015-10-12 0001383183 CBMX:WarrantPurchaseAgreementMember us-gaap:PrivatePlacementMember 2015-10-12 0001383183 us-gaap:PrivatePlacementMember 2015-10-12 0001383183 CBMX:WarrantsAmendmentMember 2015-10-11 2015-10-12 0001383183 CBMX:SeriesCConvertiblePreferredStockMember 2016-02-03 2016-02-04 0001383183 CBMX:SeriesCConvertiblePreferredStockMember 2016-02-04 0001383183 CBMX:SeriesEInvestorsMember 2016-02-03 2016-02-04 0001383183 CBMX:SeriesFOfferingMember 2016-03-23 2016-03-24 0001383183 CBMX:SeriesFOfferingMember 2016-03-24 0001383183 CBMX:SeriesFConvertiblePreferredStockAndWarrantsFinancingMember 2016-03-24 0001383183 us-gaap:SeriesFPreferredStockMember 2016-03-24 0001383183 us-gaap:SeriesFPreferredStockMember us-gaap:MaximumMember 2016-03-24 0001383183 us-gaap:SeriesFPreferredStockMember 2016-03-23 2016-03-24 0001383183 CBMX:SeriesFOfferingMember 2016-09-30 0001383183 CBMX:SeriesFOfferingMember 2016-01-01 2016-09-30 0001383183 CBMX:SeriesFOfferingMember us-gaap:SeriesFPreferredStockMember 2016-09-30 0001383183 CBMX:SeriesFOfferingMember us-gaap:CommonStockMember 2016-09-30 0001383183 us-gaap:SeriesFPreferredStockMember 2016-09-30 0001383183 us-gaap:SeriesFPreferredStockMember 2016-01-01 2016-09-30 0001383183 CBMX:MarchTwoThousandSixteenMember 2016-09-30 0001383183 CBMX:MarchTwoThousandSixteenMember 2015-12-31 0001383183 CBMX:AprilTwoThousandFifteenMember 2016-09-30 0001383183 CBMX:AprilTwoThousandFifteenMember 2015-12-31 0001383183 CBMX:AprilTwoThousandFifteenOneMember 2016-09-30 0001383183 CBMX:AprilTwoThousandFifteenOneMember 2015-12-31 0001383183 CBMX:FebruaryTwoThousandFifteenMember 2016-09-30 0001383183 CBMX:FebruaryTwoThousandFifteenMember 2015-12-31 0001383183 CBMX:JuneTwoThousandFourteenMember 2016-09-30 0001383183 CBMX:JuneTwoThousandFourteenMember 2015-12-31 0001383183 CBMX:DecemberTwoThousandThirteenMember 2016-09-30 0001383183 CBMX:DecemberTwoThousandThirteenMember 2015-12-31 0001383183 CBMX:JuneTwoThousandThirteenMember 2016-09-30 0001383183 CBMX:JuneTwoThousandThirteenMember 2015-12-31 0001383183 CBMX:MayTwoThousandThirteenMember 2016-09-30 0001383183 CBMX:MayTwoThousandThirteenMember 2015-12-31 0001383183 CBMX:MarchTwoThousandThirteenMember 2016-09-30 0001383183 CBMX:MarchTwoThousandThirteenMember 2015-12-31 0001383183 CBMX:OctoberTwoThousandTwelveMember 2016-09-30 0001383183 CBMX:OctoberTwoThousandTwelveMember 2015-12-31 0001383183 CBMX:AprilTwoThousandElevenMember 2016-09-30 0001383183 CBMX:AprilTwoThousandElevenMember 2015-12-31 0001383183 CBMX:MarchTwoThousandSixteenMember 2016-01-01 2016-09-30 0001383183 CBMX:AprilTwoThousandFifteenMember 2016-01-01 2016-09-30 0001383183 CBMX:AprilTwoThousandFifteenOneMember 2016-01-01 2016-09-30 0001383183 CBMX:FebruaryTwoThousandFifteenMember 2016-01-01 2016-09-30 0001383183 CBMX:JuneTwoThousandFourteenMember 2016-01-01 2016-09-30 0001383183 CBMX:DecemberTwoThousandThirteenMember 2016-01-01 2016-09-30 0001383183 CBMX:JuneTwoThousandThirteenMember 2016-01-01 2016-09-30 0001383183 CBMX:MayTwoThousandThirteenMember 2016-01-01 2016-09-30 0001383183 CBMX:MarchTwoThousandThirteenMember 2016-01-01 2016-09-30 0001383183 CBMX:OctoberTwoThousandTwelveMember 2016-01-01 2016-09-30 0001383183 CBMX:AprilTwoThousandElevenMember 2016-01-01 2016-09-30 0001383183 CBMX:TransactionBonusPlanMember 2016-09-30 0001383183 CBMX:LitigationMember CBMX:SettlementAgreementMember 2002-12-31 0001383183 CBMX:LitigationMember CBMX:SettlementAgreementMember 2016-01-01 2016-09-30 0001383183 CBMX:LitigationMember CBMX:SettlementAgreementMember 2015-01-01 2015-09-30 0001383183 CBMX:LitigationMember CBMX:SettlementAgreementMember 2002-01-01 2002-12-31 0001383183 us-gaap:PrivatePlacementMember 2016-01-01 2016-09-30 0001383183 CBMX:SeriesFConvertiblePreferredStockAndWarrantsFinancingMember 2016-03-23 2016-03-24 0001383183 2016-07-01 2016-09-30 0001383183 2015-07-01 2015-09-30 0001383183 us-gaap:CostOfSalesMember 2016-07-01 2016-09-30 0001383183 us-gaap:ResearchAndDevelopmentExpenseMember 2016-07-01 2016-09-30 0001383183 us-gaap:SellingAndMarketingExpenseMember 2016-07-01 2016-09-30 0001383183 us-gaap:GeneralAndAdministrativeExpenseMember 2016-07-01 2016-09-30 0001383183 us-gaap:CostOfSalesMember 2015-07-01 2015-09-30 0001383183 us-gaap:ResearchAndDevelopmentExpenseMember 2015-07-01 2015-09-30 0001383183 us-gaap:SellingAndMarketingExpenseMember 2015-07-01 2015-09-30 0001383183 us-gaap:GeneralAndAdministrativeExpenseMember 2015-07-01 2015-09-30 0001383183 us-gaap:EmployeeStockOptionMember 2016-07-01 2016-09-30 0001383183 us-gaap:RestrictedStockMember 2016-07-01 2016-09-30 0001383183 CBMX:CommonStockWarrantsMember 2016-07-01 2016-09-30 0001383183 CBMX:SeriesEConvertiblePreferredStockMember 2016-07-01 2016-09-30 0001383183 CBMX:SeriesFConvertiblePreferredStockMember 2016-07-01 2016-09-30 0001383183 us-gaap:EmployeeStockOptionMember 2015-07-01 2015-09-30 0001383183 us-gaap:RestrictedStockMember 2015-07-01 2015-09-30 0001383183 CBMX:CommonStockWarrantsMember 2015-07-01 2015-09-30 0001383183 CBMX:SeriesEConvertiblePreferredStockMember 2015-07-01 2015-09-30 0001383183 CBMX:SeriesFConvertiblePreferredStockMember 2015-07-01 2015-09-30 0001383183 CBMX:LitigationMember CBMX:SettlementAgreementMember 2016-07-01 2016-09-30 0001383183 CBMX:LitigationMember CBMX:SettlementAgreementMember 2015-07-01 2015-09-30 0001383183 CBMX:WarrantRepurchaseAgreementsMember 2016-07-10 2016-07-11 0001383183 CBMX:SeriesEWarrantMember 2015-02-17 2015-02-18 0001383183 CBMX:SeriesFOfferingMember us-gaap:SeriesFPreferredStockMember us-gaap:SubsequentEventMember 2016-09-30 0001383183 CBMX:SeriesFOfferingMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2016-09-30 0001383183 us-gaap:AccountsReceivableMember CBMX:CommercialInsuranceTwoMember 2016-09-30 0001383183 us-gaap:AccountsReceivableMember CBMX:CommercialInsuranceTwoMember 2016-01-01 2016-09-30 0001383183 CBMX:SeriesEWarrantsMember 2016-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure CombiMatrix Corp 0001383183 10-Q 2016-09-30 false --12-31 Smaller Reporting Company Q3 2500629

4345000

653000

3248000

3235000

2682000

459000

418000

169000

200000

8208000

7201000

651000

691000

30000

1623000

1591000

129000

193000

1752000

1784000

49000

71000

34000

153000

177000

1954000

2066000

14000

13000

108952000

102651000

-2000

-102031000

-96806000

6935000

5856000

8889000

7922000

244000

235000

5000000

8000

2202

1690

2201.493

1690

2201.493

0.001

50000000

2487450

845374

2487450

845374

9190000

7292000

3211000

2481000

137000

112000

37000

45000

9327000

7404000

3248000

2526000

4327000

4028000

1476000

1400000

380000

352000

88000

133000

3532000

3658000

1055000

1295000

4562000

4212000

1450000

1249000

75000

25000

12876000

12422000

4094000

4199000

-3549000

-5018000

-846000

-1673000

-33000

-46000

-10000

-14000

-3582000

-5064000

-856000

-1687000

-656000

890000

-890000

-1877000

-5225000

-5954000

-856000

-1687000

-2.38

-6.13

-0.38

-2.00

-1.25

2000

4000

-3580000

-5060000

-856000

-1687000

195000

227000

591000

519000

302000

218000

855000

455000

35000

153000

23000

440000

-3361000

-4171000

148000

66000

3102000

164000

8000000

4900000

1064000

-2842000 4900000 -220000

143000

135000

3951000

4545000

3692000

538000

4345000

653000

1548000

1010000

-890000

890000

1877000 9000 336000 164000

23000

72000

7. COMMITMENTS AND CONTINGENCIES   Executive Severance   We provide certain severance benefits such that if an executive officer of CombiMatrix Corporation is terminated for other than cause, death or disability, the executive will receive payments equal to three months base salary plus medical and dental benefits. In addition, we have implemented a Restated Executive Change of Control Severance Plan (as amended, the Severance Plan) that affects certain of our senior management-level employees who are classified as Section 16 Officers of the Company. Pursuant to the Severance Plan, if a participating employee is involuntarily terminated (other than for death, disability or for cause) or resigns for good reason (as defined in the Severance Plan) during the two-year period following a change of control (as defined in the Severance Plan) of the Company, then, subject to execution of a release of claims against the Company, the employee will be entitled to receive: (i) one-half times annual base salary (one times annual base salary for the CEO); (ii) immediate vesting of outstanding compensatory equity awards; and (iii) payment of COBRA premiums for the participating employee and eligible dependents for a pre-determined period of time. Payment of benefits under the Severance Plan will be limited by provisions contained in Section 409A of the U.S. Internal Revenue Code. The Severance Plan is administered by a plan administrator, which initially is the Compensation Committee of the Board of Directors. In order to participate in the Severance Plan, an eligible employee must waive any prior retention or severance agreements. The Severance Plan automatically renews annually unless terminated upon 12 months prior written notice.   Also, our Board of Directors has adopted a Transaction Bonus Plan (the Transaction Bonus Plan), which provides for certain bonus payments to be made, upon the consummation of a qualifying change of control transaction, to certain employees of the Company as shall be determined by the Compensation Committee of our Board of Directors. The aggregate value of the bonuses payable under the Transaction Bonus Plan shall be the greater of (i) $1,000,000 or (ii) ten percent of the net proceeds received in connection with a qualifying change of control transaction, and the percentage of such bonus pool awarded to each eligible participant shall be determined by our Compensation Committee. As there are no transactions deemed imminent or probable, no amounts have been recognized in the consolidated financial statements relating to these plans.   Litigation   In 2002, we entered into a settlement agreement with Nanogen, Inc. (Nanogen) to settle all pending litigation between the parties. Pursuant to the terms of the settlement agreement, we agreed to make quarterly payments to Nanogen equal to 12.5% of total sales of products developed by us and our affiliates based on the patents that had been in dispute in the litigation, up to an annual maximum amount of $1.5 million. The minimum quarterly payments under the settlement agreement are $25,000 per quarter until the patents expire in 2018. Royalty expenses recognized under the agreement were $25,000 and $75,000 for both of the three and nine months ended September 30, 2016 and 2015, respectively, and are included in patent amortization and royalties in the accompanying consolidated statements of operations.   From time to time, we are subject to other claims and legal actions that arise in the ordinary course of business. We believe that the ultimate liability with respect to these claims and legal actions, if any, will not have a material effect on our financial position, results of operations or cash flows. Any legal costs resulting from claims or legal actions are expensed as incurred.

4300000

99000

3248000

3347000

3033000

0.10

418000

316000

346000

591000

519000

34000

63000

494000

21000

46000

452000

186000

173000

14000

19000

153000

11000

15000

147000

3264103

835954

66687

59000

2701754

436662

70028

38800

643260

83866

3264103

835954

66687

59000

2701754

436662

70028

38800

643260

83866

4345000

3903000

4345000

653000

3250000

-2000

4345000

3901000

4345000

653000

3248000

99000

3033000

350000

P36M

0.10

22000

76000

168000

4000

10000

72000

158000

-72000

-124000

34000

73.65

26.25

1000

0.075

29.55

32.505

29.55

16.50

32.505

5.17

16.50

32.51

16.50

30.90

46.80

29.55

321.00

32.51

102800

2201.493

8000

0.06

46676

102678

258.397875

21.1977

83871

1000

2067183

6310

1630521

13179

26.25 3.87 4700000

890000

1900000

1000

1820000

P5Y6M

1.132

0.015

336000

168000

2701754

643317

100847

1831

2067183

100847

1831

46676

1690

388365

32788

18334

11252

8746

300

656000

1000 656000 2200000 0.75

1000

8000000

1060000

200000

The Series F investors have agreed to be subject to a blocker that would prevent each of their respective common stock ownership at any given time from exceeding 4.99% of our outstanding common stock (which may be increased on 61 days’ notice, but not above 9.99%).

P5Y P5Y6M 2021-03-31 2020-08-31 2020-08-31 2020-08-31 2018-04-30 2018-12-31 2019-06-30 2019-05-31 2019-03-31 2018-09-30 2016-04-30 1000000 0.10

25000

75000

25000

75000

0.59

-1.08

-0.44

1502680

825956

2253834

845395

-3.48 -7.21 -0.38 -2.00

19000

13000

7000

5000

52000

59000

17000

19000

8248000

4230000

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   Use of Estimates. The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) in the United States of America requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.   Principles of Consolidation. The accompanying consolidated financial statements include the accounts of the Company and our wholly owned and majority-owned subsidiaries. Investments for which we possess the power to direct or cause the direction of the management and policies, either through majority ownership or other means, are accounted for under the consolidation method. Material intercompany transactions and balances have been eliminated in consolidation. Investments in companies in which we maintain an ownership interest of 20% to 50% or exercise significant influence over operating and financial policies are accounted for under the equity method. The cost method is used where we maintain ownership interests of less than 20% and do not exercise significant influence over the investee.   Revenue Recognition. We recognize revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been performed, (iii) amounts are fixed or determinable and (iv) collectability of amounts is reasonably assured.   Service revenues from providing diagnostic tests are recognized when the testing process is complete and test results are reported to the ordering physician or clinic. These diagnostic services are billed to various payors, including commercial insurance companies, healthcare institutions, government payors including various state Medicaid programs, and individuals. We report revenues from contracted payors based on a contractual rate, or in the case of state Medicaid contracts, published fee schedules for our tests. We report revenues from non-contracted payors based on the amounts expected to be collected. The differences between the amounts billed and the amounts expected to be collected from non-contracted payors are recorded as contractual allowances to arrive at net recognized revenues. The expected revenues from non-contracted payors are based on the historical collection experience of each payor or payor group, as appropriate, and also take into account recent collection trends. In each reporting period, we review our historical collection experience for non-contracted payors and adjust our expected revenues for current and subsequent periods accordingly. We also recognize additional revenue from actual cash payments that exceed amounts initially recognized, in the period the payments are received. Because a substantial portion of our revenues is from non-contracted third-party payors, it is likely that we will be required to make adjustments to accounting estimates with respect to contractual allowances in the future, which may positively or adversely affect our results of operations. In all cases described above, we report revenues net of any applicable statutory taxes collected from customers, as applicable. No single customer exceeded 10% of revenues for the three or nine months ending September 30, 2016, nor for the three months ended September 30, 2015. For the nine months ended September 30, 2015, 10% of our revenues were generated from one customer.   Cash Equivalents and Short-Term Investments. We consider all highly liquid investments purchased with original maturities of three months or less when purchased to be cash equivalents. Short-term investments consist of fixed income investments with maturities between three and 12 months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Companys consolidated balance sheet. Unrealized holding gains and losses are reported within comprehensive loss in the consolidated statements of comprehensive loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations or other observable inputs. If a decline in the fair value of a short-term investment below our cost basis is determined to be other than temporary, such investment is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. To-date, no permanent impairment charges have been realized or recorded.   Fair Value Measurements. We measure fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; line-height: 115%"> </td> <td style="width: 24px; text-align: justify; line-height: 115%">●</td> <td style="width: 48px; text-align: justify; line-height: 115%">Level 1:</td> <td style="text-align: justify; line-height: 115%">Observable market inputs such as quoted prices in active markets;</td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%"> </td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%">●</td> <td style="text-align: justify; line-height: 115%">Level 2: </td> <td style="text-align: justify; line-height: 115%">Observable market inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%"> </td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%">●</td> <td style="text-align: justify; line-height: 115%">Level 3:</td> <td style="text-align: justify; line-height: 115%">Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions.</td></tr> </table>   We classify our cash equivalents within the fair value hierarchy as Level 1 as these assets are valued using quoted prices in active markets for identical assets at the measurement date. We classify short-term investments within the fair value hierarchy as Level 2, primarily utilizing broker quotes in a non-active market for valuation of these investments. Financial instruments that contain valuation inputs that are not readily determinable from active markets or from similar securities trading in active markets, such as derivative financial instruments, are classified within the fair value hierarchy as Level 3.   Impairment of Long-Lived Assets. Long-lived assets and intangible assets are reviewed for potential impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. In the event the sum of the expected undiscounted future cash flows resulting from the use of the asset is less than the carrying amount of the asset, an impairment loss equal to the excess of the assets carrying value over its fair value is recorded. If an asset is determined to be impaired, the loss is measured based on quoted market prices in active markets, if available. If quoted market prices are not available, the estimate of fair value is based on various valuation techniques, including a discounted value of estimated future cash flows.   During the third quarter of 2015, management determined that the carrying value of a cost-basis investment in the stock of a privately held company was impaired, resulting in a one-time, non-cash impairment charge of $97,000 for the three and nine months ended September 30, 2015.   Derivative Financial Instruments. We evaluate financial instruments for freestanding or embedded derivatives. Derivative instruments that do not qualify for permanent equity classification are recorded as liabilities at fair value, with changes in value recognized as other income (expense) in the consolidated statements of operations in the period of change. Derivative liabilities are categorized as either short-term or long-term based upon managements estimates as to when the derivative instrument may be realized or based upon the holders ability to realize the instrument.   Concentration of Credit Risks. Cash and cash equivalents are invested in deposits with certain financial institutions and may, at times, exceed federally insured limits. We have not experienced any significant losses on our deposits of cash and cash equivalents. We do not believe that we are exposed to significant credit risk on cash and cash equivalents or on our short-term investments. As of September 30, 2016, accounts receivable from two commercial insurance carriers of $418,000 and $346,000 exceeded 10% of our total accounts receivable balance. As of December 31, 2015, accounts receivable from one commercial insurance carrier of $316,000 exceeded 10% of our total accounts receivable balance.   Substantially all of the components and raw materials used in providing our testing services, including array slides and reagents, are currently provided to us from a limited number of sources or in some cases from a single source. Although we believe that alternative sources for those components and raw materials are available, any supply interruption in a sole-sourced component or raw material might result in up to a several-month production delay and materially harm our ability to provide testing services until a new source of supply, if any, could be located and qualified.   Accounts Receivable and Allowance for Doubtful Accounts. For our contracted third-party payors, governmental payors or direct-bill customers, accounts receivable are stated at principal amounts and are primarily comprised of amounts contractually due from customers for services performed. For our non-contracted customers, accounts receivable are stated at amounts expected to be collected based on historical collection experience with the third-party payor. The payment realization cycle for certain governmental and commercial insurance payors can be lengthy, involving denial, appeal and adjudication processes, and is subject to periodic adjustments that may be significant. Accounts receivable are periodically written off when identified as uncollectible after appropriate collection efforts have been exhausted. Such write-offs increase the contractual allowances (which reduce revenues) for those accounts in the period of adjustment. Collection of governmental, private health insurer, and client receivables are generally a function of providing complete and correct billing information to the insurers and clients within the filing deadlines required by each payor.   Collection of receivables due from patients and private-pay clients is generally subject to increased credit risk due to credit-worthiness or inability to pay. For these customers, an allowance for doubtful accounts is recorded for estimated uncollectible amounts, and involves significant assumptions and judgments. Specifically, the allowance for doubtful accounts is adjusted periodically and is principally based upon specific identification of past due or disputed accounts. We also review the age of receivables to assess our allowance at each period end. Additions to the allowance for doubtful accounts are charged to bad debt expense as a component of general and administrative expenses in the consolidated statements of operations.   Stock-Based Compensation. The compensation cost for all employee stock-based awards is measured at the grant date, based on the fair value of the award, and is recognized as an expense, on a straight-line basis, over the employees requisite service period (generally the vesting period of the equity award) which is generally four years. The fair value of each stock option award is estimated on the date of grant using a Black-Scholes option valuation model. The fair value of each restricted stock unit (RSU) award is based on the number of shares granted and the closing price of our common stock as reported on NASDAQ on the date of grant. Stock-based compensation expense is recognized only for those awards that are expected to vest using an estimated forfeiture rate. We estimate pre-vesting option forfeitures at the time of grant and reflect the impact of estimated pre-vesting option forfeitures in compensation expense recognized. Stock-based compensation expense for all periods presented attributable to our functional expense categories from stock option and RSU awards vesting during the periods presented were as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="text-align: center; line-height: 115%">Three Months Ended</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="text-align: center; line-height: 115%">Nine Months Ended</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30,</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30,</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%; line-height: 115%">Cost of services</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">14</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">11</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">34</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">21</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Research and development</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Sales and marketing</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">19</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">15</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">63</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">46</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">General and administrative</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">153</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">147</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">494</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">452</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">Total non-cash stock compensation</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">186</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">173</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">591</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">519</td> <td style="line-height: 115%"> </td></tr> </table>   Net Loss Per Share. Basic and diluted net loss per share has been computed by dividing the net loss by the weighted average number of common shares issued and outstanding during the periods presented. Options and warrants to purchase common stock as well as preferred stock convertible into shares of common stock are anti-dilutive and therefore are not included in the determination of the diluted net loss per share. The following table reflects the excluded dilutive securities:     <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="text-align: center; line-height: 115%">Three Months Ended</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="text-align: center; line-height: 115%">Nine Months Ended</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30,</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30,</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%; line-height: 115%">Common stock options</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 12%; text-align: right; line-height: 115%">66,687</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 12%; text-align: right; line-height: 115%">70,028</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 12%; text-align: right; line-height: 115%">66,687</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 12%; text-align: right; line-height: 115%">70,028</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Restricted stock units</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">59,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">38,800</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">59,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">38,800</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Common stock warrants</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2,701,754</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">643,260</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2,701,754</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">643,260</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Series E preferred stock convertible into common stock</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">83,866</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">83,866</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Series F preferred stock convertible into common stock</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">436,662</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">436,662</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Excluded potentially dilutive securities</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,264,103</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">835,954</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,264,103</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">835,954</td> <td style="line-height: 115%"> </td></tr> </table>   Segments. We have determined that we operate in one segment for financial reporting purposes.   Recent Accounting Pronouncements. In August 2016, the Financial Accounting Standards Board (FASB) issued new accounting guidance aimed at reducing the existing diversity in GAAP regarding how certain cash receipts and cash payments are classified in the statement of cash flows. The new guidance is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is also permitted. We do not expect the adoption of this guidance to have a material impact on our consolidated statements of cash flows.   In March 2016, the FASB issued guidance regarding employee share-based payment accounting. The guidance is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification on the statement of cash flows and provides the choice for companies to estimate forfeitures during the vesting period of an award (which is required under current GAAP) or recognize forfeitures at the time an award is cancelled and forfeited. The standard is effective for us on January 1, 2017. We do not expect the adoption of this guidance to have a significant impact on our consolidated financial statements. However, we have elected to change our policy regarding forfeitures to recognize if and when an award is cancelled and forfeited rather than estimating forfeitures up front. We will be required to implement this policy change using the modified retrospective approach, during the first quarter of 2017. We estimate that the impact from implementing this policy change will be to reduce retained earnings and increase additional paid-in capital by approximately $40,000, but we will not know the actual amount until after the fourth quarter of 2016.   In February 2016, the FASB issued guidance regarding leases, which requires lessees to recognize on the balance sheet a right-of-use asset, representing their right to use the underlying asset for the lease term, and a lease liability for all leases with terms greater than 12 months. The guidance also requires qualitative and quantitative disclosures designed to assess the amount, timing and uncertainty of cash flows arising from leases. The guidance requires the use of a modified retrospective transition approach, which includes a number of optional practical expedients that entities may elect to apply. The guidance is effective for us beginning January 1, 2019, and we are currently evaluating the impact that this guidance will have on our consolidated financial statements.   In January 2016, the FASB issued accounting guidance regarding recognition and measurement of financial assets and financial liabilities. This guidance enhances the reporting model for financial instruments, which includes amendments to address aspects of recognition, measurement, presentation and disclosure. The guidance is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those annual periods. We do not expect the adoption of this guidance to have a significant impact on our consolidated financial statements.   In July 2015, the FASB issued accounting guidance regarding simplifying the measurement of inventory. The new guidance applies only to inventory for which cost is determined by methods other than last-in, first-out and the retail inventory method, which includes inventory that is measured using first-in, first-out or average cost. Inventory within the scope of this standard is required to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The new standard will be effective for us on January 1, 2017. We do not expect the adoption of this guidance to have a material impact on our consolidated financial statements.   In August 2014, the FASB issued new guidance requiring management of all entities to evaluate whether there are conditions and events that raise substantial doubt about the entitys ability to continue as a going concern within one year after the financial statements are issued (or available to be issued when applicable). The guidance is effective for fiscal years ending after December 15, 2016 and for annual and interim periods thereafter. While we do not expect the adoption of this guidance to have a material effect on our consolidated financial statements, adoption will increase disclosures in the notes to our consolidated financial statements if management concludes that substantial doubt about our ability to continue as a going concern within twelve months of the date that our consolidated financial statements are issued is present.   In May 2014, the FASB issued new accounting guidance regarding revenue recognition from contracts with customers, which when effective will supersede existing revenue recognition requirements and will eliminate most industry-specific guidance from GAAP. The core principle of the new guidance is to require an entity to recognize as revenue the amount that reflects the consideration to which it expects to be entitled in exchange for goods or services as it transfers control to its customers. The new guidance requires additional qualitative and quantitative disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. An entity can apply the new guidance retrospectively to each prior reporting period presented (i.e., the full retrospective method) or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. As originally issued, the new revenue recognition standard would be effective for us beginning January 1, 2017. However, in 2015, the FASB voted to defer the effective date of the new guidance for one year. We are currently evaluating the appropriate transition method and any further impact of this guidance on our consolidated financial statements and related disclosures.   Reclassifications. Certain prior period amounts have been reclassified to conform to the current period presentation.

3. CASH AND SHORT-TERM INVESTMENTS   As of September 30, 2016, we held $4.3 million in cash, cash equivalents and short-term investments, which are reported at fair value. Cash, cash equivalents and short-term investments consisted of the following as of September 30, 2016 and December 31, 2015 (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">As of September 30, 2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">As of December 31, 2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Unrealized</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Fair</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Unrealized</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Fair</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Cost</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Gains</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Losses</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Value</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Cost</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Gains</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Losses</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Value</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 36%; line-height: 115%">Cash and money market securities</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 5%; text-align: right; line-height: 115%">4,345</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 5%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 5%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 5%; text-align: right; line-height: 115%">4,345</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 5%; text-align: right; line-height: 115%">653</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 5%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 5%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 5%; text-align: right; line-height: 115%">653</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Commercial paper</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Certificates of deposit</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">3,250</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(2</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">3,248</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">4,345</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">4,345</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,903</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(2</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,901</td> <td style="line-height: 115%"> </td></tr> </table>   There were no realized gains or losses for the periods ended September 30, 2016 or 2015.

4. FAIR VALUE MEASUREMENTS   The following table summarizes, for each major category of financial assets measured on a recurring basis, the respective fair value at September 30, 2016 and December 31, 2015 and the classification by level of input within the fair value hierarchy defined above (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Fair Value Measurements</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 115%">September 30, 2016</td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Total</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 1</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 2</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 3</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Assets:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 52%; padding-left: 10pt; line-height: 115%">Cash equivalents</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">3,033</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">3,033</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">Short-term investments</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 20pt; line-height: 115%">Cash equivalents</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,033</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,033</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Fair Value Measurements</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 115%">December 31, 2015</td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Total</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 1</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 2</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 3</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Assets:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 52%; padding-left: 10pt; line-height: 115%">Cash equivalents</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">99</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">99</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">Short-term investments</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">3,248</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">3,248</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 20pt; line-height: 115%">Cash equivalents</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,347</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">99</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,248</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> </table>   The carrying amounts of accounts receivable, accounts payable, accrued expenses, capital leases and the secured promissory note approximate fair value due primarily to the short-term nature of these financial instruments.

5. SECURED PROMISSORY NOTE   On May 20, 2014 (Execution Date), we executed a secured promissory note (the Note) with ACC Investment Ltd. in the amount of $350,000, payable in equal amortized payments over a thirty-six month period (the Term) from the Execution Date. The Note bears an annual interest rate of 10% and is secured by certain laboratory equipment used in our microarray services business. Legal and other closing costs totaling $22,000 were capitalized with the Note and are being amortized over the Term as interest expense. As of September 30, 2016 and December 31, 2015, components of the Note were as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">September 30,</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">December 31,</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 60%; line-height: 115%">Carrying value</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 17%; text-align: right; line-height: 115%">76</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 17%; text-align: right; line-height: 115%">168</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Unamortized legal and closing costs</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(4</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(10</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">72</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">158</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Less- current portion</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(72</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(124</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Long-term portion</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">34</td> <td style="line-height: 115%"> </td></tr> </table>

6. STOCKHOLDERS EQUITY   Series A through E Convertible Preferred Stock and Warrants Financings   Between 2012 and 2015, we executed several financing transactions whereby we issued convertible preferred stock and warrants to purchase common stock to investors. As of September 30, 2016, none of the Series A through E convertible preferred stock remained outstanding. For as long as the Series A warrants remain unexercised through their expiration date, except under certain permitted circumstances, we may not issue, or enter into any agreement to issue, common stock or common stock equivalents at a price per share below the $73.65 exercise price of the Series A warrants, unless waivers from the Series A investors are obtained. Until the time that less than 7.5% of the Series B, C and E warrants remain unexercised through their expiration date, except under certain permitted circumstances, we may not issue, or enter into any agreement to issue, common stock or common stock equivalents at prices per share below the $29.55, $29.55 and $32.51 exercise prices of the Series B, C and E warrants, respectively, unless waivers from the Series B, C and E investors are obtained. In addition, until there are no longer Series A, C and E warrants outstanding we may not sell any variable rate securities except for certain exempt issuances.   Series E Convertible Preferred Stock Financing   On February 13, 2015, we and certain accredited institutional pre-existing investors (the Series E Investors) entered into a securities purchase agreement (the Series E Purchase Agreement), pursuant to which we sold 102,800 shares common stock at a price of $26.25 per share, 2,201.493 shares of Series E 6% Convertible Preferred Stock (the Series E Preferred Stock) and warrants to purchase 46,676 shares of common stock initially at an exercise price of $29.55 per share, which was the consolidated closing bid price of our common stock on NASDAQ immediately prior to entering into the Series E Purchase Agreement (the Series E Warrants, and the transactions contemplated by the Series E Purchase Agreement, the Series E Financing). The Series E Preferred Stock and Series E Warrants were sold in a fixed combination consisting of one share of Series E Preferred Stock and a Series E Warrant to purchase approximately 21.1977 shares of common stock. Each fixed combination of Series E Preferred Stock and Series E Warrants were sold at a price of $1,000. The Series E Preferred Stock sold was convertible into 83,871 shares of common stock at an initial conversion price of $26.25 per share. The closing under the Series E Purchase Agreement occurred on February 18, 2015 (the Series E Closing Date), where we received gross proceeds of $4.9 million from the Series E Investors. After closing-related costs and expenses, net proceeds from the Series E Financing were approximately $4.7 million. Given that the effective conversion price of the Series E Preferred Stock, inclusive of amounts allocated to common stock and Series E Warrants, was below the closing market price of our common stock at the time of the Series E Closing Date, we recognized a beneficial conversion feature in the amount of $890,000. Since the Series E Preferred Stock was immediately convertible into common stock, the beneficial conversion feature was treated as a deemed dividend charged to retained earnings.    The Series E Warrants issued have a 5 ½ year term and have a cashless exercise provision in the event there is no effective registration statement covering the common stock issuable upon exercise of the Series E Warrants. The Series E Warrants are not subject to price based anti-dilution protection. See below for modifications made to the Series E Preferred Stock and the Series E Warrants.   Private Placement Warrant Financing   Substantially concurrently with the closing of the Series E Financing, on February 13, 2015, we entered into a separate securities purchase agreement (the Warrant Purchase Agreement) with selected accredited institutional pre-existing investors (the Private Placement Investors), pursuant to which we agreed to sell to the Private Placement Investors warrants to purchase 102,678 shares of Common Stock (the Private Placement Warrants, and the transactions contemplated by the Warrant Purchase Agreement, the Warrant Financing). In consideration of an aggregate of $1,000, we had agreed to sell the Private Placement Warrants, which would not be issued unless and until our stockholders approved amending our Certificate of Incorporation to increase our authorized common stock to permit the issuance of the common stock issuable upon exercise of the Private Placement Warrants (the Charter Amendment). We estimated the fair value of the Private Placement Warrants using the Black-Scholes valuation model to be $1.82 million, which was classified as a warrant subscription payable within additional paid-in capital in our consolidated balance sheet using the following assumptions: (i) closing stock price and Private Placement Warrants contractual exercise price; (ii) 5.5 year term; (iii) historical volatilities commensurate with the term of the Private Placement Warrants of 113.2%; and (iv) risk-free interest rates commensurate with the term of the Private Placement Warrants of 1.5%. We allocated the proceeds received from the Series E Financing to the Private Placement Warrants based on the relative fair value of the instruments issued to the Series E Investors. As a result of the special stockholders meeting held on April 28 2015, we issued the Private Placement Warrants to the Private Placement Investors and the warrant subscription payable was reclassified to additional paid-in capital.   Each Private Placement Warrant initially had an exercise price of $32.505 per share of common stock (subject to adjustment for stock splits and the like), which was 110% of the consolidated closing bid price of our common stock on NASDAQ immediately prior to entering into the Warrant Purchase Agreement, and is exercisable at any time after the six month anniversary of entering into the Warrant Purchase Agreement and on or prior to the close of business on the five year anniversary of the initial exercise date, subject to a beneficial ownership limitation. The Private Placement Warrants are not subject to price based anti-dilution protection. If, at the time of exercise of a Private Placement Warrant, there is no effective registration statement registering for resale the shares of common stock issuable upon exercise of the Private Placement Warrant, the holder may exercise the Private Placement Warrant on a cashless basis. When exercised on a cashless basis, a portion of the Private Placement Warrant is cancelled in payment of the purchase price payable in respect of the number of shares of common stock purchasable upon such exercise.   Modification of Certain Other Outstanding Warrants   In connection with the purchase of the Private Placement Warrants, we modified previously issued and outstanding warrants held by the Private Placement Investors that were issued in connection with the Series A, B and C financings described above, to (i) reduce the exercise prices thereunder to $29.55, which represents the consolidated closing bid price of our common stock on NASDAQ immediately prior to the date we entered into the Warrant Purchase Agreement; (ii) prohibit the exercise of such modified warrants for a period of six months after the date of the modification; and (iii) extend the exercise period of such modified warrants for an additional six months (such modifications, collectively, the Warrant Price Modifications). Separately, we also agreed to a Warrant Price Modification with a holder of Series C Warrants solely in consideration for such holders waiver of certain preemptive rights. We estimated the change in fair value of these warrants immediately prior to and immediately subsequent to the Warrant Price Modification to be $336,000, and such amount was recorded as a non-cash equity offering cost.   Series E Modifications   On October 12, 2015, we entered into an Amendment No. 1 to Common Stock Purchase Warrants (the Warrants Amendment) with each of the holders of the Series E Warrants and each of the holders of the Private Placement Warrants. Under the terms of the Warrants Amendment, all of the Series E Warrants and 100,847 of the Private Placement Warrants had their exercise prices reduced to $16.50 per share. Accordingly, with respect to the Private Placement Warrants, 100,847 of the Private Placement Warrants have an exercise price of $16.50 per share and 1,831 of the Private Placement Warrants retain their original exercise price of $32.505 per share. In consideration for entering into the Warrants Amendment, each Series E Investor agreed to irrevocably waive ab initio and for all time its right to receive cash dividends on its shares of our Series E Preferred Stock. We estimated the change in fair value of the Series E Warrants and the affected Private Placement Warrants prior to and immediately subsequent to the Warrants Amendment to be $168,000, which was recognized as a deemed dividend and as an increase to additional paid-in capital during the fourth quarter of 2015.    On February 4, 2016, we entered into a Series E 6% Convertible Preferred Stock Repurchase Agreement (the Repurchase Agreement) with the Series E Investors. Pursuant to the terms of the Repurchase Agreement, we agreed to pay each Series E Investor $300 per share of Series E Preferred Stock, or approximately $656,000, in consideration for the right to repurchase the Series E Investors Series E Preferred Stock at a price per share of $1,000 (the Repurchase Price), which was the original price per share paid by the Series E Investors for their Series E Preferred Stock in February 2015. We recognized the $656,000 payments as a deemed dividend paid to the Series E investors.   Immediately following the closing of our Series F public offering discussed below, we paid $2.2 million to the Series E Investors to repurchase all of the outstanding Series E Preferred Stock, in accordance with the terms of the Repurchase Agreement. Since none of the Series E Preferred Stock had converted by the time we repurchased the Series E Preferred Stock, the original $890,000 beneficial conversion feature that we recognized as a deemed dividend in 2015 was reversed as a return of capital from the Series E Preferred stockholders to the common stockholders.   Series F Convertible Preferred Stock and Warrants Financing   On March 24, 2016 (the Series F Closing), we closed an underwritten public offering (the Series F Offering) and issued 8,000 immediately separable units of securities to investors, with each unit consisting of: (i) one share of Series F convertible preferred stock (Series F Preferred Stock) convertible into shares of our common stock equal to 1,000 divided by the conversion price of $3.87, which was 75% of the consolidated closing bid price of our common stock on the NASDAQ Capital Market on March 18, 2016, the date we executed the underwriting agreement (UA date); and (ii) 258.397875 warrants, each to purchase one share of our common stock at an exercise price per share equal to $5.17 (Series F Warrants), which was 100% of the consolidated closing bid price of our common stock on the NASDAQ Capital Market on the UA date. The Series F Preferred Stock, the Series F Warrants, and the shares of common stock underlying the Series F Preferred Stock and Series F Warrants were registered on Form S-1, which was declared effective by the SEC on March 18, 2016. The Series F Preferred Stock was immediately convertible and the Series F Warrants were immediately exercisable for shares of common stock and have a term of five years. The Series F Warrants are exercisable for cash or, solely in the absence of an effective registration statement or prospectus, by cashless exercise. In total, there were 2,067,183 shares of common stock issuable upon conversion of the Series F Preferred Stock and up to 2,067,183 shares of common stock issuable upon exercise of the Series F Warrants. The units were sold for a purchase price equal to $1,000 per unit, resulting in gross proceeds received by us of $8 million. Total offering-related costs paid through September 30, 2016 were $1.06 million, resulting in net proceeds recognized of $6.94 million. Given that the effective conversion price of the Series F Preferred Stock was below the closing market price of our common stock at the time of the Series F Closing, we recognized a beneficial conversion feature in the amount of $1.9 million. Since the Series F Preferred Stock was immediately convertible into common stock, the beneficial conversion feature was treated as a deemed dividend charged to retained earnings at closing. Also, from the time of the Series F Closing through September 30, 2016, 6,310 shares of the Series F Preferred Stock have converted into 1,630,521 shares of common stock. Subsequent to September 30, 2016 and through the date of this report, an additional 51 shares of Series F Preferred Stock were converted into 13,179 shares of common stock.   The Series F Preferred Stock is non-voting (except to the extent required by law and except for certain consent rights relating to amending the certificate of incorporation or bylaws, and the like), but ranks senior to our common stock with respect to distributions upon our dissolution, liquidation or winding-up. Until the volume weighted average price of our common stock on NASDAQ exceeds 200% of the conversion price of the Series F Preferred Stock for any 20 of 30 consecutive trading days, and the daily dollar trading volume during such period exceeds $200,000 per trading day, the Series F Preferred Stock is subject to full ratchet price based anti-dilution protection, subject to certain limitations. Also, the Company can force holders of Series F Preferred Stock to convert into our common stock if the volume-weighted average price of our common stock exceeds 200% of the Series F Preferred Stock conversion price for any 20 of 30 consecutive trading days, and the daily dollar trading volume during such period exceeds $200,000 per trading day, subject to certain other conditions. The Series F investors have agreed to be subject to a blocker that would prevent each of their respective common stock ownership at any given time from exceeding 4.99% of our outstanding common stock (which may be increased on 61 days notice, but not above 9.99%).   The Series F Warrants have a 5-year term and have a cashless exercise provision in the event there is no effective registration statement covering the common stock issuable upon exercise of the Series F Warrants. The Series F Warrants are not subject to price based anti-dilution protection. The Series F Warrants are listed on the NASDAQ Capital Market under the trading symbol CBMXW.    Common Stock Purchase Warrants Repurchase Agreement   On July 11, 2016, we entered into a Common Stock Purchase Warrants Repurchase Agreement (the Warrants Repurchase Agreement) with the holders (the Holders) of our outstanding common stock purchase warrants issued in October 2012, March 2013, May 2013, June 2013, June 2014, February 2015 and April 2015 (collectively, the Warrants) in connection with our Series A, Series B, Series C and Series E financings. Pursuant to the terms of the Warrants Repurchase Agreement, we have agreed to repurchase such Warrants from each Holder upon execution of a Fundamental Transaction (as defined in such Warrants) at various negotiated prices per Warrant share as set forth in the Warrants Repurchase Agreement. Under the terms of the Warrants Repurchase Agreement, we will repurchase half of such Warrants upon the announcement of a Fundamental Transaction and the remaining half of such Warrants upon the closing of a Fundamental Transaction. In addition, upon the closing of a Fundamental Transaction, all Securities Purchase Agreements and Registration Rights Agreements associated with the original issuances of such Warrants will be terminated and the various restrictions set forth therein will no longer be of any force or effect. In connection with entering into the Warrants Repurchase Agreement, we were granted certain consents and waivers relating to a Fundamental Transaction. In the event that a Fundamental Transaction is announced and consummated, we will be obligated to repurchase such Warrants for approximately $459,000 of cash consideration paid to the Holders. One half of this amount will be due within three business days of announcing the Fundamental Transaction, and the remaining half will be due within three business days of closing the Fundamental Transaction. In the event that we announce a Fundamental Transaction but never close, for whatever reason, then one-half of such Warrants will be repurchased and cancelled and one-half will remain issued and outstanding. In the event that a Fundamental Transaction is never announced nor consummated, we will not be obligated to repurchase such Warrants, and the underlying terms and conditions of such Warrants will remain in effect.   Warrants   Outstanding warrants to purchase common stock are as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="text-align: center; line-height: 115%">Shares of Common Stock Issuable from Warrants</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Outstanding as of</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">September 30,</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">December 31,</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Exercise</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Price</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Expiration</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-decoration: underline; line-height: 115%">Equity-classified warrants:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 31%; padding-left: 10pt; line-height: 115%">March 2016</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 16%; text-align: right; line-height: 115%">2,067,183</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 15%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">5.17</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 18%; text-align: center; line-height: 115%">March 2021</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">April 2015</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">100,847</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">100,847</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">16.50</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">August 2020</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">April 2015</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,831</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,831</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">32.51</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">August 2020</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">February 2015</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">46,676</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">46,676</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">16.50</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">August 2020</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">June 2014</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,690</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,690</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">30.90</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">April 2018</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">December 2013</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">388,365</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">388,365</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">46.80</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">December 2018</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">June 2013</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">32,788</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">32,788</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">29.55</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">June 2019</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">May 2013</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">32,788</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">32,788</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">29.55</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">May 2019</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">March 2013</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">18,334</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">18,334</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">29.55</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">March 2019</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">October 2012</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">11,252</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">11,252</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">29.55</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">September 2018</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">April 2011</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">8,746</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">321.00</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">April 2016</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">Total</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">2,701,754</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">643,317</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td></tr> </table>

Use of Estimates. The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) in the United States of America requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

Principles of Consolidation. The accompanying consolidated financial statements include the accounts of the Company and our wholly owned and majority-owned subsidiaries. Investments for which we possess the power to direct or cause the direction of the management and policies, either through majority ownership or other means, are accounted for under the consolidation method. Material intercompany transactions and balances have been eliminated in consolidation. Investments in companies in which we maintain an ownership interest of 20% to 50% or exercise significant influence over operating and financial policies are accounted for under the equity method. The cost method is used where we maintain ownership interests of less than 20% and do not exercise significant influence over the investee.

Revenue Recognition. We recognize revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been performed, (iii) amounts are fixed or determinable and (iv) collectability of amounts is reasonably assured.   Service revenues from providing diagnostic tests are recognized when the testing process is complete and test results are reported to the ordering physician or clinic. These diagnostic services are billed to various payors, including commercial insurance companies, healthcare institutions, government payors including various state Medicaid programs, and individuals. We report revenues from contracted payors based on a contractual rate, or in the case of state Medicaid contracts, published fee schedules for our tests. We report revenues from non-contracted payors based on the amounts expected to be collected. The differences between the amounts billed and the amounts expected to be collected from non-contracted payors are recorded as contractual allowances to arrive at net recognized revenues. The expected revenues from non-contracted payors are based on the historical collection experience of each payor or payor group, as appropriate, and also take into account recent collection trends. In each reporting period, we review our historical collection experience for non-contracted payors and adjust our expected revenues for current and subsequent periods accordingly. We also recognize additional revenue from actual cash payments that exceed amounts initially recognized, in the period the payments are received. Because a substantial portion of our revenues is from non-contracted third-party payors, it is likely that we will be required to make adjustments to accounting estimates with respect to contractual allowances in the future, which may positively or adversely affect our results of operations. In all cases described above, we report revenues net of any applicable statutory taxes collected from customers, as applicable. No single customer exceeded 10% of revenues for the three or nine months ending September 30, 2016, nor for the three months ended September 30, 2015. For the nine months ended September 30, 2015, 10% of our revenues were generated from one customer.

Cash Equivalents and Short-Term Investments. We consider all highly liquid investments purchased with original maturities of three months or less when purchased to be cash equivalents. Short-term investments consist of fixed income investments with maturities between three and 12 months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Companys consolidated balance sheet. Unrealized holding gains and losses are reported within comprehensive loss in the consolidated statements of comprehensive loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations or other observable inputs. If a decline in the fair value of a short-term investment below our cost basis is determined to be other than temporary, such investment is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. To-date, no permanent impairment charges have been realized or recorded.

Fair Value Measurements. We measure fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; line-height: 115%"> </td> <td style="width: 24px; text-align: justify; line-height: 115%">●</td> <td style="width: 48px; text-align: justify; line-height: 115%">Level 1:</td> <td style="text-align: justify; line-height: 115%">Observable market inputs such as quoted prices in active markets;</td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%"> </td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%">●</td> <td style="text-align: justify; line-height: 115%">Level 2: </td> <td style="text-align: justify; line-height: 115%">Observable market inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%"> </td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%">●</td> <td style="text-align: justify; line-height: 115%">Level 3:</td> <td style="text-align: justify; line-height: 115%">Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions.</td></tr> </table>   We classify our cash equivalents within the fair value hierarchy as Level 1 as these assets are valued using quoted prices in active markets for identical assets at the measurement date. We classify short-term investments within the fair value hierarchy as Level 2, primarily utilizing broker quotes in a non-active market for valuation of these investments. Financial instruments that contain valuation inputs that are not readily determinable from active markets or from similar securities trading in active markets, such as derivative financial instruments, are classified within the fair value hierarchy as Level 3.

Impairment of Long-Lived Assets. Long-lived assets and intangible assets are reviewed for potential impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. In the event the sum of the expected undiscounted future cash flows resulting from the use of the asset is less than the carrying amount of the asset, an impairment loss equal to the excess of the assets carrying value over its fair value is recorded. If an asset is determined to be impaired, the loss is measured based on quoted market prices in active markets, if available. If quoted market prices are not available, the estimate of fair value is based on various valuation techniques, including a discounted value of estimated future cash flows.   During the third quarter of 2015, management determined that the carrying value of a cost-basis investment in the stock of a privately held company was impaired, resulting in a one-time, non-cash impairment charge of $97,000 for the three and nine months ended September 30, 2015.

Derivative Financial Instruments. We evaluate financial instruments for freestanding or embedded derivatives. Derivative instruments that do not qualify for permanent equity classification are recorded as liabilities at fair value, with changes in value recognized as other income (expense) in the consolidated statements of operations in the period of change. Derivative liabilities are categorized as either short-term or long-term based upon managements estimates as to when the derivative instrument may be realized or based upon the holders ability to realize the instrument.

Concentration of Credit Risks. Cash and cash equivalents are invested in deposits with certain financial institutions and may, at times, exceed federally insured limits. We have not experienced any significant losses on our deposits of cash and cash equivalents. We do not believe that we are exposed to significant credit risk on cash and cash equivalents or on our short-term investments. As of September 30, 2016, accounts receivable from two commercial insurance carriers of $418,000 and $346,000 exceeded 10% of our total accounts receivable balance. As of December 31, 2015, accounts receivable from one commercial insurance carrier of $316,000 exceeded 10% of our total accounts receivable balance.   Substantially all of the components and raw materials used in providing our testing services, including array slides and reagents, are currently provided to us from a limited number of sources or in some cases from a single source. Although we believe that alternative sources for those components and raw materials are available, any supply interruption in a sole-sourced component or raw material might result in up to a several-month production delay and materially harm our ability to provide testing services until a new source of supply, if any, could be located and qualified.

Accounts Receivable and Allowance for Doubtful Accounts. For our contracted third-party payors, governmental payors or direct-bill customers, accounts receivable are stated at principal amounts and are primarily comprised of amounts contractually due from customers for services performed. For our non-contracted customers, accounts receivable are stated at amounts expected to be collected based on historical collection experience with the third-party payor. The payment realization cycle for certain governmental and commercial insurance payors can be lengthy, involving denial, appeal and adjudication processes, and is subject to periodic adjustments that may be significant. Accounts receivable are periodically written off when identified as uncollectible after appropriate collection efforts have been exhausted. Such write-offs increase the contractual allowances (which reduce revenues) for those accounts in the period of adjustment. Collection of governmental, private health insurer, and client receivables are generally a function of providing complete and correct billing information to the insurers and clients within the filing deadlines required by each payor.   Collection of receivables due from patients and private-pay clients is generally subject to increased credit risk due to credit-worthiness or inability to pay. For these customers, an allowance for doubtful accounts is recorded for estimated uncollectible amounts, and involves significant assumptions and judgments. Specifically, the allowance for doubtful accounts is adjusted periodically and is principally based upon specific identification of past due or disputed accounts. We also review the age of receivables to assess our allowance at each period end. Additions to the allowance for doubtful accounts are charged to bad debt expense as a component of general and administrative expenses in the consolidated statements of operations.

Stock-Based Compensation. The compensation cost for all employee stock-based awards is measured at the grant date, based on the fair value of the award, and is recognized as an expense, on a straight-line basis, over the employees requisite service period (generally the vesting period of the equity award) which is generally four years. The fair value of each stock option award is estimated on the date of grant using a Black-Scholes option valuation model. The fair value of each restricted stock unit (RSU) award is based on the number of shares granted and the closing price of our common stock as reported on NASDAQ on the date of grant. Stock-based compensation expense is recognized only for those awards that are expected to vest using an estimated forfeiture rate. We estimate pre-vesting option forfeitures at the time of grant and reflect the impact of estimated pre-vesting option forfeitures in compensation expense recognized. Stock-based compensation expense for all periods presented attributable to our functional expense categories from stock option and RSU awards vesting during the periods presented were as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="text-align: center; line-height: 115%">Three Months Ended</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="text-align: center; line-height: 115%">Nine Months Ended</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30,</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30,</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%; line-height: 115%">Cost of services</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">14</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">11</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">34</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">21</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Research and development</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Sales and marketing</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">19</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">15</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">63</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">46</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">General and administrative</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">153</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">147</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">494</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">452</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">Total non-cash stock compensation</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">186</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">173</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">591</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">519</td> <td style="line-height: 115%"> </td></tr> </table>

Net Loss Per Share. Basic and diluted net loss per share has been computed by dividing the net loss by the weighted average number of common shares issued and outstanding during the periods presented. Options and warrants to purchase common stock as well as preferred stock convertible into shares of common stock are anti-dilutive and therefore are not included in the determination of the diluted net loss per share. The following table reflects the excluded dilutive securities:     <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="text-align: center; line-height: 115%">Three Months Ended</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="text-align: center; line-height: 115%">Nine Months Ended</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30,</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30,</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%; line-height: 115%">Common stock options</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 12%; text-align: right; line-height: 115%">66,687</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 12%; text-align: right; line-height: 115%">70,028</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 12%; text-align: right; line-height: 115%">66,687</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 12%; text-align: right; line-height: 115%">70,028</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Restricted stock units</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">59,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">38,800</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">59,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">38,800</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Common stock warrants</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2,701,754</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">643,260</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2,701,754</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">643,260</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Series E preferred stock convertible into common stock</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">83,866</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">83,866</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Series F preferred stock convertible into common stock</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">436,662</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">436,662</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Excluded potentially dilutive securities</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,264,103</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">835,954</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,264,103</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">835,954</td> <td style="line-height: 115%"> </td></tr> </table>

Recent Accounting Pronouncements. In August 2016, the Financial Accounting Standards Board (FASB) issued new accounting guidance aimed at reducing the existing diversity in GAAP regarding how certain cash receipts and cash payments are classified in the statement of cash flows. The new guidance is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is also permitted. We do not expect the adoption of this guidance to have a material impact on our consolidated statements of cash flows.   In March 2016, the FASB issued guidance regarding employee share-based payment accounting. The guidance is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification on the statement of cash flows and provides the choice for companies to estimate forfeitures during the vesting period of an award (which is required under current GAAP) or recognize forfeitures at the time an award is cancelled and forfeited. The standard is effective for us on January 1, 2017. We do not expect the adoption of this guidance to have a significant impact on our consolidated financial statements. However, we have elected to change our policy regarding forfeitures to recognize if and when an award is cancelled and forfeited rather than estimating forfeitures up front. We will be required to implement this policy change using the modified retrospective approach, during the first quarter of 2017. We estimate that the impact from implementing this policy change will be to reduce retained earnings and increase additional paid-in capital by approximately $40,000, but we will not know the actual amount until after the fourth quarter of 2016.   In February 2016, the FASB issued guidance regarding leases, which requires lessees to recognize on the balance sheet a right-of-use asset, representing their right to use the underlying asset for the lease term, and a lease liability for all leases with terms greater than 12 months. The guidance also requires qualitative and quantitative disclosures designed to assess the amount, timing and uncertainty of cash flows arising from leases. The guidance requires the use of a modified retrospective transition approach, which includes a number of optional practical expedients that entities may elect to apply. The guidance is effective for us beginning January 1, 2019, and we are currently evaluating the impact that this guidance will have on our consolidated financial statements.   In January 2016, the FASB issued accounting guidance regarding recognition and measurement of financial assets and financial liabilities. This guidance enhances the reporting model for financial instruments, which includes amendments to address aspects of recognition, measurement, presentation and disclosure. The guidance is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those annual periods. We do not expect the adoption of this guidance to have a significant impact on our consolidated financial statements.   In July 2015, the FASB issued accounting guidance regarding simplifying the measurement of inventory. The new guidance applies only to inventory for which cost is determined by methods other than last-in, first-out and the retail inventory method, which includes inventory that is measured using first-in, first-out or average cost. Inventory within the scope of this standard is required to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The new standard will be effective for us on January 1, 2017. We do not expect the adoption of this guidance to have a material impact on our consolidated financial statements.   In August 2014, the FASB issued new guidance requiring management of all entities to evaluate whether there are conditions and events that raise substantial doubt about the entitys ability to continue as a going concern within one year after the financial statements are issued (or available to be issued when applicable). The guidance is effective for fiscal years ending after December 15, 2016 and for annual and interim periods thereafter. While we do not expect the adoption of this guidance to have a material effect on our consolidated financial statements, adoption will increase disclosures in the notes to our consolidated financial statements if management concludes that substantial doubt about our ability to continue as a going concern within twelve months of the date that our consolidated financial statements are issued is present.   In May 2014, the FASB issued new accounting guidance regarding revenue recognition from contracts with customers, which when effective will supersede existing revenue recognition requirements and will eliminate most industry-specific guidance from GAAP. The core principle of the new guidance is to require an entity to recognize as revenue the amount that reflects the consideration to which it expects to be entitled in exchange for goods or services as it transfers control to its customers. The new guidance requires additional qualitative and quantitative disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. An entity can apply the new guidance retrospectively to each prior reporting period presented (i.e., the full retrospective method) or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. As originally issued, the new revenue recognition standard would be effective for us beginning January 1, 2017. However, in 2015, the FASB voted to defer the effective date of the new guidance for one year. We are currently evaluating the appropriate transition method and any further impact of this guidance on our consolidated financial statements and related disclosures.

Reclassifications. Certain prior period amounts have been reclassified to conform to the current period presentation.

Stock-based compensation expense for all periods presented attributable to our functional expense categories from stock option and RSU awards vesting during the periods presented were as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="text-align: center; line-height: 115%">Three Months Ended</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="text-align: center; line-height: 115%">Nine Months Ended</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30,</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30,</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%; line-height: 115%">Cost of services</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">14</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">11</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">34</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">21</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Research and development</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Sales and marketing</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">19</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">15</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">63</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">46</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">General and administrative</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">153</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">147</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">494</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">452</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">Total non-cash stock compensation</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">186</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">173</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">591</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">519</td> <td style="line-height: 115%"> </td></tr> </table>

The following table reflects the excluded dilutive securities:     <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="text-align: center; line-height: 115%">Three Months Ended</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="text-align: center; line-height: 115%">Nine Months Ended</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30,</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30,</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%; line-height: 115%">Common stock options</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 12%; text-align: right; line-height: 115%">66,687</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 12%; text-align: right; line-height: 115%">70,028</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 12%; text-align: right; line-height: 115%">66,687</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 12%; text-align: right; line-height: 115%">70,028</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Restricted stock units</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">59,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">38,800</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">59,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">38,800</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Common stock warrants</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2,701,754</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">643,260</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2,701,754</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">643,260</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Series E preferred stock convertible into common stock</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">83,866</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">83,866</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Series F preferred stock convertible into common stock</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">436,662</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">436,662</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Excluded potentially dilutive securities</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,264,103</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">835,954</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,264,103</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">835,954</td> <td style="line-height: 115%"> </td></tr> </table>

As of September 30, 2016, we held $4.3 million in cash, cash equivalents and short-term investments, which are reported at fair value. Cash, cash equivalents and short-term investments consisted of the following as of September 30, 2016 and December 31, 2015 (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">As of September 30, 2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">As of December 31, 2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Unrealized</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Fair</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Unrealized</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Fair</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Cost</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Gains</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Losses</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Value</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Cost</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Gains</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Losses</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Value</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 36%; line-height: 115%">Cash and money market securities</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 5%; text-align: right; line-height: 115%">4,345</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 5%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 5%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 5%; text-align: right; line-height: 115%">4,345</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 5%; text-align: right; line-height: 115%">653</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 5%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 5%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 5%; text-align: right; line-height: 115%">653</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Commercial paper</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Certificates of deposit</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">3,250</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(2</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">3,248</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">4,345</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">4,345</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,903</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(2</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,901</td> <td style="line-height: 115%"> </td></tr> </table>

The following table summarizes, for each major category of financial assets measured on a recurring basis, the respective fair value at September 30, 2016 and December 31, 2015 and the classification by level of input within the fair value hierarchy defined above (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Fair Value Measurements</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 115%">September 30, 2016</td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Total</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 1</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 2</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 3</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Assets:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 52%; padding-left: 10pt; line-height: 115%">Cash equivalents</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">3,033</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">3,033</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">Short-term investments</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 20pt; line-height: 115%">Cash equivalents</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,033</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,033</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Fair Value Measurements</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 115%">December 31, 2015</td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Total</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 1</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 2</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 3</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Assets:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 52%; padding-left: 10pt; line-height: 115%">Cash equivalents</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">99</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">99</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">Short-term investments</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">3,248</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">3,248</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 20pt; line-height: 115%">Cash equivalents</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,347</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">99</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,248</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> </table>

As of September 30, 2016 and December 31, 2015, components of the Note were as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">September 30,</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">December 31,</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 60%; line-height: 115%">Carrying value</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 17%; text-align: right; line-height: 115%">76</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 17%; text-align: right; line-height: 115%">168</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Unamortized legal and closing costs</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(4</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(10</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">72</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">158</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Less- current portion</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(72</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(124</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Long-term portion</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">34</td> <td style="line-height: 115%"> </td></tr> </table>

Outstanding warrants to purchase common stock are as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="text-align: center; line-height: 115%">Shares of Common Stock Issuable from Warrants</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Outstanding as of</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">September 30,</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">December 31,</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Exercise</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Price</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Expiration</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-decoration: underline; line-height: 115%">Equity-classified warrants:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 31%; padding-left: 10pt; line-height: 115%">March 2016</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 16%; text-align: right; line-height: 115%">2,067,183</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 15%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">5.17</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 18%; text-align: center; line-height: 115%">March 2021</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">April 2015</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">100,847</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">100,847</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">16.50</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">August 2020</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">April 2015</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,831</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,831</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">32.51</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">August 2020</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">February 2015</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">46,676</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">46,676</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">16.50</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">August 2020</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">June 2014</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,690</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,690</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">30.90</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">April 2018</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">December 2013</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">388,365</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">388,365</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">46.80</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">December 2018</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">June 2013</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">32,788</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">32,788</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">29.55</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">June 2019</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">May 2013</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">32,788</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">32,788</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">29.55</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">May 2019</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">March 2013</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">18,334</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">18,334</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">29.55</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">March 2019</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">October 2012</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">11,252</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">11,252</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">29.55</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">September 2018</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">April 2011</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">8,746</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">321.00</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">April 2016</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">Total</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">2,701,754</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">643,317</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td></tr> </table>

The cost method is used where we maintain ownership interests of less than 20% and do not exercise significant influence over the investee.

6940000 0.125 1500000 25000 2018 2.00 1.10 1.00 CBMX

1. OVERVIEW AND BACKGROUND   CombiMatrix Corporation (the Company, we, us and our) was originally incorporated in October 1995 as a California corporation and later reincorporated as a Delaware corporation in September 2000. In December 2002, we merged with, and became a wholly owned subsidiary of Acacia Research Corporation (Acacia). In August 2007, we split-off from Acacia and became publicly traded on The NASDAQ Stock Market. As a result of the split-off, we ceased to be a subsidiary of, or affiliated with, Acacia.   Description of the Company   We are a family health-focused clinical molecular diagnostic laboratory specializing in pre-implantation genetic screening, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. We strive to provide best-in-class clinical laboratory support to healthcare professionals, allowing them to maximize the clinical utility of their patients test results and to optimize patient care. Our testing focuses on advanced technologies, including single nucleotide polymorphism chromosomal microarray analysis, next generation sequencing, fluorescent in situ hybridization and high resolution karyotyping. Our approach to testing is to offer sophisticated technology along with high-quality clinical support to our ordering physicians and their patients. Our laboratory facilities and corporate headquarters are located in Irvine, California.   We also own a one-third minority interest in Leuchemix, Inc. (Leuchemix), a private drug development company focused on developing a series of compounds to address a number of oncology-related diseases.   Basis of Presentation   The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, certain information and notes required by generally accepted accounting principles in annual financial statements have been omitted or condensed. These interim consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2015, as reported by us in our Annual Report on Form 10-K filed with the SEC on February 18, 2016. The year-end consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. The consolidated financial statements include all adjustments of a normal recurring nature which, in the opinion of management, are necessary for a fair statement of our financial position as of September 30, 2016, and results of operations and cash flows for the interim periods presented. The results of operations for the three and nine months ended September 30, 2016 are not necessarily indicative of the results to be expected for the entire year.   Reverse Stock Split   On January 29, 2016, we filed a Certificate of Amendment to our Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a reverse split of our common stock at a ratio of one-for-fifteen (the Reverse Stock Split), which became effective at the close of business on that day. As a result, each share of CombiMatrix common stock outstanding as of January 29, 2016 was automatically changed into one-fifteenth of a share of common stock. No fractional shares were issued in connection with the Reverse Stock Split, and cash paid to stockholders for potential fractional shares was insignificant. The number of shares of common stock subject to outstanding options, warrants and convertible securities were also reduced by a factor of fifteen as of January 29, 2016. All historical share and per share amounts reflected throughout this document have been adjusted to reflect the Reverse Stock Split. The authorized number of shares and the par value per share of our common stock were not affected by the Reverse Stock Split.   Liquidity and Risks   We have a history of incurring net losses and net operating cash flow deficits. We are also deploying new technologies and continue to develop and improve existing commercial diagnostic testing services and related technologies. As of September 30, 2016, we had cash, cash equivalents and short-term investments of $4.3 million and anticipate that our cash, cash equivalents and short-term investments will be sufficient to meet our cash requirements for at least the next twelve months. In order for us to ultimately achieve profitability, we may be required to obtain capital from external sources, increase revenues and reduce operating costs. However, there can be no assurance that our operations will become profitable or that external sources of financing, including the issuance of debt and/or equity securities, will be available at times and at terms acceptable to us, or at all. The issuance of additional equity or convertible debt securities will also cause dilution to our stockholders. If external financing sources are not available or are inadequate to fund our operations, we will be required to reduce operating costs, including research projects and personnel, which could jeopardize our future strategic initiatives and business plans.   Our business operations are also subject to certain risks and uncertainties, including:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify; line-height: 115%"> </td> <td style="width: 24px; text-align: justify; line-height: 115%">●</td> <td style="text-align: justify; line-height: 115%">market acceptance of our technologies and services;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%">●</td> <td style="text-align: justify; line-height: 115%">technological advances that may make our technologies and services obsolete or less competitive;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%">●</td> <td style="text-align: justify; line-height: 115%">increases in operating costs, including costs for supplies, personnel and equipment;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%">●</td> <td style="text-align: justify; line-height: 115%">variability in third-party reimbursement of our tests;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%">●</td> <td style="text-align: justify; line-height: 115%">the availability and cost of capital; and</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%">●</td> <td style="text-align: justify; line-height: 115%">governmental regulation that may restrict our business.</td></tr> </table>   Our services are concentrated in a highly competitive market that is characterized by rapid technological advances, frequent changes in customer requirements and evolving regulatory requirements and industry standards. Failure to anticipate or respond adequately to technological advances, changes in customer requirements, changes in regulatory requirements or industry standards, or any significant delays in the development or introduction of planned services, could have a material adverse effect on our business and operating results. The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the matters discussed herein.

4998000

4000000

459000

Segments. We have determined that we operate in one segment for financial reporting purposes.

8889000

7922000

97000

40000

0.001

0.50

0.20

2016

EX-101.SCH 7 cbmx-20160930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Overview and Background link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Cash and Short-term Investments link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Secured Promissory Note link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Cash and Short-term Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Secured Promissory Note (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Overview and Background (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Summary of Significant Accounting Policies - Schedule of Employee Service Share-based Compensation, Allocation (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Cash and Short-term Investments (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Cash and Short-term Investments - Schedule of Cash, Cash Equivalents and Investments (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Fair Value Measurements - Fair Value, Assets Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Secured Promissory Note (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Secured Promissory Note - Schedule of Secured Promissory Note (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Stockholders' Equity - Schedule of Stockholders' Equity Note, Warrants or Rights (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 cbmx-20160930_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 cbmx-20160930_def.xml XBRL DEFINITION FILE EX-101.LAB 10 cbmx-20160930_lab.xml XBRL LABEL FILE Series F Preferred Stock [Member] Class of Stock [Axis] Series E Preferred Stock [Member] Maximum [Member] Range [Axis] Minimum [Member] Revenue [Member] Concentration Risk Benchmark [Axis] No Single Customer [Member] Customer [Axis] One Customer [Member] Accounts Receivable [Member] Commercial Insurance One [Member] Concentration Risk Type [Axis] Cost of Service [Member] Income Statement Location [Axis] Research and Development [Member] Sales and Marketing [Member] General and Administrative Expense [Member] Common Stock Options [Member] Antidilutive Securities [Axis] Restricted Stock [Member] Common Stock Warrants [Member] Series E Convertible Preferred Stock [Member] Series F Convertible Preferred Stock [Member] Cash and Money Market Securities [Member] Cash and Cash Equivalents [Axis] Commercial Paper [Member] Investment Type [Axis] Certificates of Deposit [Member] Fair Value, Measurements, Recurring [Member] Measurement Frequency [Axis] Fair Value, Inputs, Level 3 [Member] Fair Value, Hierarchy [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Secured Debt [Member] Long-term Debt, Type [Axis] Series A Warrants [Member] Class of Warrant or Right [Axis] Series B Warrants [Member] Series C Warrants [Member] Series E Purchase Agreement [Member] Plan Name [Axis] Series E 6% Convertible Preferred Stock [Member] Series E Warrant [Member] Common Stock [Member] Equity Components [Axis] Warrant Purchase Agreement [Member] Modification of Certain Outstanding Warrants [Member] Scenario [Axis] Private Placement [Member] Sale of Stock [Axis] Fixed Combination [Member] Private Placement Investors [Member] Related Party [Axis] Modification Of Certain Other Outstanding Warrants [Member] Series E Modifications [Member] Warrants Amendment [Member] Series C Convertible Preferred Stock [Member] Series E Investors [Member] Series F Offering [Member] Series F Convertible Preferred Stock And Warrants Financing [Member] March, 2016 [Member] April 2015 [Member] April 2015 [Member] February 2015 [Member] June 2014 [Member] December 2013 [Member] June 2013 [Member] May 2013 [Member] March 2013 [Member] October 2012 [Member] April 2011 [Member] Transaction Bonus Plan [Member] Other Commitments [Axis] Litigation [Member] Settlement Agreement [Member] Agreements [Axis] Warrant Repurchase Agreements [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Subsequent Event [Member] Subsequent Event Type [Axis] Commercial Insurance Two [Member] Series E Warrants [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement [Table] Statement [Line Items] ASSETS Current assets: Cash and cash equivalents Short-term investments Accounts receivable, net of allowance for doubtful accounts of $244 and $235 Supplies Prepaid expenses and other assets Total current assets Property and equipment, net Other assets Total assets LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable, accrued expenses and other Current portion, long-term debt Total current liabilities Capital lease obligations, net of current portion Secured promissory note payable, net of current portion Deferred rent Total liabilities Commitments and contingencies (Note 7) Stockholders' equity: Convertible preferred stock; $0.001 par value; 5,000,000 shares authorized; Series F - 8,000 shares authorized; 1,690 and none issued and outstanding Series E - 2,202 shares authorized; none and 2,201.493 issued and outstanding Common stock; $0.001 par value; 50,000,000 shares authorized; 2,487,450 and 845,374 shares issued and outstanding Additional paid-in capital Accumulated other comprehensive loss Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Allowance for doubtful accounts Convertible preferred stock, par value Convertible preferred stock, shares authorized Convertible preferred stock, shares issued Convertible preferred stock, shares outstanding Common stock par value Common stock authorized Common stock ,shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues: Diagnostic services Royalties Total revenues Operating expenses: Cost of services Research and development Sales and marketing General and administrative Patent amortization and royalties Impairment of cost-basis investment Total operating expenses Operating loss Other income (expense): Interest income Interest expense Total other income (expense) Net loss Deemed dividend from issuing Series F convertible preferred stock and warrants Deemed dividend paid for right to repurchase Series E convertible preferred stock Deemed dividend from issuing Series E convertible preferred stock and warrants Net loss attributable to common stockholders Basic and diluted net loss per share Deemed dividend paid for right to repurchase Series E convertible preferred stock Deemed dividend from issuing Series E convertible preferred stock Deemed dividend from issuing Series F convertible preferred stock Basic and diluted net loss per share attributable to common stockholders Basic and diluted weighted average common shares outstanding Statement of Comprehensive Income [Abstract] Net loss Unrealized gain on available-for-sale investments Total comprehensive loss Statement of Cash Flows [Abstract] Operating activities: Adjustments to reconcile net loss to net cash flows from operating activities: Depreciation and amortization Non-cash stock compensation Provision for bad debts Impairment for cost-basis investment Changes in assets and liabilities: Accounts receivable Supplies, prepaid expenses and other assets Accounts payable, accrued expenses and other Net cash flows from operating activities Investing activities: Purchases of property and equipment Purchase of available-for-sale investments Sale of available-for-sale investments Net cash flows from investing activities Financing activities: Proceeds from issuance of Series F convertible stock and common stock warrants Costs from issuance of Series F convertible convertible stock and common stock warrants Repurchase of Series E convertible prefered stock and dividends Proceeds from issuance of Series E convertible stock, common stock and warrants EX-101.PRE 11 cbmx-20160930_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2016	Nov. 04, 2016
Document And Entity Information
Entity Registrant Name	CombiMatrix Corp
Entity Central Index Key	0001383183
Document Type	10-Q
Document Period End Date	Sep. 30, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		2,500,629
Trading Symbol	CBMX
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2016

XML 13 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 4,345	$ 653
Short-term investments		3,248
Accounts receivable, net of allowance for doubtful accounts of $244 and $235	3,235	2,682
Supplies	459	418
Prepaid expenses and other assets	169	200
Total current assets	8,208	7,201
Property and equipment, net	651	691
Other assets	30	30
Total assets	8,889	7,922
Current liabilities:
Accounts payable, accrued expenses and other	1,623	1,591
Current portion, long-term debt	129	193
Total current liabilities	1,752	1,784
Capital lease obligations, net of current portion	49	71
Secured promissory note payable, net of current portion		34
Deferred rent	153	177
Total liabilities	1,954	2,066
Commitments and contingencies (Note 7)
Stockholders' equity:
Common stock; $0.001 par value; 50,000,000 shares authorized; 2,487,450 and 845,374 shares issued and outstanding	14	13
Additional paid-in capital	108,952	102,651
Accumulated other comprehensive loss		(2)
Accumulated deficit	(102,031)	(96,806)
Total stockholders' equity	6,935	5,856
Total liabilities and stockholders' equity	8,889	7,922
Series F Preferred Stock [Member]
Stockholders' equity:
Convertible preferred stock; $0.001 par value; 5,000,000 shares authorized; Series F - 8,000 shares authorized; 1,690 and none issued and outstanding Series E - 2,202 shares authorized; none and 2,201.493 issued and outstanding
Series E Preferred Stock [Member]
Stockholders' equity:
Convertible preferred stock; $0.001 par value; 5,000,000 shares authorized; Series F - 8,000 shares authorized; 1,690 and none issued and outstanding Series E - 2,202 shares authorized; none and 2,201.493 issued and outstanding

XML 14 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Allowance for doubtful accounts	$ 244	$ 235
Convertible preferred stock, par value	$ 0.001	$ 0.001
Convertible preferred stock, shares authorized	5,000,000	5,000,000
Common stock par value	$ 0.001	$ 0.001
Common stock authorized	50,000,000	50,000,000
Common stock ,shares issued	2,487,450	845,374
Common stock, shares outstanding	2,487,450	845,374
Series F Preferred Stock [Member]
Convertible preferred stock, shares authorized	8,000	8,000
Convertible preferred stock, shares issued	1,690
Convertible preferred stock, shares outstanding	1,690
Series E Preferred Stock [Member]
Convertible preferred stock, shares authorized	2,202	2,202
Convertible preferred stock, shares issued		2,201.493
Convertible preferred stock, shares outstanding		2,201.493

XML 15 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenues:
Diagnostic services	$ 3,211	$ 2,481	$ 9,190	$ 7,292
Royalties	37	45	137	112
Total revenues	3,248	2,526	9,327	7,404
Operating expenses:
Cost of services	1,476	1,400	4,327	4,028
Research and development	88	133	380	352
Sales and marketing	1,055	1,295	3,532	3,658
General and administrative	1,450	1,249	4,562	4,212
Patent amortization and royalties	25	25	75	75
Impairment of cost-basis investment		97		97
Total operating expenses	4,094	4,199	12,876	12,422
Operating loss	(846)	(1,673)	(3,549)	(5,018)
Other income (expense):
Interest income	7	5	19	13
Interest expense	(17)	(19)	(52)	(59)
Total other income (expense)	(10)	(14)	(33)	(46)
Net loss	(856)	(1,687)	(3,582)	(5,064)
Deemed dividend from issuing Series F convertible preferred stock and warrants			(1,877)
Deemed dividend paid for right to repurchase Series E convertible preferred stock			(656)
Deemed dividend from issuing Series E convertible preferred stock and warrants			890	(890)
Net loss attributable to common stockholders	$ (856)	$ (1,687)	$ (5,225)	$ (5,954)
Basic and diluted net loss per share	$ (0.38)	$ (2.00)	$ (2.38)	$ (6.13)
Deemed dividend paid for right to repurchase Series E convertible preferred stock			(0.44)
Deemed dividend from issuing Series E convertible preferred stock			0.59	(1.08)
Deemed dividend from issuing Series F convertible preferred stock			(1.25)
Basic and diluted net loss per share attributable to common stockholders	$ (0.38)	$ (2.00)	$ (3.48)	$ (7.21)
Basic and diluted weighted average common shares outstanding	2,253,834	845,395	1,502,680	825,956

XML 16 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Statement of Comprehensive Income [Abstract]
Net loss	$ (856)	$ (1,687)	$ (3,582)	$ (5,064)
Unrealized gain on available-for-sale investments			2	4
Total comprehensive loss	$ (856)	$ (1,687)	$ (3,580)	$ (5,060)

XML 17 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Operating activities:
Net loss	$ (3,582)	$ (5,064)
Adjustments to reconcile net loss to net cash flows from operating activities:
Depreciation and amortization	195	227
Non-cash stock compensation	591	519
Provision for bad debts	302	218
Impairment for cost-basis investment		97
Changes in assets and liabilities:
Accounts receivable	(855)	(455)
Supplies, prepaid expenses and other assets	(35)	(153)
Accounts payable, accrued expenses and other	23	440
Net cash flows from operating activities	(3,361)	(4,171)
Investing activities:
Purchases of property and equipment	(148)	(66)
Purchase of available-for-sale investments	(4,998)	(4,000)
Sale of available-for-sale investments	8,248	4,230
Net cash flows from investing activities	3,102	164
Financing activities:
Proceeds from issuance of Series F convertible stock and common stock warrants	8,000
Costs from issuance of Series F convertible convertible stock and common stock warrants	(1,064)
Repurchase of Series E convertible prefered stock and dividends	(2,842)
Proceeds from issuance of Series E convertible stock, common stock and warrants		4,900
Costs from issuance of Series E convertible convertible stock, common stock and warrants		(220)
Repayments of long-term debt	(143)	(135)
Net cash flows from financing activities	3,951	4,545
Change in cash and cash equivalents	3,692	538
Cash and cash equivalents, beginning	653	1,010
Cash and cash equivalents, ending	4,345	1,548
Non-cash financing activities:
Deemed dividends from issuing Series E convertible preferred stock	(890)	890
Deemed dividends from issuing Series F convertible preferred stock	1,877
Accrued property, plant and equipment	9
Property and equipment purchased under capital lease	23	72
Warrant modifications recognized as non-cash Series E offering-related costs		336
Tenant improvements recognized as deferred rent		$ 164

XML 18 R7.htm IDEA: XBRL DOCUMENT

Overview and Background

9 Months Ended

Sep. 30, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Overview and Background

1. OVERVIEW AND BACKGROUND

Description of the Company

Basis of Presentation

Reverse Stock Split

Liquidity and Risks

Our business operations are also subject to certain risks and uncertainties, including:

	●	market acceptance of our technologies and services;

	●	technological advances that may make our technologies and services obsolete or less competitive;

	●	increases in operating costs, including costs for supplies, personnel and equipment;

	●	variability in third-party reimbursement of our tests;

	●	the availability and cost of capital; and

	●	governmental regulation that may restrict our business.

XML 19 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

●	Level 1:	Observable market inputs such as quoted prices in active markets;

●	Level 2:	Observable market inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

●	Level 3:	Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions.

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2016		2015		2016		2015

Cost of services	$	14	$	11	$	34	$	21
Research and development		-		-		-		-
Sales and marketing		19		15		63		46
General and administrative		153		147		494		452
Total non-cash stock compensation	$	186	$	173	$	591	$	519

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2016		2015		2016		2015

Common stock options		66,687		70,028		66,687		70,028
Restricted stock units		59,000		38,800		59,000		38,800
Common stock warrants		2,701,754		643,260		2,701,754		643,260
Series E preferred stock convertible into common stock		-		83,866		-		83,866
Series F preferred stock convertible into common stock		436,662		-		436,662		-
Excluded potentially dilutive securities		3,264,103		835,954		3,264,103		835,954

Segments. We have determined that we operate in one segment for financial reporting purposes.

Reclassifications. Certain prior period amounts have been reclassified to conform to the current period presentation.

XML 20 R9.htm IDEA: XBRL DOCUMENT

Cash and Short-term Investments

9 Months Ended

Sep. 30, 2016

Cash and Cash Equivalents [Abstract]

Cash and Short-term Investments

3. CASH AND SHORT-TERM INVESTMENTS

	As of September 30, 2016								As of December 31, 2015
			Unrealized				Fair				Unrealized					Fair
	Cost		Gains		Losses		Value		Cost		Gains		Losses			Value

Cash and money market securities	$	4,345	$	-	$	-	$	4,345	$	653	$	-	$	-		$	653
Commercial paper		-		-		-		-		-		-		-			-
Certificates of deposit		-		-		-		-		3,250		-		(2	)		3,248
	$	4,345	$	-	$	-	$	4,345	$	3,903	$	-	$	(2	)	$	3,901

There were no realized gains or losses for the periods ended September 30, 2016 or 2015.

- Definition

The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.

+ References + Details

XML 21 R10.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

9 Months Ended

Sep. 30, 2016

Fair Value Disclosures [Abstract]

Fair Value Measurements

4. FAIR VALUE MEASUREMENTS

			Fair Value Measurements
September 30, 2016	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	3,033	$	3,033	$	-	$	-
Short-term investments		-		-		-		-
Cash equivalents	$	3,033	$	3,033	$	-	$	-

			Fair Value Measurements
December 31, 2015	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	99	$	99	$	-	$	-
Short-term investments		3,248		-		3,248		-
Cash equivalents	$	3,347	$	99	$	3,248	$	-

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 22 R11.htm IDEA: XBRL DOCUMENT

Secured Promissory Note

9 Months Ended

Sep. 30, 2016

Debt Disclosure [Abstract]

Secured Promissory Note

5. SECURED PROMISSORY NOTE

	September 30,			December 31,
	2016			2015

Carrying value	$	76		$	168
Unamortized legal and closing costs		(4	)		(10	)
		72			158
Less- current portion		(72	)		(124	)
Long-term portion	$	-		$	34

XML 23 R12.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

9 Months Ended

Sep. 30, 2016

Equity [Abstract]

Stockholders' Equity

6. STOCKHOLDERS’ EQUITY

Series A through E Convertible Preferred Stock and Warrants Financings

Series E Convertible Preferred Stock Financing

Private Placement Warrant Financing

Modification of Certain Other Outstanding Warrants

Series E Modifications

Series F Convertible Preferred Stock and Warrants Financing

Common Stock Purchase Warrants Repurchase Agreement

Warrants

Outstanding warrants to purchase common stock are as follows:

	Shares of Common Stock Issuable from Warrants
	Outstanding as of
	September 30,		December 31,		Exercise
	2016		2015		Price		Expiration
Equity-classified warrants:
March 2016		2,067,183		-	$	5.17	March 2021
April 2015		100,847		100,847	$	16.50	August 2020
April 2015		1,831		1,831	$	32.51	August 2020
February 2015		46,676		46,676	$	16.50	August 2020
June 2014		1,690		1,690	$	30.90	April 2018
December 2013		388,365		388,365	$	46.80	December 2018
June 2013		32,788		32,788	$	29.55	June 2019
May 2013		32,788		32,788	$	29.55	May 2019
March 2013		18,334		18,334	$	29.55	March 2019
October 2012		11,252		11,252	$	29.55	September 2018
April 2011		-		8,746	$	321.00	April 2016
Total		2,701,754		643,317

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 24 R13.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Sep. 30, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

7. COMMITMENTS AND CONTINGENCIES

Executive Severance

Litigation

XML 25 R14.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

Use of Estimates

Principles of Consolidation

Revenue Recognition

Cash Equivalents and Short-Term Investments

Fair Value Measurements

●	Level 1:	Observable market inputs such as quoted prices in active markets;

●	Level 2:	Observable market inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

●	Level 3:	Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions.

Impairment of Long-Lived Assets

Derivative Financial Instruments

Concentration of Credit Risks

Accounts Receivable and Allowance for Doubtful Accounts

Stock-Based Compensation

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2016		2015		2016		2015

Cost of services	$	14	$	11	$	34	$	21
Research and development		-		-		-		-
Sales and marketing		19		15		63		46
General and administrative		153		147		494		452
Total non-cash stock compensation	$	186	$	173	$	591	$	519

Net Loss Per Share

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2016		2015		2016		2015

Common stock options		66,687		70,028		66,687		70,028
Restricted stock units		59,000		38,800		59,000		38,800
Common stock warrants		2,701,754		643,260		2,701,754		643,260
Series E preferred stock convertible into common stock		-		83,866		-		83,866
Series F preferred stock convertible into common stock		436,662		-		436,662		-
Excluded potentially dilutive securities		3,264,103		835,954		3,264,103		835,954

Segments

Segments. We have determined that we operate in one segment for financial reporting purposes.

Recent Accounting Pronouncements

Reclassifications

Reclassifications. Certain prior period amounts have been reclassified to conform to the current period presentation.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation

Stock-based compensation expense for all periods presented attributable to our functional expense categories from stock option and RSU awards vesting during the periods presented were as follows (in thousands):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2016		2015		2016		2015

Cost of services	$	14	$	11	$	34	$	21
Research and development		-		-		-		-
Sales and marketing		19		15		63		46
General and administrative		153		147		494		452
Total non-cash stock compensation	$	186	$	173	$	591	$	519

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following table reflects the excluded dilutive securities:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2016		2015		2016		2015

Common stock options		66,687		70,028		66,687		70,028
Restricted stock units		59,000		38,800		59,000		38,800
Common stock warrants		2,701,754		643,260		2,701,754		643,260
Series E preferred stock convertible into common stock		-		83,866		-		83,866
Series F preferred stock convertible into common stock		436,662		-		436,662		-
Excluded potentially dilutive securities		3,264,103		835,954		3,264,103		835,954

XML 27 R16.htm IDEA: XBRL DOCUMENT

Cash and Short-term Investments (Tables)

9 Months Ended

Sep. 30, 2016

Cash and Cash Equivalents [Abstract]

Schedule of Cash, Cash Equivalents and Investments

	As of September 30, 2016								As of December 31, 2015
			Unrealized				Fair				Unrealized					Fair
	Cost		Gains		Losses		Value		Cost		Gains		Losses			Value

Cash and money market securities	$	4,345	$	-	$	-	$	4,345	$	653	$	-	$	-		$	653
Commercial paper		-		-		-		-		-		-		-			-
Certificates of deposit		-		-		-		-		3,250		-		(2	)		3,248
	$	4,345	$	-	$	-	$	4,345	$	3,903	$	-	$	(2	)	$	3,901

XML 28 R17.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2016

Fair Value Disclosures [Abstract]

Fair Value, Assets Measured on Recurring Basis

			Fair Value Measurements
September 30, 2016	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	3,033	$	3,033	$	-	$	-
Short-term investments		-		-		-		-
Cash equivalents	$	3,033	$	3,033	$	-	$	-

			Fair Value Measurements
December 31, 2015	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	99	$	99	$	-	$	-
Short-term investments		3,248		-		3,248		-
Cash equivalents	$	3,347	$	99	$	3,248	$	-

XML 29 R18.htm IDEA: XBRL DOCUMENT

Secured Promissory Note (Tables)

9 Months Ended

Sep. 30, 2016

Debt Disclosure [Abstract]

Schedule of Secured Promissory Note

As of September 30, 2016 and December 31, 2015, components of the Note were as follows (in thousands):

	September 30,			December 31,
	2016			2015

Carrying value	$	76		$	168
Unamortized legal and closing costs		(4	)		(10	)
		72			158
Less- current portion		(72	)		(124	)
Long-term portion	$	-		$	34

XML 30 R19.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2016

Equity [Abstract]

Schedule of Stockholders' Equity Note, Warrants or Rights

Outstanding warrants to purchase common stock are as follows:

	Shares of Common Stock Issuable from Warrants
	Outstanding as of
	September 30,		December 31,		Exercise
	2016		2015		Price		Expiration
Equity-classified warrants:
March 2016		2,067,183		-	$	5.17	March 2021
April 2015		100,847		100,847	$	16.50	August 2020
April 2015		1,831		1,831	$	32.51	August 2020
February 2015		46,676		46,676	$	16.50	August 2020
June 2014		1,690		1,690	$	30.90	April 2018
December 2013		388,365		388,365	$	46.80	December 2018
June 2013		32,788		32,788	$	29.55	June 2019
May 2013		32,788		32,788	$	29.55	May 2019
March 2013		18,334		18,334	$	29.55	March 2019
October 2012		11,252		11,252	$	29.55	September 2018
April 2011		-		8,746	$	321.00	April 2016
Total		2,701,754		643,317

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 31 R20.htm IDEA: XBRL DOCUMENT

Overview and Background (Details Narrative) $ in Thousands	Sep. 30, 2016 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash, cash equivalents and short term investments	$ 4,300

- Definition

Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.

+ References + Details

XML 32 R21.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Cost method, description			The cost method is used where we maintain ownership interests of less than 20% and do not exercise significant influence over the investee.
Impairment of cost-basis investment		$ 97		$ 97
Increase in additional paid in capital			$ 40
Revenue [Member] \| No Single Customer [Member]
Concentration credit risk percentage			10.00%
Revenue [Member] \| One Customer [Member]
Concentration credit risk percentage				10.00%
Accounts Receivable [Member] \| Commercial Insurance One [Member]
Concentration credit risk percentage			10.00%		10.00%
Fair value, concentration of risk, accounts receivable	418		$ 418		$ 316
Accounts Receivable [Member] \| Commercial Insurance Two [Member]
Concentration credit risk percentage			10.00%
Fair value, concentration of risk, accounts receivable	$ 346		$ 346
Minimum [Member]
Equity method investment, ownership percentage	20.00%		20.00%
Maximum [Member]
Equity method investment, ownership percentage	50.00%		50.00%

XML 33 R22.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Employee Service Share-based Compensation, Allocation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Allocated Share-based Compensation Expense	$ 186	$ 173	$ 591	$ 519
Cost of Service [Member]
Allocated Share-based Compensation Expense	14	11	34	21
Research and Development [Member]
Allocated Share-based Compensation Expense
Sales and Marketing [Member]
Allocated Share-based Compensation Expense	19	15	63	46
General and Administrative Expense [Member]
Allocated Share-based Compensation Expense	$ 153	$ 147	$ 494	$ 452

XML 34 R23.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Anti-dilutive Securities	3,264,103	835,954	3,264,103	835,954
Common Stock Options [Member]
Anti-dilutive Securities	66,687	70,028	66,687	70,028
Restricted Stock [Member]
Anti-dilutive Securities	59,000	38,800	59,000	38,800
Common Stock Warrants [Member]
Anti-dilutive Securities	2,701,754	643,260	2,701,754	643,260
Series E Convertible Preferred Stock [Member]
Anti-dilutive Securities		83,866		83,866
Series F Convertible Preferred Stock [Member]
Anti-dilutive Securities	436,662		436,662

XML 35 R24.htm IDEA: XBRL DOCUMENT

Cash and Short-term Investments (Details Narrative) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash and Cash Equivalents [Abstract]
Cash, cash equivalents and short-term investments	$ 4,300
Realized investment gains losses	$ 0	$ 0

- Definition

+ References + Details

XML 36 R25.htm IDEA: XBRL DOCUMENT

Cash and Short-term Investments - Schedule of Cash, Cash Equivalents and Investments (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Cost	$ 4,345	$ 3,903
Unrealized Gain
Unrealized Loss		(2)
Fair Value	4,345	3,901
Commercial Paper [Member]
Cost
Unrealized Gain
Unrealized Loss
Fair Value
Certificates of Deposit [Member]
Cost		3,250
Unrealized Gain
Unrealized Loss		(2)
Fair Value		3,248
Cash and Money Market Securities [Member]
Cost	4,345	653
Unrealized Gain
Unrealized Loss
Fair Value	$ 4,345	$ 653

XML 37 R26.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Fair Value, Assets Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Short-term Investments		$ 3,248
Total	4,300
Fair Value, Measurements, Recurring [Member]
Cash equivalents	3,033	99
Short-term Investments		3,248
Total	3,033	3,347
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Cash equivalents	3,033	99
Short-term Investments
Total	3,033	99
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]
Cash equivalents
Short-term Investments		3,248
Total		3,248
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Cash equivalents
Short-term Investments
Total

- Definition

+ References + Details

XML 38 R27.htm IDEA: XBRL DOCUMENT

Secured Promissory Note (Details Narrative) - Secured Debt [Member] $ in Thousands	May 20, 2014 USD ($)
Debt Instrument, Face Amount	$ 350
Debt Instrument, Term	36 months
Debt Instrument, Interest Rate, Stated Percentage	10.00%
Debt Issuance Cost	$ 22

XML 39 R28.htm IDEA: XBRL DOCUMENT

Secured Promissory Note - Schedule of Secured Promissory Note (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Debt Disclosure [Abstract]
Carrying value	$ 76	$ 168
Unamortized legal and closing costs	(4)	(10)
Notes Payable	72	158
Less- current portion	(72)	(124)
Long-term portion		$ 34

XML 40 R29.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands								9 Months Ended
	Jul. 11, 2016	Mar. 24, 2016	Feb. 04, 2016	Oct. 12, 2015	Feb. 18, 2015	Feb. 13, 2015	Feb. 13, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Proceeds from issuance of convertible preferred stock								$ 8,000
Class of warrant or right, outstanding								2,701,754		643,317
Warrant Repurchase Agreements [Member]
Common stock purchase warrants repurchase agreement, description	On July 11, 2016, we entered into a Common Stock Purchase Warrants Repurchase Agreement (the “Warrants Repurchase Agreement”) with the holders (the “Holders”) of our outstanding common stock purchase warrants issued in October 2012, March 2013, May 2013, June 2013, June 2014, February 2015 and April 2015 (collectively, the “Warrants”) in connection with our Series A, Series B, Series C and Series E financings.
Repurchase of warrant	$ 459
Private Placement [Member]
Class of warrant or right, exercise price of warrants or rights				$ 32.505				$ 32.505
Percentage of closing bid price of common stock								110.00%
Class of warrant or right, outstanding				1,831
Series E Warrant [Member]
Warrant term					5 years 6 months
Series F Preferred Stock [Member]
Convertible preferred stock, shares issued upon conversion		2,067,183
Minimum percentage of weighted average price of common stock								200.00%
Warrant term								5 years
Sold for purchase price equal to per unit		$ 1,000
Gross proceeds received		$ 8,000
Trading volume during such period exceeds								$ 200
Preferred stock, description								The Series F investors have agreed to be subject to a blocker that would prevent each of their respective common stock ownership at any given time from exceeding 4.99% of our outstanding common stock (which may be increased on 61 days’ notice, but not above 9.99%).
Series E 6% Convertible Preferred Stock [Member]
Debt instrument, convertible, beneficial conversion feature					$ 890
Series C Convertible Preferred Stock [Member]
Preferred stock, dividend rate, percentage			6.00%
Stock repurchase program, authorized amount per share			$ 300
Stock repurchase program, authorized amount			$ 656
Stock repurchase program, original share price, per share			$ 1,000
Series E Investors [Member]
Debt instrument, convertible, beneficial conversion feature			$ 890
Payments as deemed dividend paid			656
Repurchase all outstanding stock			$ 2,200
Series F Offering [Member]
Stock issued during period, shares, new issues		8,000
Convertible preferred stock, shares issued upon conversion		1,000
Convertible preferred stock conversion price		$ 3.87
Debt instrument, convertible, beneficial conversion feature								$ 1,900
Percentage of conversion price of common stock		75.00%
Total offering related costs paid								1,060
Net proceeds from issuance of stock								$ 6,940
Series F Offering [Member] \| Common Stock [Member]
Convertible preferred stock, shares issued upon conversion								1,630,521
Series F Offering [Member] \| Common Stock [Member] \| Subsequent Event [Member]
Convertible preferred stock, shares issued upon conversion								13,179
Series F Offering [Member] \| Series F Preferred Stock [Member]
Convertible preferred stock, shares issued upon conversion								6,310
Series F Offering [Member] \| Series F Preferred Stock [Member] \| Subsequent Event [Member]
Convertible preferred stock, shares issued upon conversion								51
Series E Purchase Agreement [Member]
Share price						$ 26.25	$ 26.25
Stock issued during period, shares, new issues							102,800
Convertible preferred stock conversion price						26.25	$ 26.25
Series E Purchase Agreement [Member] \| Fixed Combination [Member]
Share price						$ 1,000	$ 1,000
Series E Purchase Agreement [Member] \| Series E 6% Convertible Preferred Stock [Member]
Stock issued during period, shares, new issues							2,201.493
Proceeds from issuance of convertible preferred stock					4,900
Proceeds from issuance of convertible preferred stock net					$ 4,700
Series E Purchase Agreement [Member] \| Series E 6% Convertible Preferred Stock [Member] \| Common Stock [Member]
Convertible preferred stock, shares issued upon conversion						83,871	83,871
Warrant Purchase Agreement [Member] \| Private Placement [Member]
Class of warrant or right, exercise price of warrants or rights				$ 16.50
Warrants not settleable in cash, fair value disclosure						$ 1,820	$ 1,820
Expected term								5 years 6 months
Expected volatility rate								113.20%
Risk free interest rate								1.50%
Class of warrant or right, outstanding				100,847
Warrant Purchase Agreement [Member] \| Modification of Certain Outstanding Warrants [Member] \| Private Placement [Member]
Class of warrant or right, exercise price of warrants or rights						$ 29.55	$ 29.55
Warrant Purchase Agreement [Member] \| Common Stock [Member] \| Private Placement Investors [Member]
Warrants to purchase of common stock initially						102,678	102,678
Warrant Purchase Agreement [Member] \| Private Placement Investors [Member]
Preferred stock, dividend rate, percentage						6.00%
Proceeds from issuance of warrants						$ 1
Modification Of Certain Other Outstanding Warrants [Member]
Class of warrant or right, exercise price of warrants or rights								$ 29.55
Fair value adjustment of warrants								$ 336
Series E Modifications [Member] \| Private Placement [Member]
Class of warrant or right, exercise price of warrants or rights				$ 16.50
Class of warrant or right, outstanding				100,847
Warrants Amendment [Member]
Fair value adjustment of warrants				$ 168
Series F Convertible Preferred Stock And Warrants Financing [Member]
Class of warrant or right, exercise price of warrants or rights		$ 5.17
Warrants to purchase of common stock initially		258.397875
Percentage of closing bid price of common stock		100.00%
Maximum [Member] \| Series F Preferred Stock [Member]
Convertible preferred stock, shares issued upon conversion		2,067,183
Series A Warrants [Member] \| Maximum [Member]
Share price								$ 73.65
Percentage of warrant remain unexercised through expiration date								7.50%
Series B Warrants [Member]
Class of warrant or right, exercise price of warrants or rights								$ 29.55
Series C Warrants [Member]
Class of warrant or right, exercise price of warrants or rights								29.55
Series E Warrants [Member]
Class of warrant or right, exercise price of warrants or rights								$ 32.51
Series E Warrant [Member] \| Series E Purchase Agreement [Member] \| Common Stock [Member]
Warrants to purchase of common stock initially						46,676	46,676
Class of warrant or right, number of securities called by each warrant or right						21.1977	21.1977

XML 41 R30.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Schedule of Stockholders' Equity Note, Warrants or Rights (Details) - $ / shares	9 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Shares of Common Stock Issuable from Warrants Outstanding	2,701,754	643,317
March, 2016 [Member]
Shares of Common Stock Issuable from Warrants Outstanding	2,067,183
Exercise Price	$ 5.17	$ 5.17
Expiration term	Mar. 31, 2021
April 2015 [Member]
Shares of Common Stock Issuable from Warrants Outstanding	100,847	100,847
Exercise Price	$ 16.50	$ 16.50
Expiration term	Aug. 31, 2020
April 2015 [Member]
Shares of Common Stock Issuable from Warrants Outstanding	1,831	1,831
Exercise Price	$ 32.51	$ 32.51
Expiration term	Aug. 31, 2020
February 2015 [Member]
Shares of Common Stock Issuable from Warrants Outstanding	46,676	46,676
Exercise Price	$ 16.50	$ 16.50
Expiration term	Aug. 31, 2020
June 2014 [Member]
Shares of Common Stock Issuable from Warrants Outstanding	1,690	1,690
Exercise Price	$ 30.90	$ 30.90
Expiration term	Apr. 30, 2018
December 2013 [Member]
Shares of Common Stock Issuable from Warrants Outstanding	388,365	388,365
Exercise Price	$ 46.80	$ 46.80
Expiration term	Dec. 31, 2018
June 2013 [Member]
Shares of Common Stock Issuable from Warrants Outstanding	32,788	32,788
Exercise Price	$ 29.55	$ 29.55
Expiration term	Jun. 30, 2019
May 2013 [Member]
Shares of Common Stock Issuable from Warrants Outstanding	32,788	32,788
Exercise Price	$ 29.55	$ 29.55
Expiration term	May 31, 2019
March 2013 [Member]
Shares of Common Stock Issuable from Warrants Outstanding	18,334	18,334
Exercise Price	$ 29.55	$ 29.55
Expiration term	Mar. 31, 2019
October 2012 [Member]
Shares of Common Stock Issuable from Warrants Outstanding	11,252	11,252
Exercise Price	$ 29.55	$ 29.55
Expiration term	Sep. 30, 2018
April 2011 [Member]
Shares of Common Stock Issuable from Warrants Outstanding		8,746
Exercise Price	$ 321.00	$ 321.00
Expiration term	Apr. 30, 2016

XML 42 R31.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2002
Transaction Bonus Plan [Member]
Maximum bonuses payable	$ 1,000		$ 1,000
Maximum bonuses payable, percent	10.00%		10.00%
Litigation [Member] \| Settlement Agreement [Member]
Litigation settlement percentage					12.50%
Maximum annual litigation payment					$ 1,500
Minimum quarterly litigation payment					$ 25
Patent expire year					2018
Royalty expenses	$ 25	$ 75	$ 25	$ 75

EXCEL 43 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 44 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 45 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 47 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 160 190 1 false 66 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://CBMX/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://CBMX/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://CBMX/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://CBMX/role/StatementsOfOperations Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://CBMX/role/StatementsOfComprehensiveLoss Consolidated Statements of Comprehensive Loss (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://CBMX/role/StatementsOfCashFlows Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Overview and Background Sheet http://CBMX/role/OverviewAndBackground Overview and Background Notes 7 false false R8.htm 00000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://CBMX/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Cash and Short-term Investments Sheet http://CBMX/role/CashAndShort-termInvestments Cash and Short-term Investments Notes 9 false false R10.htm 00000010 - Disclosure - Fair Value Measurements Sheet http://CBMX/role/FairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 00000011 - Disclosure - Secured Promissory Note Sheet http://CBMX/role/SecuredPromissoryNote Secured Promissory Note Notes 11 false false R12.htm 00000012 - Disclosure - Stockholders' Equity Sheet http://CBMX/role/StockholdersEquity Stockholders' Equity Notes 12 false false R13.htm 00000013 - Disclosure - Commitments and Contingencies Sheet http://CBMX/role/CommitmentsAndContingencies Commitments and Contingencies Notes 13 false false R14.htm 00000014 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://CBMX/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://CBMX/role/SummaryOfSignificantAccountingPolicies 14 false false R15.htm 00000015 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://CBMX/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://CBMX/role/SummaryOfSignificantAccountingPolicies 15 false false R16.htm 00000016 - Disclosure - Cash and Short-term Investments (Tables) Sheet http://CBMX/role/CashAndShort-termInvestmentsTables Cash and Short-term Investments (Tables) Tables http://CBMX/role/CashAndShort-termInvestments 16 false false R17.htm 00000017 - Disclosure - Fair Value Measurements (Tables) Sheet http://CBMX/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://CBMX/role/FairValueMeasurements 17 false false R18.htm 00000018 - Disclosure - Secured Promissory Note (Tables) Sheet http://CBMX/role/SecuredPromissoryNoteTables Secured Promissory Note (Tables) Tables http://CBMX/role/SecuredPromissoryNote 18 false false R19.htm 00000019 - Disclosure - Stockholders' Equity (Tables) Sheet http://CBMX/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://CBMX/role/StockholdersEquity 19 false false R20.htm 00000020 - Disclosure - Overview and Background (Details Narrative) Sheet http://CBMX/role/OverviewAndBackgroundDetailsNarrative Overview and Background (Details Narrative) Details http://CBMX/role/OverviewAndBackground 20 false false R21.htm 00000021 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://CBMX/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://CBMX/role/SummaryOfSignificantAccountingPoliciesTables 21 false false R22.htm 00000022 - Disclosure - Summary of Significant Accounting Policies - Schedule of Employee Service Share-based Compensation, Allocation (Details) Sheet http://CBMX/role/SummaryOfSignificantAccountingPolicies-ScheduleOfEmployeeServiceShare-basedCompensationAllocationDetails Summary of Significant Accounting Policies - Schedule of Employee Service Share-based Compensation, Allocation (Details) Details 22 false false R23.htm 00000023 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://CBMX/role/SummaryOfSignificantAccountingPolicies-ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 23 false false R24.htm 00000024 - Disclosure - Cash and Short-term Investments (Details Narrative) Sheet http://CBMX/role/CashAndShort-termInvestmentsDetailsNarrative Cash and Short-term Investments (Details Narrative) Details http://CBMX/role/CashAndShort-termInvestmentsTables 24 false false R25.htm 00000025 - Disclosure - Cash and Short-term Investments - Schedule of Cash, Cash Equivalents and Investments (Details) Sheet http://CBMX/role/CashAndShort-termInvestments-ScheduleOfCashCashEquivalentsAndInvestmentsDetails Cash and Short-term Investments - Schedule of Cash, Cash Equivalents and Investments (Details) Details 25 false false R26.htm 00000026 - Disclosure - Fair Value Measurements - Fair Value, Assets Measured on Recurring Basis (Details) Sheet http://CBMX/role/FairValueMeasurements-FairValueAssetsMeasuredOnRecurringBasisDetails Fair Value Measurements - Fair Value, Assets Measured on Recurring Basis (Details) Details 26 false false R27.htm 00000027 - Disclosure - Secured Promissory Note (Details Narrative) Sheet http://CBMX/role/SecuredPromissoryNoteDetailsNarrative Secured Promissory Note (Details Narrative) Details http://CBMX/role/SecuredPromissoryNoteTables 27 false false R28.htm 00000028 - Disclosure - Secured Promissory Note - Schedule of Secured Promissory Note (Details) Sheet http://CBMX/role/SecuredPromissoryNote-ScheduleOfSecuredPromissoryNoteDetails Secured Promissory Note - Schedule of Secured Promissory Note (Details) Details 28 false false R29.htm 00000029 - Disclosure - Stockholders' Equity (Details Narrative) Sheet http://CBMX/role/StockholdersEquityDetailsNarrative Stockholders' Equity (Details Narrative) Details http://CBMX/role/StockholdersEquityTables 29 false false R30.htm 00000030 - Disclosure - Stockholders' Equity - Schedule of Stockholders' Equity Note, Warrants or Rights (Details) Sheet http://CBMX/role/StockholdersEquity-ScheduleOfStockholdersEquityNoteWarrantsOrRightsDetails Stockholders' Equity - Schedule of Stockholders' Equity Note, Warrants or Rights (Details) Details 30 false false R31.htm 00000031 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://CBMX/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://CBMX/role/CommitmentsAndContingencies 31 false false All Reports Book All Reports cbmx-20160930.xml cbmx-20160930.xsd cbmx-20160930_cal.xml cbmx-20160930_def.xml cbmx-20160930_lab.xml cbmx-20160930_pre.xml true true ZIP 49 0001493152-16-014579-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-16-014579-xbrl.zip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
RLQY MK]XTNM0 -V*)TY_5?NW&*'J%H#VA6( -80<,4>Y"/(+?L6A?RSU[LK L)J'A M.4YWLTKB7*A,]9[PO77:#3/TD/5LLF:PY8/9)CJ)#6)@&C6)$)=_?7'X@G[7 M533T^YVSV0>/9>T $IQ HBL4T >/)DJ\"LQ/517/_>5 13:YK^!'O^SH9/+M M&:=_\')S\;V&V@D&\*)W=O'3BO43&MR3\TV"^S,$!$G0??6$:KUU@O?)^A25 MVT(R3(8=9%7[*^RHD J,,6XU?N)B&JQ4QO8 WSYO<<9#^-R!9=N+_.VHALUJ M@Z-704/A6Z0.PEH( );^ ;40ZF(1+/2HEM1'V'SNC:?M.:7X^;>?J&K$:Y,& M+MM>Y.^#-CENJF_Q:^K(OG8KN$*BH']36KXH$LX(9T;C0*0>F52YSLW/E&5A MF ?Q&);5( :R">48,#O@1$8'J^B2)0HMUQ2$=$[/\1I-8\^\?[/YOJE-D<\F M/TV:;2;S9$-&]".U'XP_40YRSGFW80'6()P$^'?N!AB'NCA;-9X:6P?S\VX+9T\F\VZ?; ) MOT_Y6ZDFF8J23\.?L_3Z9\P*71(??3"IV@^ ZO1: M[X#_N5GZMP!5Q* "&> M.H2H@!'BEF?2'Q/ZHU/+*RT*77'G\W%=9S&S7B<=2T)+&_!F/L))* MF7QO+/.X'.,9,6L(+-HHA*[GR'.J#G5*DDW*"X]=43(X#XBU*7R0^8$YD5Y' M/X$),8EG>^)>IEB[S/6!S.ETI,OG0$/,9NFS6LIVZ9)@RK[IE1@&-'FV]&\! MP/;;X4PVF\XM0.T"KHK,5@'BH:M2M0=K1RKF!?HT ,LAT5K6DY$VPTVG"6D% M[9VC (8'C_?Q=0@2JR!E%.^@.A*9=]8Q3YG(875Z0A#,?=!H-OM5!L$<+9CJ MT.'\XQE3<%0IWT+$HU3^48I:Q5,45(2N3E"<\XM9NON:N7MA>EO5U5-U!H$" M/)P7>*(UU&?PSCT$E^-&VJ;/,O&0RKH4Y<[I0*@Z?V*Q4GB'A;\W(0.%=14C MD0P"MZCY%@Q-Q<^5_)+MSE),@H_IT"CM$+WO'!CA&[Z[. L/#P]G:A10^SU0 M?D @4,'"/".W!ELU:P[?6MN]D_4&\ZS:V[J[4GE:'RIWY2"H'3\)UA@BF.O; M$-F'0'$T1Z1 L"0=2#Q >E?>$:Q:O=M=0.OQJ# 5X*C?T5,EXVC/*G41NG&B M8E9ALQ5Z,W=G*E48+')<=3ZW0T:!?6+67$[R_4%V<<$R?U@'B7(/^!BB<1" 2]T7D,5B'0QSGV-.1XL,O.L/@LS*\^5[\7"-^=F$)8A M,G*_2/7[&U!7LL"?=D).Y]8%N7NV=X-HWP%NO.9[4A$1*MP[<2DREKXE00>2 M T%U=[KB)A8Y!5-UP3;URP'? )J&%%C2]KC:@$L?AV*@K^I18;3 BVMCJ4N! MJ8R KW.8*L\!%=^YMSITO0J&@65>@8;BLFA#N#@!H75%7R02_%9;UHC[A5=F MND[)?5O,R,N1:^"5"U]!Y28,TOQ8&0^T#47FU>O9FU9\V%[%G<5MMJ">',N' M14Y;_^ZD>T[F%&'[[OBD1[_,%A::1$2!G07FOE$7#]'I.SQ@9R(<=TW9WT(X MJ<;O'C@)S.,N0>9P1 VZX&'(&BAU,_ZC;)9RN*KJ@G7N!_\S MCVZQH(XNLU7U"-4M#5.YCS^;2Q&U*"#/P1HHL'3ZGBAH]FLGE\$EUQH,7I9% MKM2%R1&K _@P+8GQ\)(!O!4#&;Y^H-# <@6O?D*7T_+7@'.38D17_6Y%7="C M!#:6LOW2:W)(2AXH"/_]V*"[;E4,16JIG$Q(D\%W\G*B2]80I"P1'7['H%J5 M:J*<-8,QIHUU]2PZT?AP.:'B:4 O1MI)AQQA),&@Y**9@4BBJ=:RO [ZZ!&: M>:".8U4U?N\0+,"J[$37D#&01C'QACBR3.&_L:D @-+O@N^ECTMN:BN:['9 MO7M_SDCW3CK2((/'LZKBTFBV:N^V=O?2U+^3#_LV*_O%L$P"\XA;Q/M>WZ)Y MH(:_NDF$=P+X;D1F#A([>.VE5JBN7Z09TFI>9'SR6:D@5=^F1RUM[M/ILE6; MX.424$D9A.KFG%/JC_E5Z;%) MCZ6NGY O9.-S%_-\8T=?VM#.+0<>\31.F+S&B:J1B!R+.2;4O:&E:Y/!Z;@N M1BBJZ4V6W- 5.I'"4R'>-A!Z,;R2,3!1C[XQ)\PM,2Q6Z?]'7\3@H$/&]5L< M7"2'_CU7K5:.T8'ERUF$FY6(S*:H-1L..8[@XP=3!%VF!K?T]!"3&\XMH]IE MI2&@33.G\PMNHW!5O:@H3@,V[9_+2')>!W_:]U + M3W!=O%)%'W5N05I&2$)[*P,/LRKG()K:"S]*U!1I6DD("<+ 6*)*%JK,-WVC M2O/."#1KW- V-F%E!3AP0RRW+!B64J'\8-!9*/ MU M-9$%054F##YVTA1*O\SJJ-B>-DXB51!^R7JJ2>FTF.'055\-I!N,!"=G.5VZ MHUM'+2Y8>Y2YLQF\&TC2Q;D?D6+W%'V]4!GA?6COY&)3@I5M6X29M'YAFK7P MQ0'KC1H=ICE,VXNQ3,'XY>PEVRXOJZ2Q%MSO6N3JS3J%5[ !\1JI@A==X/6T MZB?BC\MT$&\2P#N,X2#>JU=\1;O!);44JI#R"!P7(RXF9RO.I(S?^.;(<@D M&.H),!'95.CLOJZ;CVZC?$#B8L^?]*'!=1[I$H"P?HFX2HL:UB&FQ(6L1^'< MV#>7#8B%0KY3CIR%,4^'+MW0*43(9VMT)*4!=;.$9'\4&'7C&AH1>6DUHSW2 MNS&M 6P"U>E#0G#^H.MC:HIUB*(X%5&NKUK7+P&16.IS$8[P:"59VK>)2A)M +56=JXPRBNH5OQ_8GX(VRT"$@90HZW^EE M]>7J5Z>5%0<4!L@:"9V@&L5,,90ZKB,)3S*E>V;QK7".,L9CU(_T[DA5U\3@ MPU\NK]Y>_LNL7]L\WTFYM^,9O:$@W7=T=R&P2G[E%C ME@^%I.-&O()J;V^;;V"7L8[A%4V*ZAE;$(.YRXJ0G,P8)J:)%YYIQ47]C//^ M=;4!G(^$"@-@]!["F!%LZI1*$*.1E0H64S]L^]**JUYWY-(*-^2\ MKVCTJ:T5-[(J;!NPG/[U1>_%(][PI$I5>+B//WREL^>/?.3\#H^<"=Z^=0L> M5R3J4;X8Y;^@ ] (C*]4I;V[,K=:J_I-L$B]ZF/?!-+3PXOK'?8X:C![V.;\ MNR^E#2?#J2=#$\C@I:$19-B>-#RSJ=IJL_XYU&["\ "_([^C=<+S"!%^Y% A MTV4#4T-KT(AO,FZF9@LL5E.%)G.U&+C5^Y_])N3PI5YTKZ4G95%*N/!C>D[*II#S:D%0^DW?PX+#<-:#HBU""ALG3 M$ UN!T$7@59#7!/\2S_BUN/6X];C=K=PN[G(=-X8X[*-P.7O"\O5-\Z,#Q]W;>(= MFU*D;13VO:+021L'H^\3A4XN5DTQ>@IMF$*G1\VWNDN$=+I,O9.(H=[\6M#U ME;IUV#Y??(4@GKVDM'63?'1PA)R$%^82T8B4^#)@;LAJG*_3S_1D;@J9SW;& M??-D7@SYZ<6J)U^>S&TD\UISAG/L8,+GNC*A'H4X !;ZG\\ MH8Z0>(5V%"GNG8*.&GVI/PUH8+BYVVD?ZD]YC"#Q#5XOQ994U^XU8KX:3-#H M&\52J5)?*,[*PK;WO._JZ$'PR6G_<(M-Q/0,83-Y\\X5Y%N:0D=K#$6>Z_OQ MQ@%-R9GF\0G8SX\AL^":9?"^*C!;AY!%@[CY%C2LF>7"-DYVYB;J-IBZ-;S3 MB]X@G,"XBW1]M9MNQA(:Z(*IOD^L=,ML_18+3=51?MN79QO>*]E?Z&WFQ0!_ MH7>/4.XO]#:, 9IW&:<9%T@]/9I%C[T6UX;?G?-7&!M!!G^AMQ%D\-+0"#+X M"[T[<;72[\CO://P/$*$FWJAUTEE@]N+X+5S\.9BLW7'8Z:&I87'983<\.VWCA8BVX+AW M];Q&]%S<9AROGXM;'.3@3_"5=U4=9+"@!M*M?&PAM[:_GT=S5]@,;L^/ MP_->&^\:M07!GGE;S+RM#GVT%7K?<"NT5Q>9CWMAK[?.R\R>2ONILO>)/EZ* MVD"E%G3AVT9L^,Y<*)MD!=ZII%FG7C4.PF[AWMV M [^5M#H_/@TO6IG/VS=*>:EJ#ZW6+U5S[/3S]2QXH.' ;'\"P,1E'(/YQ[:W MG_,LA1]C@!1?9!A0P"JHZ1 X*;OAY\2(/+\AJ6#W#7 M(5V+?R_3*(W!>7&6":ZPJP!-IGZ=X9AS9Q3Z^\NKU^:W\Y]^,.T(4MAD5"UP M7V (KARW+2<&=#.B3232EC5([@3B)E))#63434$54$"8(%&Q1 M@ \-<8(V-PU R VX-'1^.!0QN7 X!GPH%3B@/+T^Z N@5TKST(>%R(.W Q= M[^N>AHC2LY# DGCQ08YM'X9;68QX5K<>#>XN>A ]X/C& WT:' (4I4AD^/ M94'=&WX3H$^H50*/9Z>-V0>H00(\93=19,$HPFX+ 8Y-SY&V9IIZBA/+"0:0 M"0HB(B[@TDCB)@X5AAK$]$WIB^# !/+TD68\D#@1("12(")&+BQ1*IX6XTF2 M387@SA5Z#KWF8D>&F#M=SD2^PHO?2& %%$T .(@S;KA=:RXB97CX)K73%NC/'C(09WF$>IQGU* Z3/+N1 M \%=..)1)F,6+80D2C&Q"?L1@&KD5OS+4,BBQ(8B3D^3&\'*@F4*WQ0!^+>D MG"#X QH @G+Q1RDQ.PJ1H6[A D%8CJ"A7ODA@+>" LFN4_EG_4T1RQ3 (*J% M8<48<9\DNM^*?@)%\BMOG+3D7:U1*D3./Z.TC/(IP=%E!?$$65; DX1[V$U- MG(.:* ^M/J^$^H! ^$=VB[P2!K>"UQ38'(79*1XA']!J$S*>#K^Z>(*O5@B4 M0^XG,Q+I,D@C(/((^[_ )N$!3?/9=Y238 @FK"!""4S'=R>'6)D7!OVR0.+2"Y'#?D_!?!)_Q46).F*, M6B% S9 P'LB,T>:!],5H9O<]K_\?TO_O13]'(5_-!"1(8W@_:R[-VPH^5DK, M2IG6LOTHH4742 @P$QQ,=+)AIT1N@>= /^="MWPRKB \*'/^*BZ*7\6U2#TF M4W)D\$G26?@'@BO [DOLR43ZDT1&?9F@BX;?C("]> ?DVM#W064!XQ9&M+M' M('[8JH153\V2D7=C]PPQHRIM; 1KF#[:&T6J).@ NJ)%M3JU6T M1>*^5O!*W=#+F&=6]BC:.4@F9CC)& PD>6"D9)"(F#P$WIRRHJ9]3R;)]*YC M<,?X5(ZJMD$!VY\+YE#2VMQ_2]M'T"+B)DK*J+#FGS6?O3 M&)%MJ!HQ9%JL1>8$5XY"T>J"V1"GP@!?@]08KZPB"LD[VYKJ0R/>DD7!(3:! M(M(1_LSR #HFRPD,$ B1Z"#)K"135>2E]B=GI0 ^'G"0@:P\&.0HPQ%)$L4= MSB9"=P>,$*W:(KO'2CD\)!%1FJ+YJT WD=EJ 1V#,2>H,R_0?UN[DZ>#2"]H MCQ"T,B$I.Z7L!\&RO)29H,MZF'4ID^D-_)3ETSF)!=3890#/<8LMO:R<#UT]T5 W(MD^H5^O$[ M EF'@30]O%EO:J ]:5Z^_B(4*=VI$N$]"#[85UFQ $\ESB;",KL;++G.?-^B MD=E:.]A@JDT#3,4[PZ:/X&(D\D_J-8C6"@3_ESF?XBLHPZ3=]@$$R4E"R!ONI^N3*I]Z,M]NU[0 ,SX9 MSRB-KJWF0(_:>GR8#6%?3&!LK45>Z(:I0#..#-F(BYO*9\PCJ1.,JNPCE^&9 M-)U$@ 3U47!)*O ]4Y/"[?T$ZVC?GNK'4/F5&%$ VUQG""I\!OYT:D0[2P5E M+@,G>)S#.BS,N3!X>$E* _02B0\+OOX3)Q!00<;XQQ\>,N>UG*S@]K?S[7?/ MNKN.&S O14OXI35 RD8RP9Z\3Y4U!CK0W7N7DK>P>@,I!YL.< ,AK;X -&:6 MI58F&.30Y3ND*QL"XIY%/(/+K\8AQ2TV<]4!H.W?"Y!4=F8IF .'?:1M9[P! MG52UP&U<5][9[/.45<]<9V;!F4PM; #U48I:^$!Q,5(98U,=X<< 2S86N77J M260KJ21F525(DQ(#'328XYUY[] .@*9RJDVA2"1U?4;602\H'/=PI;.8!,Y:L"NOIEDA9B*OT@M:O M;CMIY%XY$#G'(["$=JZ,OF")8SU'[TGX3$I\TVE!U$C7&7EU.3@H^8W$$ M> M#TN0ZS $;#(ALH1<1GBS)<0<%].F+:K<(<&P=(:ELA% !/@D7"*Y8G!EC^/N M)EG,<=-=8GPW4W\+9+21V.2X31IC1ZNCN2UWT14";H,"Z=Y:G\.S30H#J MSGG:V#T^^DN#.VEA0!!RB 050>]BV0XMBN:)5^5A9F4RJ+F8-MRX)TL$GJ8] M*P"0;+3$?LU-IL\,!EB+SBZ%501F=W<(B*\TG@/G!'][( %%V32@+^7=JR0; MDXNSD^D4")J3@V0S<*J10BS10R?D7,_ M$[M^$?6#M]5/!*#,A&?AN_T>>\5Z_CY M SHN$V 2^NG3\(M5'/S^-QAK[FPURQ7>59ES.*V]"/Q=V&.'.Z,M0+46N>R7 MA0DK4-J'((HZPVX6 -R*ZXRNT9#SX+9U([G_];,9X-6<]]]]RT% M94K/G5!@;"@A6"I84/VP[:$2*P7/?H##-AK!^@$.>X1R/\"A80S0O.;+S1@8 MX.G1+'KLM;@VO%>Z;UG?"#+X 0Z-((.7AD:0P0]P>(X5MMY*W^_([VCS\#Q" MA)LZP$'1@8 Y6UM1%6ZX)?I3=KKJH.W-]U3OKGHWM?D-Z?>6E%U/RATAY;&7 MRETAY=&&I/*9O(,M#:P0=%N7+@^(&Y%D$[H8OAKBFN!?MK_O4W-7\+CUN/6X M;7$ON"WU:(T2P15DXRC_7= 5W/:QX89"B(L6HJ8UR#WUR%T; MM* !^#8"E[^+E%O\8,WS8"Q3J8J]I&8=\K"IVL.C354VC# M#;XO=J;5ZZY2Z'2=[=?'DRMY',:\T9 MSG%3GJ^[^=IN@BZ^Z;[=>G1WS/U M]TSW7>::=T>D&?<:/3V:18^]%M>&7^GR-^L:009_S[019/#2T @R^'NF.W'C MS^_([VCS\#Q"A)MZSW0\IJ:;54>YAM\U?<1BF[O)U.N%O?-5ZWJ:C\"64N/L M,#P\.O?4: 8UO&PTB1J;E(UGLI9;NG=9Y#+F.;-H(\M4%JM:R"9X6YLJ:,!A MCBU$3UL0?'P>GGL$>PYN+X+7SL&;B\W6'8_=THAK;VX6-XX(SPZ[X=EI&^OT MVX+CWLEQ>-3S&M%S<9MQO'XN;G&0@S_!5][A=(BAR',;[,192I!CV9M,:2Y) M99Y:R*WM;S/1W!4V@]OSX_"\U\8K,&U!L&?>%C-OJT,?;87>-]P*[=7]VN-> MV.NM\XZMI])^JNQ]HH^7HC90J07-X;81&YI[=\$D*T2J9\;.N5S6##N\W"W4 M9W[+AO+FX5'O).P>[MG%\%;2ZOSX-+QH93YOWRCEI:H]M%J_5,VQT^NX2O]< M-]P7WZ%_$ZD1_O/NCU+>1 D.]KY,!U>C+"^^BGS$<4QP33O^RMN;V?OS./X M^6%@;Z@1),>'-"B^%P:W(AB)9!!\=W)P'(QEDN@Y]M@=*:1_!Z)"(+4P5(C" M3@$XA"]:)(;HFF%S]AQGV4_@*S3<.1A&,@]P,KPX"-[810F*Y1:FV>]2X7)Z M,'W5 2"J[RTP^Z+EWHI8?]JE3T\;-M_9W[MO_/V=[DF#+_!<+F!^VEC?*J%= MO5O5 MK*CQ[1RV![<:\9& ^_1_YKF M[RIVYUL:L:ZU%\ M^!2\O@??RV.T.7![R?9\V%K)]BY$LT0+>PGNB5 U!N=_C^3*=X,]TI^(])\S MI58^7/-8?R+6_XTI.X]TK]-W'>=>IWN=OB=8WX9.?^:P8:N'SEOON>-WY'>T M=7C\COR._(ZV5P*[?,>TX]Z:.J9A60B-2LY2,=4#DQ]?"+OAGD1/V?FJ U@T M-*<;ZVET$AZ?K#I N/D]H?:4F*O6XWM">D)N?;&=)J17KSM$S-[* Z(]*1M* M2J]@/2$](9M$R(TIUV>*JK=QL10[W8D\EE$23**)6+6BIPGYF&9JA29@QN.V MR2MXW'K<>MQZW'K<>MQZW&X;M\_DPV^I7S7"-P0("T&W_@9BDBFY:AW?T]G M=RIJMIAZ^GCZ>/IX^GCZM)\^Q^'1:1OG >P3C;P,-9L^+Y^I'>A38/C!>^GK MU9(GJ\[7:]'1S_8UPW*=[IY"PE7/&9O3*N\QI3J>T"TD],[8>4]D3^2])K)7 MV7M"Z./P8M_:#>\GH;W:W@,B^T#>L\F22K^[V6S .CJ7/[:O^&RG MB"@>P4O^ S_B$?MUED_QE'THTRBETMF(\!>,-0*#+ VB(#=(#/J(Q9 :A^=" M341,4UNJMN38I+S61)F@N*>+.'Z*J\4)O)D/_K%I>G\:).)&) B<3"=E$=S* M8D0=QVNO&TF11WD\F@8# 9O +NG]#"!J6'-RWYF$=UE6@'WFK'1/6Q>LQU\ MN(\_H*(/2-,'6LF3=:!]]:U.7MXF-JPCSZ,/-)X%N&O(2KN8-M-QZ;[5/I^/IX^GCZM*\; MPX/Q>MWZ'C4T1O>58ENH%%L]^FNL O*$]H3>>T+OC#OAB=P8GV2VN#=YSN+( M_:V#W*KH;7U&S_IVM%<_32@^;(=--QN]32PH]AM== M*N@QO.X2P&:>.OEROR95)S5W!8\:CYH6HN:9%*DO]_.U*/< >''1;.1[2GI* M[ALE?:&?)V0S0RY?Z+>KA3#K[C'K:=3L@T%/'R]#^T C7_"WJ2C=5XYLH0[L M^.1L5Q20)_0SQOJ>RBVD\D[Y$Y[0C7%*GJ^=YZK--V>;=U;M0-^*?E%O]+EK MC3HO::JE;;1&D)AF:_-;9(: @O$D2]'YPF>Q ^8O62&"6Y&+(%*Z[Z?:?,_+ M_2WK;&M?JDV7G-1;P2:/+#SQV%Z]7')KR'Y$^+N+DM:\\J\FM?/<;S(\OHRY MP<+9A,*A';[P,-^JM+DD:8F#1NW6]0[7H?'SBM]"HY^3:-Q!@#^*09!(JYQ[ 9$_G&2 M*=1&<:::![U/@:$A,Y9VE<+=9QHHOQX2;\Z%VKJWN/W*_"-=OLVYQ.L0V-EZ367:C=*6_ER@SVH(_9$OJ=XZ)E4WN:+2NXK"EE<0')5 MP)]'60+H5SA3MIABJ<1O49Y'::$^Y5]P8[L[!O936:@B2K&2(KC5FR9PBBR8 ME'D\BI3 E ?%"J)+X;@K8(C&*Y!X;=/%=O!=R-7O41[OXN*I'F%6BX M-C1"=;-WPFUN%AFB$#FV#6>C5]UK8?;EI?N![4:4E^X+LM]]$WDLE=AI1'N% MVL;R55]%W @R;*^*V)/!D.%S+N/=5M'-Q?V[;Q.91_:LZ7X"/,*>/*7@9B#B MC&%[%<#C(D=$K!<=^$-)>*&T=R=.(J7D4(J!S01S=K>T"'D,SS;A%&AG:YH\ M:CQJ6I&\>$J+V>/NYEK,?HSR>!18GW67[A?T-E;1?Q0>]L["[OD^C1!_Q&*G MN]90LA&+/05/C[TL<[@Q2IX>=%?MU-1\8IY_O[%@P.CWHVX#//\-V;3+22Z3 M:AK2KKKN3T%1]_ P/&]E#S2/X2VML$D[LZF+F >GSW0)JJGAS)/4:'E=J@)M MQV(D;2HR\I:C,4(3GA\O]B6:BQV/7V\UGJ=@_.C@M(T$VCVKT9R(X[WHYV64 M3[WIN ]+)[VPMW(?DR:@QR/8&P\?O]YH/$_$<7C02@)MRFB8I,WB7BD[%W#82G/8]JJGSDUCC34*SOEY>-QK M8T#F,>RMQ[,%A0?GWGHLI4G7;D":%G1XT[$XRQN>G;=QJ)!'L#<'%P MVD;+OB'#873HXA%S.Q=U?(RFWFKLDU+S"/96PUN--:C0M1N-ID0:]GZ)-QH+ M\^_GX?%:NQ V=P6/8&\TO-%87HGN4:SQ*2XRG99KXX2!#6FV;GATVD;T> 1[ MT^%-QP9,1]4 ;I_.-VQ)P.8+M?=I8,3.-,C?4?J.<"GZ]9$27-,%O+S0UYYK=LJF7+V6$W/#MM8UIHWVC5.SD.CU=N M ]($2FTRS&WQQIZI)]E!.U]'@@8@!V-:-Y J*!7V,!R)7 2W(AA',BW@GR"[30'J MD9P$$O$+KZ?9((E0*BA&40J&]7N:JSS(@C0K J$[*@<*J"*'8#A!8&4Z3$J1 MQB+(P)K"?WQOU_](HK/>18+,5"X91H= J_2:%\2 M)?\3EPI4U/^@PA#J_:?A$'Y(KS]2V/LB*%/)*_QZ]?9%,!"Q'$>)^NN+SO&+ MO_4N3@[A__[RXQ+0U #_&39V3?NY$D61"-SO9\ >_">Z%C7 +]6GX='AX5&G M>]0Y[AI@JP48SFH39KG+ZUS0#WA@%N\KP5LGA?/D M&YY"_UH.GKY)6.$&$/T9G*N59;U[T#7[6Q:\Y]S3<>?HV.P)?CZ94<-OLI2B M+[#(=1)>I@-C/M_+%!3L/%U][[8/'[OM@9"OON811G%7TW$_2Y8VNOBZO_QX MY_E9<_\IOXY2^2<)'2" DCWT"VP:L* 06/SUTU!O/4JNX!,BO7HK50R;*/-J MC%\[I^_9E_;I".4@^/3O=U_^_>'=;\'E+V^#UY=O_NOO7S[]^LM;@JN_#0AG MA^HM/5%O\U/^@(W[\F-4Y/);\";+)[IK-D'T$KTQ#?3)&7YU$J73T'QR_I/S MQULQ__-2.1^C,UC]*2OSZF\_!+D2C!,'W2V44Q!7T]*($GLR#7-06HH?>BB2ZQ;F+[B/P"O@$?7&$*1LJ_D0&+C#O"+ M+^,(!#+X F)*Y^T.MH.7%5;X:PYB" Y[<_WPC*!0DT06G6PXY#%X^J$9<"80 M1)<3HCZ M&M]:O@@NV22U96">P5TC8*PH^YO@6:K!,!K+9$J0C$24%*/.,(LIAHT3<-1B M &&<)2(N$_!Y@86O4X@N90P*HX_RF %+JXE XRG_Q!ETH!DFN>C(\22)M($- MKD6*@TL#(*(0*7PKQ.^D40&+ZR6E8OTP!KL+#HG$P"T"W3;%OY"&F@CX*FC> M&'R0&Y%D$[33M("BY)@Z"&!3"KYQ(U#P)GEV(P<"!% A!GC"0+4I%_YR@F/ MX2$'#3&B!]880H!.83."@5-G<9/ @&-\QQB#(?FG((ZT2Y<%B'8QU9PJ\V " M:$"GPNBI'M(%%!1K$$7;@]4R8'!>@[/ZL MC,L(O'O<;):4]-GOH BS8CJ!)7AKT00P'8&:!RR8;4I%.,$$ H&A,H093Q * M=\, ;9+A_�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end